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Abstract 
 
Mounting evidence suggests lower vitamin D status is associated with increased risk of 
cardiovascular disease (CVD) and type 2 diabetes (T2D), which are the leading causes of 
morbidity and mortality in the world. Findings from the Caerphilly Prospective Study (CAPS) 
(n=452 men), showed a higher dietary vitamin D intake was associated with lower fasted 
plasma triacylglycerol concentration, an independent risk marker for CVD, after over 20 years 
follow-up. Over the past decade hypovitaminosis D of the general population has become a 
concern throughout the world due in part to limitations in the endogenous vitamin D synthesis 
from ultraviolet radiation, which has increased the importance of dietary vitamin D intake. 
There are only a few foods naturally rich in vitamin D, such as oily fish and egg yolk, 
however the vitamin D content and form can vary and oily fish is only regularly consumed by 
a small section of the UK population. To address this, a retail study was conducted to 
investigate the vitamin D content and form (vitamin D3 and 25-hydroxyvitamin D3 (25(OH) 
D3)) in eggs from different production systems (indoor, organic and free-range) and 
supermarkets (n=3) between July to November of 2012. Vitamin D3 was significant higher in 
free range and organic, compared with indoor eggs, while 25(OH) D3 was only higher in 
organic eggs. Total vitamin D content (vitamin D3 and 25(OH) D3) of each egg was 
approximately 2 µg, which would contribute 20% of vitamin D recommended dose of 10 
µg/day. However, there is debate over the possible detrimental effect on human health of the 
relatively high cholesterol content of eggs. Further findings from CAPS demonstrated that 
higher egg consumption was not associated with incident of CVD, T2D or all-cause mortality, 
but a higher egg consumption (up to 1 egg per day) was associated with a higher risk of stroke 
and elevated fasting glucose in subjects with impaired glucose tolerance (fasting glucose ≥6.1 
mmol/L) and/or T2D.  
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Due to the relatively low natural enrichment of vitamin D in foods, fortification has 
become a recognised strategy to increase dietary vitamin D intake. Milk is used successfully 
as a vehicle for vitamin D fortification in a few countries, but there remains some uncertainty 
about the effects of milk consumption on risk of CVD. Thus, an updated dose-response meta-
analysis which included all of the published prospective cohort studies up to May 2016 was 
conducted. It was found that milk was not associated with CVD or all-cause mortality, and 
suggested a beneficial role of fermented dairy or cheese by lowering the risk of CVD and 
mortality. Vitamin D fortified milk and dairy are not available in many countries such as the 
UK. Furthermore, limited evidence suggests that supplementation of 25(OH) D3 has a greater 
efficacy for improving vitamin D status, than vitamin D3. Thus, a further study was designed 
with the aim to increase the vitamin D content of milk by a food chain approach by feeding 
vitamin D (vitamin D3 or 25(OH) D3) supplements to dairy cows. This study showed feeding 
dairy cows with 25(OH) D3 either pre-calving or post-calving was more effective in raising 
plasma 25(OH) D3 concentration than vitamin D3 supplementation, but vitamin D 
concentration in the milk was not affected by treatments. The mean 25(OH) D3 concentration 
of the enriched milk was 0.88 µg/L. Thus, fortification was favoured as a strategy for 
increasing dietary vitamin D intake. A randomised, controlled, cross-over and double-blinded 
24-hour acute intervention study was conducted in 17 men with sub-optimal vitamin D status 
(mean plasma 25(OH) D concentration was 31.7 ± 3.4 nmol/L) to compare the effects of 20 
µg 25(OH) D3 with 20 µg vitamin D3 fortified dairy drink and a control dairy drink on 
vitamin D status (plasma 25(OH) D3) and CVD risk markers. Consumption of 25(OH) D3 
fortified dairy drink was found to be more effective and faster at raising plasma 25(OH) D3 
concentrations postprandially. In summary, vitamin D fortified foods are needed to address 
the high prevalence of low vitamin D status within population. Fortification using 25(OH) D3 
would appear to have advantages over vitamin D3. 
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Chapter 1 - Introduction 
Background of vitamin D 
Vitamin D is known to be essential for normal bone growth and quality, thus, the classic 
functions of vitamin D relate to calcium absorption, homeostasis and bone mineralisation with 
deficiency leading to childhood rickets and adult osteomalacia (1). More recently, there is 
mounting evidence to show that vitamin D is involved in many additional non-skeletal 
functions in the body and the role of vitamin D deficiency in increasing the risk of many 
common and serious diseases, including osteoporosis, cardiovascular disease, common 
cancers and diabetes (2). The estimated benefit of increased vitamin D status in reducing the 
economic burden of disease in terms of CVD in Western Europe could be €7480 million/year 
(3). 
Vitamin D is a fat-soluble vitamin, humans usually obtain vitamin D naturally from 
sunlight. The physiologically active vitamin D form is 1, 25(OH)2 D which is synthesised 
after two hydroxylation reactions in the body, the first in the liver where vitamin D is 
transformed to 25-hydroxyvitamin D3 (25(OH) D), the second occurs in the kidneys where 
25(OH) D is converted to1,25(OH)2 D (1; Figure 1.1). Plasma or serum 25(OH) D is used as 
an indicator of vitamin D status (4). Although there is no agreement on the specific threshold 
of vitamin D status on disease outcomes, a low serum or plasma concentration of 25(OH) D 
(<25 nmol/L) is regarded as increasing the risk of rickets (1). Estimates of vitamin D status 
indicate widespread inadequacy with low status most prevalent in the Middle East and South 
Asia (5). Even within Europe, Hypponen and Power (6) concluded that the prevalence of 
hypovitaminosis D in the general population was alarmingly high especially during winter 
and spring. In UK, 23% of adults are estimated to have plasma vitamin D below 25 nmol/L 
(7). There are several reasons which contribute to the low vitamin D status, such as 
increasingly indoor lifestyle, skin pigmentation, ageing and sunscreen use all of which reduce 
the cutaneous production of vitamin D (8). Therefore, dietary intake of vitamin D has become 
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more important than before (9) and in recognition of this in 2016 the UK Scientific Advisory 
Committee on Nutrition (SACN) revised the national population dietary recommendations 
from zero to 10 g vitamin D daily for all adults. However, there are very few foods that are 
naturally enriched with vitamin D, such as egg yolk, oily fish (10) and strategies to improve 
dietary intake are essential.  
 
Figure 1.1 Schematic representation of the vitamin D synthesis (Holick and Chen, 2008). 
 
Strategies of increase vitamin D intake from diet  
In general, there are two ways to increase vitamin D intake from diet. An earlier study 
indicated it is feasible to enrich vitamin D in eggs by feeding a vitamin D supplement to 
poultry (11). In addition, a study (12) showed free-range farming is an efficient strategy to 
enrich vitamin D in eggs. However, a recent study showed that consumption of one egg per 
day is not associated with increased risk of CVD in the general population, but was associated 
with an increased risk of CVD in diabetic subjects (13). The other method is adding vitamin 
D into food as vitamin D fortified foods, which are available in a few countries, such as USA 
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and Canada (14). As milk is consumed by the vast majority of the population on a daily basis, 
milk is the predominant vehicle for vitamin D fortification in USA and Canada (14, 15). 
However, one recent publication with data from two large Swedish cohorts (16) reported that 
higher milk consumption was associated with a doubling of mortality risk including CVD 
mortality in the cohort of women. Since this paper was published in 2014, there has been 
mounting debate from different researchers regarding its seemingly contradictory results 
relative to other studies and meta-analyses (17, 18). Therefore, it is important to determine 
whether the chosen foods of milk or eggs have any long term detrimental effect on the 
populations’ health before researching a strategy on enriched or fortified vitamin D in natural 
foods.  
 
Aims and objective of the thesis 
The overall objective of current thesis is to investigate the role of foods as dietary sources of 
vitamin D, particular eggs and dairy. The specific research question, hypothesis and objective 
pertinent to this thesis is summarised at the beginning of each chapter. 
 
There are three sections in the current thesis: 
Section 1: Introduction and Literature Review, including Study 1. 
 Study 1. To critically review vitamin D intake from natural, enriched and fortified 
foods. Furthermore, to review the evidence from human intervention studies on the 
relative effects of 25(OH) D3 and D3 supplementation on vitamin D status. 
Section 2: Role of eggs dietary sources of vitamin D, including Studies 2, 3 and 4. 
 Study 2. To examine the effect of dietary vitamin D intake on CVD events and all-
cause mortality in a prospective epidemiological study - evidence from the Caerphilly 
Cohort. 
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 Study 3. To examine the effect of egg consumption on CVD events and diabetes in an 
epidemiological study - evidence from the Caerphilly Cohort. 
 Study 4. To examine the vitamin D content (vitamin D3 and 25(OH) D3) of retail eggs 
in the UK, and possible effect of production system (indoor vs outdoor), supermarket 
and purchase date. 
Section 3: Role of dairy dietary sources of vitamin D, including studies 5, 6 and 7. 
 Study 5. A comprehensive systematic review followed by a dose-response meta-
analysis was conducted to examine linear and non-linear associations between milk 
and dairy products with CHD, CVD events and all-cause mortality using existing 
prospective cohort studies of adequate quality. 
 Study 6. To investigate the effect of feeding cows different rates and forms of vitamin 
D on vitamin D forms and concentration in blood and milk.  
 Study 7. To investigate the acute effect of a dairy drink fortified with either vitamin D3 
or 25(OH) D3 on vitamin D status and predictors of CVD risk in humans. 
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Chapter 2 - Literature review: Are 25(OH) D3 enriched or fortified foods 
needed for increasing vitamin D status? 
 
The present chapter aims to provide a review of the vitamin D intake from natural, enriched 
and fortified foods. Furthermore, to review the evidence from human intervention studies on 
the relative effects of 25(OH) D3 and D3 supplementation on vitamin D status. 
 
JG conceived and wrote the manuscript, all authors critically reviewed and approved. 
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Abstract  
Humans derive vitamin D from the diet or synthesise it using ultraviolet radiation on the 
skin. However, there are several limitations for humans to get sufficient vitamin D through 
sunlight. Thus, diet has become more important for contributing to vitamin D intake and 
status. Unfortunately, there are only a few types of foods (e.g. egg yolk, oily fish) naturally 
rich in vitamin D. Therefore, vitamin D enriched foods from supplementing the animals’ diet 
with vitamin D or vitamin D fortification of foods have been studied as strategies to increase 
vitamin D intake. By reviewing vitamin D enrichment studies, it was clear that the 
cholecalciferol (vitamin D3) and calcifediol (25(OH) D3) contents of egg yolk, fish and milk 
did increase in response to vitamin D3 supplementation of diets for hens, fish or cows. 
However, evidence from supplementation studies with laying hens showed 25(OH) D3 
supplementation to the diet only resulted in a pronounced increase of 25(OH) D3 in the eggs. 
Therefore, the benefits of supplementing the animals’ diet with vitamin D3 or 25(OH) D3 will 
depend on which form of vitamin D has more impact on raising human vitamin D status or 
health outcome. From the second part of the review of randomised controlled trials, it is 
apparent that a 25(OH) D3 oral supplement can be absorbed faster and is also more efficient in 
raising serum 25(OH) D concentration compared with vitamin D3 supplementation, although 
evidence showing the biological activity of 25(OH) D3 varies between 3.13 to 7.14 times that 
of vitamin D3 due to the different characteristics of the investigated subjects or study design. 
Furthermore, supplementation with 25(OH) D3 may have more benefits on human health to 
the general population or clinical patients. Therefore, fortification by using 25(OH) D3 would 
appear to have advantages over vitamin D3. Further studies are needed to assess the effects of 
25(OH) D3 enriched or fortified foods in clinical trials to fill the research gaps.  
 
Key words: Vitamin D deficiency, food enrichment, food fortification, vitamin D3, 25(OH) 
D3 
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Introduction 
Vitamin D is usually synthesised in the skin when exposed to ultraviolet radiation, so it has 
been known as ‘sunshine vitamin’[1]. Traditionally, it has been thought that the primary role 
of vitamin D is related to calcium absorption and bone health. Children and adults with 
vitamin D deficiency have an increased risk of development of rickets or osteomalacia [2].  A 
resurgence of childhood rickets has recently highlighted the need for adequate vitamin D 
status in many parts of the world [3-5]. In addition, mounting evidence from epidemiology 
indicates that vitamin D status is inversely associated with risk of cardiovascular disease, 
cancers and diabetes [1, 6], although there is some uncertainty about what defines an adequate 
vitamin D status [7]. 
Several studies indicate that vitamin D deficiency is prevalent and is considered a serious 
issue throughout the world [8-10], even in sunnier climates such as Australia and New 
Zealand [11, 12]. There are several factors which have contributed to the low vitamin D status 
commonly seen today such as lifestyle changes (increased indoor lifestyle, sun screens use), 
latitude, human characteristics (e.g. skin pigmentation, ageing, clothing, low-fat diet trend) 
[13, 14]. Therefore, foods that contribute to vitamin D intake have become more important 
than before. However, there are only a few foods naturally enriched with vitamin D, such as 
oily fish and egg yolks [15]. 
In the first section of this review the possibility of the enrichment of vitamin D in foods of 
animal original through feeding supplements of cholecalciferol (vitamin D3) and/or calcifediol 
(25(OH) D3) to laying hens, fish and bovines is considered. The second section summaries 
information from human intervention studies which compare the relative effects of 25(OH) D3 
and vitamin D3 in increasing serum 25(OH) D concentration.  
 
Vitamin D absorption, synthesis, and metabolism  
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Generally the term vitamin D refers to vitamin D2 and vitamin D3. Vitamin D2 is produced by 
fungi whilst vitamin D3 is produced by humans or animals [16]. Humans usually synthesise 
vitamin D3 in the skin [17] where 7-dehydrocholesterol in the epidermis is converted to 
previtamin D3 when skin is exposed to sunlight. Then, previtamin D3 undergoes a 
temperature-dependent isomerisation to vitamin D3 over a period of about three days [6]. 
Whilst, vitamin D (vitamin D2 or vitamin D3) can also be obtained from the diet [17], as it is 
fat-soluble it is absorbed with long-chain triglycerides in the small intestine [18]. It is then 
incorporated into chylomicrons and transported in lymph to the blood and into the general 
circulation [19].  
After entering the circulation, there were two hydroxylation reactions to convert vitamin D 
to the biologically active form [6]. The first hydroxylation reaction is in the liver where 
vitamin D is hydroxylated to 25(OH) D by the vitamin D-25-hydroxylase (25-OHase); The 
second hydroxylation reaction is in the kidney where 25(OH) D is converted to 1, 25(OH)2 D 
by the 25-hydroxyvitamin D-1α-hydroxylase (1-OHase) [6]. The 1, 25(OH)2 D metabolite is 
the biologically active form of vitamin D. The different side chain in the vitamin D2 and 
vitamin D3 molecules are maintained during the transformations, vitamin D2  being converted 
to 25(OH) D2 and then to 1,25(OH)2 D2 whilst vitamin D3 is converted to 25(OH) D3 and then 
to 1,25(OH) D3 [20]. 
 
Foods of animal origin as dietary sources of vitamin D 
Within the few vitamin D rich foods the vitamin D content can differ considerably between 
food suppliers. One US retail study analysed the vitamin D content of eggs collected from 12 
individual retail supermarkets across the country and reported a broad range of vitamin D3 and 
25(OH) D3 concentrations 9.7-18 µg/kg and 4.3-13.2 µg/kg, respectively [21]. A recent UK 
study [22] showed vitamin D3 and 25(OH) D3 concentrations of eggs were significantly 
different depending on the egg production system. Egg yolks produced by birds kept in indoor 
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systems had much lower concentrations of vitamin D3 than the egg yolks produced from 
outdoor systems, while 25(OH) D3 concentrations of the eggs was only higher in organic 
eggs. Similarly, vitamin D contents of fish have been shown to vary due to the different 
production system. The study of Lu et al. [23] showed that vitamin D3 content of wild salmon 
was three times higher than that of the farmed salmon. In addition, studies [24, 25] have 
shown 25(OH) D3 content of several species of marine and freshwater fish to be less than 0.02 
µg/100g. Therefore, foods generally regarded as rich sources of vitamin D may not be 
sustainable contributors of vitamin D intake to the general population, due to variability in 
vitamin D content which in turn may be influenced by production systems or different 
species.  
 
Enrichment of animal origin foods as dietary sources of vitamin D 
Vitamin D enriched eggs 
In general there are two main ways to enrich the vitamin D content of eggs: increased sunlight 
exposure and vitamin D supplementation of the birds’ diet. Because hens can synthesis 
vitamin D from natural sunlight, free-range egg production systems may be an inexpensive 
way to enrich vitamin D in their eggs. A study by Kuhn et al. [26] showed free-range to be an 
effective way to enrich vitamin D in eggs, (mean 14.3 μg/100 g dry matter) whereas the 
vitamin D content of the commercial free-range eggs had relatively low vitamin D contents 
(mean 3.8 μg/100 g dry matter).  
Several studies [27-32] have shown that the vitamin D3 content of the eggs can be 
enhanced by feeding vitamin D3 supplements to the hens (Table 1). The results of all studies 
showed the egg yolk vitamin D3 concentration was efficiently increased by vitamin D3 
supplementation of their diet. In addition, the study of Yao et al. [31] indicated a linear dose-
response relationship existed between vitamin D3 dietary supplementation and vitamin D3 
concentrations of the egg yolk. As 25(OH) D3 is a metabolite of vitamin D3, 25(OH) D3 
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content in eggs can also be enhanced by supplementing the birds’ diet with vitamin D3 when 
vitamin D3 supplement was fed to hens. However, the response in 25(OH) D3 in the egg yolk 
is much less than that of vitamin D3. Study of Browning et al. [32] indicated that a 2-fold 
increase in 25(OH) D3 of egg yolk and a 4-fold increase in vitamin D3 of egg yolk resulted 
from a 4-fold increase in the vitamin D3 in the diet (2,500 to 10,000 IU/kg). Similarly, 
evidence from another study [27] showed that the increase of vitamin D3 in egg yolk was 
about 7-fold as a result of feeding a diet with a vitamin D3 content increased by 3.5 times 
(from 2496 to 8640 IU/kg), while the corresponding increase in 25(OH) D3 content was only 
about 1.5-fold.  
There are only a few studies examining the effect of feeding birds with diets supplemented 
with 25(OH) D3. In the EU, 25(OH) D3 has only recently been authorised for addition to 
poultry diets, and the maximum content of the vitamin D3 and 25(OH) D3 combination for 
laying hens is 80 µg/kg [33]. The study of Browning et al. [32] showed the addition of 
25(OH) D3 to the vitamin D3 supplement resulted in elevation of the 25(OH) D3 content of the 
egg yolk, but there was no significant increase in the vitamin D3 content of the egg yolk. A 
further study investigated dietary supplementation with 25(OH) D3 only [30], and showed that 
only 25(OH) D3 in the egg yolk was increased but not vitamin D3. These studies suggest that 
25(OH) D3 in the diet can be absorbed directly without transfer to vitamin D3. 
 
Vitamin D enriched fish 
There are very few studies [34-37] on enriching the vitamin D content of fish (Table 2). 
Mattila et al. [36] has fed rainbow trout with different doses of vitamin D3 supplements up to 
21,560 IU/kg, but results showed no significant differences in the vitamin D3 of the fish fillet. 
In contrast, the study of Horvli et al. [34] with Atlantic salmon showed a dose-response 
relationship between the vitamin D3 in the fish meat and the vitamin D3 in the diet up to 
1,147,200 IU/kg. Similar high vitamin D3 supplementation dose was reported in another two 
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studies [35, 37], which showed that the elevated vitamin D3 content of the fish liver or whole 
fish had been achieved by the additional vitamin D3 to the diet. However, the 25(OH) D3 
contents of the vitamin D3 enriched fish were not measured in these studies, and no studies 
have examined the effects by feeding fish with 25(OH) D3. 
 
Vitamin D enriched milk 
The summary of the studies investigating the vitamin D enrichment of milk by supplementing 
the bovine diet with vitamin D is presented in Table 3. An earlier study by Thompson et al. 
[38] provided large single doses of vitamin D3 supplementation of 5 × 10
6  IU or 1 × 107 IU to 
bovine feed, and reported a corresponding increase in vitamin D3 in the milk, which peaked 
between 3 and 7 days of supplementation. Furthermore, a few studies [39-42]  have 
investigated the longer term effect of supplemental vitamin D3 on the vitamin D content of the 
milk. The study of Hollis et al. [39] showed that a 10-fold enhancement of vitamin D3 intake 
from 4,000 to 40,000 IU/d  resulted in a 7.5-fold increased vitamin D3 concentration of the 
milk and a 2-fold increase in 25(OH) D3. The study of McDermott et al. [41] compared three 
different doses of vitamin D3 with a control diet, and showed an increased level of vitamin D3 
and 25(OH) D3 in the milk. However, the relationship of increasing extent of supplementation 
doses and vitamin D3 or 25(OH) D3 concentrations of the milk was not linear. Furthermore, 
the study of Weiss et al. [42] has investigated the effect of feeding 18,000 IU/day vitamin D3 
to pre-calving cows for 13 days, the vitamin D3 and 25(OH) D3 of the milk were ranged from 
13.0-18.0 IU/L and 14.3-40.8 IU/L, respectively. In addition, the study has also included 
treatment of 240,000 IU and dietary cation-an-ion difference of -138 mEq/kg per day for 13 
days, concentrations of 25(OH) D3 in the milk was increased but the treatment effect 
disappeared after 28 days. 
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Evidence from human dietary intervention studies with vitamin D enriched animal-
derived foods 
Despite numerous animal-based vitamin D enrichment studies on eggs, fish and milk, there 
are few randomised controlled trials (RCTs) on the effect of consuming vitamin D enriched 
foods on the vitamin D status of the consumer. To our knowledge, only one recent study [43] 
has investigated the effect of vitamin D enriched eggs on vitamin D status compared with 
commercial eggs. Weekly consumption of seven vitamin D3 enriched eggs or 25(OH) D3 
enriched eggs was compared with commercial eggs consumption ≤2 eggs/wk for 8-weeks 
during winter. The results showed that compared with subjects who consumed commercial 
eggs whose serum 25(OH) D decreased from baseline of 41.2 ± 14.1 nmol/L to 34.8 ± 11.4 
nmol/L after 8-week intervention, serum 25(OH) D of the subjects who consumed vitamin D3 
enriched eggs or 25(OH) D3 enriched egg were maintained at their starting values, the serum 
25(OH) D of post-intervention of subjects who consumed vitamin D3 or 25(OH) D3 enriched 
eggs were 50.4  (SD=21.4) and 49.2 (SD=16.5) nmol/L, respectively. In addition, a study by 
Hayes et al. [38], showed that vitamin D3 enriched eggs and 25(OH) D3 enriched eggs did not 
significantly change serum 25(OH) D concentration, maybe because vitamin D intake from 
both treatments was low and eggs in both treatments had similar vitamin D concentrations 
(vitamin D3 3.54±1.04 µg/egg; 25(OH) D3 4.54±1.38 µg/egg). Although there are limited 
human dietary intervention studies on vitamin D enriched foods, the study of Mattila et al. 
[30] demonstrated that the effect of foods enriched with either vitamin D3 or 25(OH) D3 on 
human vitamin D status depends on their relative effectiveness in raising serum 25(OH) D 
concentration. However, previous study [44] indicated that there is no consensus on the 
relative biological activity of 25(OH) D3 compared with vitamin D3 in raising human serum or 
plasma 25(OH) D3 concentrations. Furthermore, UK food composition tables [45] indicated 
there is no certainty on the relative potency of 25(OH) D3 compared to vitamin D3, although 5 
was used currently for calculating the total vitamin D of foods. Therefore, we summarized the 
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evidence from randomized controlled studies (RCTs) which reported the changing of serum 
25(OH) D concentrations by giving 25(OH) D3 supplement to examine the effect of 25(OH) 
D3 on raising serum 25(OH) D concentrations. In addition, we calculated the relative 
effectiveness of oral 25(OH) D3 and vitamin D3 if the two treatments were included within the 
same study. 
 
Human intervention studies on the relative effects of 25(OH) D3 and D3 supplementation 
on vitamin D status. 
Heterogeneity of intervention studies 
Eleven RCTs which investigated the effects of 25(OH) D3 treatment were identified [46-56] 
(Table 4). Nine studies administrated 25(OH) D3 supplementation only, except 2 studies 
which provided a combination supplement of 25(OH) D3 and calcium [46, 49]. Five of the 11 
studies [47, 49-52] supplemented 25(OH) D3 to generally healthy subjects whereas the other 6 
studies supplemented 25(OH) D3 to clinical patients. Most studies reported the serum 25(OH) 
D concentration at both beginning and end of the treatment, except one study [55] which only 
reported the serum 25(OH) D concentration at the end of treatment. In terms of characteristics 
of the investigated subjects, five studies included both men and women [46, 48, 51, 53, 55], 
while the other studies only included men or women. In addition, most studies reported the 
age and body mass index (BMI) of the subjects, except two studies [46, 48] that did not report 
the BMI range.  
 
Acute pharmacokinetic action of vitamin D3 and 25(OH) D3  
An early study [57] gave meals with single doses of 25(OH) D3 of 1.5, 5 or 10 µg/kg body-
weight to generally healthy subjects and showed that the peak serum 25(OH) D3 concentration 
was reached within 4-8 hours after ingestion. A later study by Jetter et al. [52] compared the 
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pharmacokinetic absorption of vitamin D3 and 25(OH) D3 by providing a single dose of 20 µg 
vitamin D3 and 25(OH) D3 to postmenopausal women. The time to reach maximum plasma 
25(OH) D3 concentration was 22 and 11 hours for vitamin D3 and 25(OH) D3, respectively. In 
addition, the peak concentration of plasma 25(OH) D3 (43.9 nmol/L) of 25(OH) D3 
supplementation was numerically higher than vitamin D3 supplementation (34.7 nmol/L), 
although there it was not significantly different. This study further compared the effect of a 
higher single dose (140 µg) of vitamin D3 and 25(OH) D3 with the time to reach peak plasma 
25(OH) D3 being 21 and 4.8 hours for vitamin D3 and 25(OH) D3 supplementation, 
respectively. In addition, the maximum plasma concentration of 25(OH) D3 for 25(OH) D3 
treatment (44 nmol/L) was numerically higher than for vitamin D3 treatment (35 nmol/L) but 
not significantly different. The results suggest that 25(OH) D3 was absorbed more quickly 
than D3 possibly because 25(OH) D3 has higher solubility in aqueous media than vitamin D3 
due to its more polar chemical structure [58]. Furthermore, as this metabolite of vitamin D3 is 
produced in the liver, the hepatic metabolism of vitamin D3 to 25(OH) D3 is circumvented and 
consequently the conversion from vitamin D3 to 25(OH) D3 would be negligible [59]. Patients 
with liver disease have an impaired ability to synthesis 25(OH) D3 from vitamin D3 [60]. The 
study of  Sitrin et al. [61] verified that 25(OH) D3 could be absorbed more efficiently than 
vitamin D3 after oral supplementation in patients with chronic cholestatic liver disease. 
Therefore, supplementation with 25(OH) D3 is not only more efficient at increasing vitamin D 
status in generally healthy people, but may also have a specific role in tackling lower vitamin 
D status in patients who are suffering from liver diseases. 
  
Chronic effects and relative effectiveness of vitamin D3 and 25(OH) D3 treatments 
Regarding the expected higher biological effect of 25(OH) D3 in raising serum 25(OH) D 
level after a longer term administration, several studies have confirmed that oral consumption 
of 25(OH) D3 is highly effective in raising serum 25(OH) D level (Table 3). However, the 
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majority of the evidence in support of a higher impact of 25(OH) D3 supplementation 
compared with vitamin D3 on serum 25(OH) D3 level is available from only four studies [51, 
52, 54, 56] where both 25(OH) D3 and vitamin D3 treatments were included in the same study. 
Although an earlier study of Barger-Lux et al. [47]  has applied three different doses of 
vitamin D3 (25, 250, 1250 µg) or 25(OH) D3 (10, 20, 50 µg) in their daily trial to the subjects 
for 8 weeks and 4 weeks, respectively. However, the effects of 25(OH) D3 and vitamin D3 
treatments are not directly comparable as the interventions were not at the same dose or 
treatment time. Thus, the study of Barger-Lux was excluded from the relative effectiveness 
analysis. In order to compare the relative effectiveness of 25(OH) D3 and vitamin D3 
supplementation on raising serum 25(OH) D concentrations, we calculated a comparison 
factor for each µg of orally consumed 25(OH) D3 or vitamin D3 in 4 studies (Table 5). The 
comparison factor of 25(OH) D3 and vitamin D3 were calculated by using endpoint serum 
25(OH) D minus baseline serum 25(OH) D, and then divided the dose of the supplementation. 
Then, calculation of the relative effectiveness of 25(OH) D3 to vitamin D3 by using 
comparison factor of vitamin D3 divide by the comparison factor of 25(OH) D3. 
The highest relative effectiveness was found in the study by Catalano et al. [54]. Weekly 
treatment of 140 µg 25(OH) D3 or 140 µg vitamin D3 supplements were provided to 
osteopenic and dyslipidaemic postmenopausal women for 24 weeks. Supplementation of 
25(OH) D3 raised serum 25(OH) D from a baseline of 55.7 nmol/L to 125.6 nmol/L, while 
vitamin D3 treatment increased serum 25(OH) D much less from baseline 50.8 nmol/L to 60.7 
nmol/L. Thus, the conversion factor derived from this study is 7.14. 
Vitamin D dietary recommendations are generally between 10 to 20 µg/day [10], thus, 
there are a few studies which have compared the effectiveness of 25(OH) D3 and vitamin D3 
using doses of 20 µg in their treatments. Cashman et al. [51] provided daily supplements of 20 
µg vitamin D3 or 20 µg 25(OH) D3 to adult men and women with a mean age of 57 years and 
with baseline serum 25(OH) D of 28.9 nmol/L during winter. After 10 weeks of 
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supplementation, the subjects’ serum 25(OH) D rose to 134.6 nmol/L and 69.0 nmol/L for the 
25(OH) D3 and vitamin D3 treatments, respectively. A conversion factor of 4.99 represented 
the relative effectiveness of each µg of 25(OH) D3 relative to vitamin D3 for raising serum 
25(OH) D concentration. However, lower relative conversion factors were achieved in other 
studies using the same dose of 20 µg vitamin D3 and 25(OH) D3. Bischoff-Ferrari et al. [62] 
supplemented healthy postmenopausal women with 20 µg 25(OH) D3 or vitamin D3 for 16 
weeks during the winter. They found that for the 25(OH) D3 treatment, serum 25(OH) D 
increased to 173.4 nmol/L from a baseline of 30.7 nmol/L, whereas for the vitamin D3 
treatment serum 25(OH) D increased to 77.4 nmol/L from a baseline level of 35.4 nmol/L. 
The conversion factor of each µg of 25(OH) D3 had 3.40 times compared with vitamin D3 in 
raising serum 25(OH) D level. A similar low conversion factor was found in another study  
[56]. Post-menopausal osteoporotic women were given either 20 µg vitamin D3 or 20 µg 
25(OH) D3 over 6 months or 12 months. The serum concentration of 25(OH) D for the 
25(OH) D3 treatment reached 161.0 nmol/L and 188.0 nmol/L from a baseline of 37.2 nmol/L 
after 6 months or 12 months administration respectively, while the comparable values for the 
vitamin D3 treatment were an increase to 80.0 nmol/L and 86.2 nmol/L from a baseline of 
40.5 nmol/L. So the conversion factor of 25(OH) D3 relative to vitamin D3 treatment at 6 
months and 12 months were 3.13 or 3.29, respectively.  
In summary, of the studies reviewed, the relative effectiveness of 25(OH) D3 relative to 
vitamin D3 for raising vitamin D status (Table 5), ranged from 3.13 to 7.14. Previous studies 
[13, 14] have demonstrated that the season may have influences on vitamin D status. There 
were two studies [47, 51] were conducted during the winter which may have minimised any 
confounding influence of cutaneous vitamin D synthesis from ultraviolet radiation. Other 
studies have longer intervention periods of six months or more, which could not have avoided 
cutaneous synthesis. Furthermore, baseline status may be another factor that influences the 
relative conversion factor. The study of Catalano et al. [54] had the highest conversion factor 
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of 7.14 in the current review, and the baseline concentration of 25(OH) D of the study 
participants was higher (>50 nmol/L) than the others. Therefore, the different relative 
effectiveness seen in different studies may be due to the different characteristics of the 
subjects or different study designs. 
Overall, it seems that 25(OH) D3 can more effectively increase serum 25(OH) D 
concentrations than vitamin D3 and may also be absorbed faster reaching a serum 25(OH) D 
plateau earlier than vitamin D3 supplementation. Furthermore, supplementation with 25(OH) 
D3 may also have more benefits on human health compared with vitamin D3. Bischoff-Ferrrari 
et al. [62] reported that 20 µg 25(OH) D3 supplementation over four months led to a 5.7 
mmHg decrease in systolic blood pressure and also improvements in several markers of 
innate immunity.  
For patients with different diseases and receiving long term medication, three studies [63-
65] showed that several drugs interfere with vitamin D and bone metabolism, which resulted 
in patients being more likely to have low vitamin D status. Thus, it is not only important to 
increase vitamin D status in the generally healthy population but also in patients with specific 
illnesses and receiving certain drugs. Therefore, the studies using 25(OH) D3 treatments in 
patients were also summarised in Table 3 [46, 48, 53-56]. It was consistently reported that 
chronic 25(OH) D3 supplementation effectively increased serum 25(OH) D concentrations. 
Ortego-Jurado et al. [55] showed a lower daily dose of 8.85 µg 25(OH) D3 to be more 
effective than a 20 µg  dose of vitamin D3  for increasing vitamin D status in patients with 
autoimmune disease who were treated with a low dose of glucocorticoids throughout the year. 
Similarly, the study of Banon et al. [53] showed that a monthly dose of 400 µg 25(OH) D3 
was safe and effective at improving vitamin D status of HIV-infected patients throughout the 
year.  
Furthermore, supplementation with 25(OH) D3 may have additional benefits on patients’ 
health. Previously, 25(OH) D3 was recommended for patients with kidney disease since 
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25(OH) D3 has a direct action on bone metabolism [66]. Hahn et al. [46] provided a daily 40 
µg 25(OH) D3 and 500 mg calcium supplement to patients who had glucocorticoid-induced 
osteopenia for 18 months. The treatment markedly increased vitamin D status from 39.2 
nmol/L to 204.9 nmol/L. In addition, this study showed 25(OH) D3 treatment can improve 
mineral and bone metabolism. Also, Jean et al. [48] offered haemodialysis patients who 
suffered with vitamin D deficiency a daily dose of 16 µg 25(OH) D3 for 6 months; vitamin D 
status reached 126 nmol/L from 30 nmol/L, at the same time 25(OH) D3 supplementation 
corrected the excess bone turnover. Similarly a study by Catalano et al. [54] not only found 
that weekly 25(OH) D3 had a significantly higher effect on vitamin D status than vitamin D3 
of the same dose with additional benefits that 25(OH) D3 improved plasma lipid levels 
(increase HDl-cholesterol (P=0.02) and decrease LDL-Cholesterol (P=0.02)) when added to 
an ongoing atorvastatin treatment. 
 
General discussion 
As an alternative to vitamin D enriched foods, vitamin D fortification of foods may also be an 
option for tackling vitamin D deficiency throughout the world. In general, fortification of 
foods refers to mandatory and voluntary fortification. The contribution of vitamin D fortified 
foods to vitamin D intake by the public varies considerably between countries as there are 
different food standard policies [10]. In practice, vitamin D2 or vitamin D3 is used for the 
fortification. Vitamin D2 is produced from some fungi whilst vitamin D3 is produced in the 
skin by animals and humans via ultraviolet radiation [67]. Previous meta-analysis of RCTs 
[68] showed that vitamin D3 supplementation is more effective in raising vitamin D status 
than vitamin D2. However, a further comprehensive systematic review and meta-analysis of 33 
RCTs [69] showed the effect of vitamin D3 supplement on serum 25(OH) D3 response 
depends on supplemental dose, duration, age of subjects and baseline level, which has further 
indicated a higher serum 25(OH) D increasing was found when intervention study with a dose 
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20 µg/d or more, subjects whose age >80 years, administration period is at least 6 to 12 
months or subjects had lower baseline 25(OH) D level. Therefore, better strategies are needed 
on raising vitamin D status in the public through the years. 
 
Conclusion  
There is no doubt that vitamin D insufficiency has become a world problem, especially in 
winter. There are a few natural foods rich in vitamin D. Thus, vitamin D enriched foods 
produced through a food chain approach such as feeding animals vitamin D supplements or 
vitamin D fortified foods are needed to guarantee an adequate dietary intake of vitamin D  by 
the general population. 
The present review summarised the limited number of RCTs investigating the effect of 
25(OH) D3 supplementation on serum 25 (OH) D concentration. We conclude that it is 
difficult to get consensus of the biological conversion factor of 25(OH) D3 supplementation 
relative to vitamin D3 for raising vitamin D status, due to different influencing factors such as 
different person characteristics (age, BMI), baseline vitamin D status and time of the year. 
However, it is unquestionable that 25(OH) D3 supplementation is more efficient in raising 
serum 25(OH) D level and also appears to be absorbed faster by the human body than the 
same dose of vitamin D3 supplementation. Secondly, by reviewing available evidence on 
vitamin D enriched eggs, fish or milk, it is a practical possibility to increase the vitamin D 
content of eggs, fish or milk by addition of vitamin D supplements into diet of poultry, fish or 
dairy cattle. However, there are a few RCTs investigating the impact of these vitamin D 
enriched foods on improving vitamin D status. Therefore, 25(OH) D3 enriched or fortified 
foods should be explored more in the future, and additional RCTs should be conducted to 
investigate the effect of 25(OH) D3 enriched or fortified foods on vitamin D status of the 
general population and patients with long-term health conditions.  
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Table 1. Summary of enrichment studies investigating the impact of vitamin D supplemental poultry feeding on vitamin D content of egg yolk. 
             Vitamin D supplement (IU/kg)  Vitamin D concentration of egg yolk (µg/100g) 
References Vitamin D3 25(OH)D3  Feeding duration (weeks) Vitamin D3 25(OH)D3 
(Mattila et al, 1999) [27] 1,064 - 6 1.4 0.5 
 2,496 - 6 3.5 0.9 
 8,640 - 6 22.0 1.5 
(Matila et al, 2003) [28] 11,200 - 4 30.0 1.9 
(Mattila et al, 2004) [29] 2,500 - 4 3.8 - 
 6,000 - 4 13.6 - 
 15,000 - 4 33.7 - 
(Browning et al, 2014) 2,500 - 9 6.5 1.6 
[32] 5,000 - 9 10.5 2.1 
 10,000 - 9 26.2 3.0 
(Yao et al, 2013) 2,200 - 3 3.0 - 
[31] 9,700 - 3 21.6 - 
 17,200 - 3 41.0 - 
 24,700 - 3 60.3 - 
 102,200 - 3 870.4 - 
(Browning et al, 2014) 2500 0 9 6.5 1.6 
[32] 2500 1380 9 6.0 3.3 
 2500 2760 9 4.9 4.5 
 5000 0 9 10.5 2.1 
 5000 1380 9 7.4 4.5 
 5000 2760 9 8.1 5.8 
 10,000 0 9 26.2 3.0 
 10,000 1380 9 23.6 3.7 
 10,000 2760 9 30.9 8.1 
(Mattila et al, 2011) - 2200 6 ≤ 0.2 2.1 
[30] - 4880 6 ≤ 0.2 4.3 
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Table 2. Summary of enrichment studies investigating the impact of vitamin D supplemental fish’s feeding on vitamin D content of fish. 
1Estimated from graph  
 
                                           Supplements to feeding  
References Vitamin D3 supplement (IU/kg) Feeding duration (weeks) Vitamin D3 of fish (µg/100g) 
  (Horvli et al, 1998) 1600 11 1 (fillet) 
  [34] 88400 11 21 (fillet) 
  
 
1147200 11 210 (fillet) 
  (Vielma et al, 1998) 2500 12 1.3 (liver)   
[35] 250000 12 73 (liver)   
 2500000 12 6900 (liver)   
(Mattila et al, 1999) 3560 16 5.7-15.4 (fish fillet) 
  [36] 6960 16 6.1-9.9 (fish fillet) 
  
 
21560 16 7.1-15.6 (fish fillet) 
  (Graff et al, 2002) 8000 9 ≤25 (whole fish)1 
  [37] 200000 9 80 (whole fish)1   
 2280000  9 650 (whole fish)1   
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Table 3. Summary of enrichment studies investigating the impact of vitamin D supplements to bovine’s feeding on vitamin D content of milk. 
References  Supplements to feeding (IU/day) Vitamin D concentration of milk (IU/L) 
Vitamin D3 25(OH)D3 Feeding duration Vitamin D3 25(OH)D3 1,25(OH)2D3 
(Hollis et al, 1981)1 4000  NA 1.72 14.88 0.22 
[39] 40000  NA 12.88 27.40 0.17 
(Reeve et al, 1982)1 [40] 15000  30 days 11.2 5.8 0.2 
(Mcdermott et al, 1985) 0    14 weeks2 3 10 4 
[41] 10,000  14 weeks 8 17 1 
 50,000  14 weeks 6 30 5 
 250,000  14 weeks 13 37 4 
(Weiss et al, 2015) 18,000 - 13 days before calving 13.0-18.8 14.3-40.8 - 
[42] - DCAD3+240,000 13 days before calving - 24.3-147.6 - 
1Feeding duration of pre-calving or post-calving are unknown. 
2 Including two weeks before calving and 12 weeks after calving. 
3 DCAD: dietary cation-anion difference of -138 mEq/kg.  
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Table 5. Summary of randomized controlled trials with both 25(OH) D3 and vitamin D3 in adults to calculate the relative effectiveness of 25(OH)D3 and 
vitamin D3 supplementation in raising serum 25(OH)D level. 
 
References Treatment (dose, duration) serum 25(OH)D raising (nmol/L) per 1 µg 1 Relative effectiveness 2 
(Cashman et al, 2012) [51] 20 µg 25(OH)D3/d × 10 weeks  4.82 
a 4.99 
 
20 µg vitamin D3/day × 10 weeks  0.97 
b 
 (Jetter et al,2014) [52] 20 µg 25(OH) D3/d × 15 weeks  7.12 
a 3.40 
 
20 µg vitamin D3/d × 15 weeks  2.51 
b 
 (Catalano et al, 2015) [54] 140 µg 25(OH) D3/week × 24 weeks 0.50 
a 7.14 
 
140 µg vitamin D3/week × 24 weeks 0.07 
b 
 (Navarro-Valverde et al, 2016) 20 µg 25(OH)D3 /d × 6 months  6.19 
a 3.13 
[56] 20 µg vitamin D3/d × 6 months  1.98 
b 
 
 
20 µg 25(OH)D3/d × 12 months  7.54 
a 3.29 
  20 µg vitamin D3/d × 12 months  2.29 
b   
1 Serum 25(OH) raising (nmol/L) per microgram supplementation = (endpoint serum 25(OH) D - baseline serum 25(OH) D)/dose)  
2 Relative effectiveness=a/b within same study 
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Chapter 3 - Vitamin D intake and risk of cardiovascular diseases and all-
cause mortality: evidence from the Caerphilly Prospective Cohort Study. 
 
The present chapter aims to examine the effect of dietary vitamin D intake on CVD events 
and all-cause mortality in epidemiological study- evidence from Caerphilly Cohort. 
 
JG, JAL, DIG designed the study; JG conducted the research and wrote the manuscript. JRC, 
PCE and JEP contributed to the interpretation of the findings.
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Abstract 
Background: Prospective data on the associations between vitamin D dietary intake and risk 
of cardiovascular disease (CVD) and all-cause mortality are limited and inconclusive. 
Objectives: To comprehensively investigate the associations between vitamin D dietary 
intake and CVD risk and all-cause mortality. 
Methods: Vitamin D dietary intake was assessed in 452 healthy men who were free from 
CVD and type 2 diabetes at baseline (1979-1983 years) in the Caerphilly Prospective Cohort 
Study (CAPS). The associations of vitamin D dietary intake and CVD risk markers were 
examined cross-sectionally at baseline and longitudinally at the 5 year, 10 year and over 20 
year follow-up examinations. Also, the predictive value of vitamin D dietary intake for 
cardiovascular events and all-cause mortality at 20 years was examined. 
Results: After 20 years follow-up, 72 stroke cases, 142 myocardial infarctions (MI), 43 heart 
failures and 281 cases of all-cause mortality were identified. There was no significant 
association between vitamin D dietary intake and stroke, MI, heart failure or all-cause 
mortality. However, higher vitamin D dietary intake was associated with a decreased 
concentration of plasma triacylglycerol at baseline and 5-years examination. In addition, a 
modest positive association was found between vitamin D dietary intake and diastolic blood 
pressure (DBP) after 20-years follow-up.   
Conclusions: The results of the current study suggest that a higher vitamin D dietary intake is 
associated with a lower plasma triacylglycerol level and a higher DBP. Further research is 
needed to confirm these findings.  
Key words: vitamin D, cardiovascular disease, all-cause mortality, Caerphilly Prospective 
Study, blood pressure, triacylglycerol 
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Introduction   
Cardiovascular disease (CVD) is one of the main causes of morbidity and mortality in the 
world. There is mounting evidence indicating an association between vitamin D deficiency 
and CVD (1-4). Recently, the UK Scientific Advisory Committee on Nutrition (SACN) (5) 
reported that in the UK 22-24% of individuals of 19-64 years, and 17-24% of those ≥65 years 
and above were vitamin D deficient (plasma 25(OH) D3 <25 nmol/L). Humans obtain vitamin 
D generally from synthesis in the skin due to sunlight ultraviolet radiation and/or foods. 
However, a number of relatively recent lifestyle changes (e.g. increased working indoors, 
sunscreen use), personal characteristics (ageing, skin pigmentation) and geographic reasons 
(latitude), limit the ability to synthesise adequate vitamin D from sunlight (6). As a result 
vitamin D intake from foods has become more important than previously. This has led SACN 
to recommend a daily intake of 10 g/day of vitamin D in all adults within the UK (5). 
The association between vitamin D deficiency and increased risk of CVD (1-4) and all-
cause mortality (7-9) has been investigated, but few prospective cohort studies have analysed 
the relationship between dietary vitamin D intake and CVD risk and all-cause mortality. In a 
10-year cohort of 361 men and 394 women (10), dietary vitamin D intake was shown to have 
a protective association for stroke, but not myocardial infraction (MI). Another women’s 
cohort study (11) reported no association between vitamin D dietary intake and all-cause 
mortality. As the evidence on the association of vitamin D dietary intake and CVD risk or all-
cause mortality from prospective cohort studies is limited, we therefore investigated the 
associations between dietary vitamin D intake and CVD events, CVD risk markers and all-
causer mortality using the Caerphilly Prospective Cohort Study (CAPS) which has over 20 
years of follow-up.  
 
Methods 
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Study population  
CAPS was initially set up in 1979-1983 to investigate the CVD risk factors based on 2512 
men (45-59 years), representing 89% of the subjects living in Caerphilly and the adjacent area 
(12), which were followed up at 5-year intervals. At Phase 2 (1984-1988), 561 men were lost 
from Phase 1 (1979-1983) and an additional 447 men were recruited to follow-up. In Phase 1, 
a representative 30% subsample of subjects (665 men) was randomly selected at baseline to 
complete a 7-day weighed dietary intake record (13). Food items were coded according to 
McCance and Widdowson (14). These men were given weighing scales with instructions on 
how to complete the weighed dietary intake for seven consecutive days. From these records 
the dietary vitamin D intake was estimated based on food composition data given by 
McCance and Widdowson (14), additionally, several manufacturers were contacted to obtain 
more information on new foodstuffs containing mixtures of ingredients (13,15). In order to 
ensure consistency of the subject group throughout the study, the 134 men from the weighed 
intake sub-group who dropped out after Phase 1 were excluded from this analysis. In addition, 
17 subjects who previously had a heart attack and subjects (n=62) with missing confounding 
factor data were excluded. Therefore, a total of 452 subjects were available for the current 
analysis.  
 
Cardiovascular disease events and all-cause mortality 
Identification of stroke and vascular disease events was described elsewhere (16, 17). In brief, 
incidents of all-cause mortality were censored by central Registry NHS in the UK. 
Identification of fatal and non-fatal vascular disease events (ICD 121-5, 10th revision) 
including MI, heart failure and stroke (IC 163-4) were according to established criteria (16, 
17). Fasting blood samples were taken at baseline and every five years to measure a wide 
range of CVD risk markers (12). At baseline (Phase 1), at 5-years (Phase 2) and at 10-years 
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(Phase 3) examinations, plasma glucose, total-cholesterol and triacylglycerol were measured 
together with systolic blood pressure (SBP) and diastolic blood pressure (DBP). Insulin and 
HDL-cholesterol were only measured in Phase 1 and 2. In Phase 5, the haemodynamic 
variables of SBP, DBP, aortic pulse wave velocity (aPWV), augmentation index (AIx) and 
mean arterial pressure were measured, the details are described elsewhere (18,19). Pulse 
pressure was calculated by subtracting DBP from SBP. The Friedewald formula (20) was 
used to calculate LDL-cholesterol. 
 
Statistics 
Data were analysed using STATA (version 13.0; STATA Corporation, 2014). The subjects 
were divided into four groups according to dietary vitamin D intake. For the analysis of 
baseline, 5-years and 10-years examinations, logistic regression and general linear regression 
statistic models were used to investigate the relationships of vitamin D intake with categorical 
and continuous variables of CVD risk markers, respectively. In addition, logistic regression 
analyses were used to estimate the odds ratio of stroke, MI, heart failure and all-cause 
mortality for the longitudinal analysis. The multivariate-adjusted model for all of the analyses 
first included confounding factors of age (years); body mass index (BMI, kg/m2); social class 
(manual worker; non-manual worker), smoking (current smoker, never-smoked, ex-smoker), 
leisure activity (with heavy work or exercise in leisure time, without heavy work or exercise 
in leisure time), alcohol (as ethanol, ml/week) and food energy intake (MJ/day). In addition, 
as vitamin D is closely functionally related with calcium, the second multivariate-adjusted 
model was further adjusted with calcium dietary intake. Results were considered statistically 
significant at P=0.05 or less.  
 
Results 
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The characteristics of the 452 subjects at baseline are shown in Table 1. The average vitamin 
D intake was 21.0 (SD=19.3) µg per week. Subjects in the lowest quartiles of vitamin D 
intake were significantly more likely to be smokers (P=0.001) and had higher food energy 
intake (P<0.001). After controlling for total energy intake from foods, those with the highest 
vitamin D intake per week tended to have a higher intake of fat (P=0.002), cereal fibre 
(P<0.001), vegetable fibre (P<0.001), and calcium (P<0.001). There were no associations 
between dietary vitamin D intake and age, BMI, social class, leisure activity, alcohol 
consumption, protein intake and carbohydrate intake. 
   Associations of vitamin D intake with different CVD risk markers were investigated at 
baseline as a cross-sectional analysis (Phase 1). There was a significant positive association 
between vitamin D intake and HDL-cholesterol (adjusted model 2 P=0.002; adjusted model 3 
P=0.003) (Table 2), with subjects consuming highest vitamin D intake (≥27.3 µg/week) 
having 0.13 mmol/L higher HDL-cholesterol levels compared with subjects consuming the 
lowest vitamin D intake (0.1-9.9 µg/week). In addition, negative associations were observed 
between vitamin D intake and total/HDL-cholesterol ratio (adjusted model 2 P=0.005; 
adjusted model 3 P=0.008) and triacylglycerol concentrations (adjusted model 2 P=0.003; 
adjusted model 3 P=0.013) with the subjects consuming ≥ 27.3 µg/week vitamin D having 
0.7 mmol/L lower total/HDL-cholesterol ratio and 0.5 mmol/L lower plasma triacylglycerol 
compared with subjects consuming the lowest vitamin D intake (0.1-9.9 µg/week). In 
addition, a positive association was found between vitamin D intake and pulse pressure 
(adjusted model 2 P=0.026; adjusted model 3 P=0.040).  
   In the longitudinal analyses of vitamin D intake and CVD risk markers at the 5-year 
examination (Phase 2), higher vitamin D intake was significantly negatively associated with 
plasma triacylglycerol concentrations (adjusted model 2 P=0.003; adjusted model 3 P=0.010) 
(Table 3). The highest vitamin D intake group had 0.48 mmol/L lower plasma triacylglycerol 
 
 
44 
 
than the lowest vitamin D intake group. There were no significant associations between 
vitamin D intake and other CVD risk markers at the 5-year examination. In the longitudinal 
analyses at the 10-year examination (Phase 3), only a modest negative association (P=0.056) 
was found between higher vitamin D intake and plasma triacylglycerol in the un-adjusted 
model but not in the multivariable adjusted models (Table 4).  
After over 20-years follow-up (Phase 5), a tendency for a lower pulse pressure was seen in 
those with the highest vitamin D intake, but this did not reach significance (Table 5). In the 
analysis of the associations of SBP and DBP with vitamin D intake,  DBP showed a positive 
correlations with vitamin D intake in the multivariate adjusted models (P=0.041 model 2, 
P=0.029 model 3), but no significant associations were found between vitamin D intake and 
SBP.  
There were no significant associations between dietary vitamin D intake and other CVD 
risk markers, i.e. fasting glucose/insulin (Supplemental material), mean arterial pressure, 
pulse wave velocity and augmentation index (Table 5). Also there were no significant 
associations of vitamin D dietary intake and cardiovascular events (stroke, MI, heart failure) 
or all-cause mortality after over the 20-years follow-up (Table 6). 
 
Discussion 
In this UK prospective cohort study of middle aged men with over 20 years follow-up, we 
found higher dietary vitamin D intake was associated with lower plasma triacylglycerol 
concentrations at baseline and the 5-year examination, but not 10-year examinations. In 
addition, baseline cross-sectional analysis indicated significant positive associations between 
vitamin D intake and HDL-cholesterol and pulse pressure, with a negative association 
between vitamin D intake and total/HDL-cholesterol ratio. After over 20 years follow up, a 
modest positive association was found between vitamin D dietary intake and DBP. In 
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contrast, no associations were found between vitamin D and other metabolite markers or 
disease outcomes of stroke, MI, heart failure and all-cause mortality. 
To our knowledge, this is the first prospective study to investigate the associations between 
dietary vitamin D intake and blood lipid profiles in a generally healthy population using both 
cross-sectional and longitudinal analyses. The negative association between dietary vitamin D 
intake and plasma triacylglycerol at baseline and 5-years examination agrees with the results 
of a 6-month randomized controlled trial (21) in post-menopausal women with type 2 
diabetes, which showed that a daily 100 µg dose of vitamin D3 significantly decreased the 
concentration of serum triacylglycerol (by 1.9 mmol/L, P=0.021). However, it is not clear 
why the negative association between vitamin D dietary intake and plasma triacylglycerol was 
found at the 5-year, but not the 10-year of the longitudinal examination. One possible reason 
may due to dietary change during the follow-up. One study (22) showed that there has been a 
trend towards a lower fat diet in UK since the 1980s. As vitamin D is fat soluble vitamin (5), 
it is likely that vitamin D intake has also declined and indeed the current study showed dietary 
vitamin D intake to be positively associated with fat intake. So the lack of association 
between dietary vitamin D intake and 10-year triacylglycerol examination may due to dietary 
vitamin D intake having declined during the follow up. In addition, our study is the first to 
show a significant positive cross-sectional association between vitamin D intake and pulse 
pressure, but no association was seen in the longitudinal analysis. In the analysis of the 
association between vitamin D and SBP or DPB, the only significant finding was a positive 
association between vitamin D intake and DBP after the 20-year follow-up and which needs 
confirmation in further studies. 
There are very few studies that have reported associations between dietary vitamin D 
intake and CVD risk or all-cause mortality. Our null finding of dietary vitamin D agree with 
an earlier prospective study of the Iowa Women’s Healthy Study (WHS) in 1999 (11), which 
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also found no association between dietary vitamin D intake and ischaemic heart disease 
mortality over an 8-year follow-up period. However, vitamin D dietary intake (4.30±3.3 
µg/day) was reported in another 10 year follow-up prospective study of 361 men and 394 
women (10) and suggested a protective role of dietary vitamin D intake on stroke but not MI. 
The different conclusions of the above studies may be due to the different characteristics of 
the study participants. For example, the mean initial age of the subjects in the CAPS (mean 
age of 51.7 years) and WHS (mean age of 53.8 years) were similar, but higher (age range of 
65-99 years) in the investigation of Marniemi et al. (10). Furthermore, our study agrees with a 
systematic review of 56 randomised controlled trails, which did not find a significant 
association between vitamin D supplementation and total mortality risk (23).  
The recent report of the UK Scientific Advisory Committee on Nutrition (5) recommended 
a daily Reference Nutrient Intake (RNI) of 10 µg vitamin D for the general population aged 4 
years and above, including pregnant and lactating women. In CAPS, only 11 out of 452 
subjects achieved the current RNI dose. Therefore, the effect of dietary vitamin D may have 
been minimised by the low dietary vitamin D intake. However, a few recent studies have used 
higher doses of vitamin D in their intervention trials (24-26), which also showed no 
associations of vitamin D supplementation with markers of CVD risk.  
The strength of the CAPS is the long (over 20 years) follow-up period. This novel study 
presents both cross-sectional and longitudinal relationships between dietary vitamin D intake 
and CVD events. The longitudinal analysis was conducted at 5, 10 and over 20 years which 
provide the opportunity to test the consistency of the influence of vitamin D intake on CVD 
events. There are however several limitations of this study. First, vitamin D dietary intake was 
only assessed at baseline, and was not repeated in the other phases to assess the extent of any 
diet change. Second, the results apply to men only, which may not represent the effect in 
women. Finally, unknown residual confounding factors may have influenced the outcomes 
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seen. In particular, the vitamin D status of the subjects was not measured initially and during 
the follow-up of CAPS and there were no assessments of sunshine exposure. In addition, 
because the small cohort size of the current study may not be representative all of UK men, 
further prospective studies with large subject numbers can provide more evidence on effect of 
the vitamin D dietary intake on CVD risk and/or all-cause mortality. 
 
Conclusion 
The current investigation from CAPS prospective cohort study provides further evidence for 
the potential benefits of vitamin D intake on circulating triacylglycerol concentrations at 
baseline and also the 5-years examination. After over 20 years follow-up, higher vitamin D 
dietary intake is associated with a higher DBP. Future studies are needed to verify the current 
findings, especially randomised controlled intervention trials on the effect of dietary vitamin 
D intake on CVD risk markers in subjects of low vitamin D status. 
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Table 1. Baseline characteristics (n=452) of participants by category of vitamin D intake1.   
 
Vitamin D intake from foods (µg/week) 
 Characteristics 0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend2 
Subjects, n  114 112 114 112 
 Age, y 52±4.5 52±4.1 51±4.4 52±4.6 0.738 
BMI, kg/m2 26.3±3.1 25.9±3.1 26.3±3.6 26.1±3.1 0.781 
Leisure activity, % 43.9 52.7 50.0 57.1 0.077 
Manual workers, % 68.4 49.1 63.2 70.5 0.327 
Current smokers, % 64.9 58.0 50.9 44.6 0.001 
Energy intake, MJ/d 6.46±1.74 7.25±1.60 7.34±1.55 7.55±1.51 <0.001 
Fat, % of food energy 36.0±6.2 36.5±6.0 38.1±4.8 37.9±5.1 0.002 
Protein, % of food energy* 13.9±2.7 13.5±2.3 13.8±2.4 14.0±2.4 0.247 
Carbohydrate, % of food energy* 45.7±8.2 46.1±7.5 46.6±5.8 45.0±6.6 0.604 
Alcohol intake, ml ethanol/wk& 37.0±62.7 32.2±38.7 21.7±27.7 29.0±35.0 0.114 
Fibre (vegetable sources), g/d& 8.5±0.3 8.4±0.2 8.4±0.3 8.6±0.3 <0.001 
Fibre (cereal sources), g/d& 7.3±1.4 7.9±1.1 8.1±1.2 9.1±1.2 <0.001 
Calcium intake, mg/week& 5567±268 6343±200 6335±225 6613±224 <0.001 
* Original data were transformed to natural logarithms for regression model. 
& Data were adjusted with energy intake from foods. 
1 All values are mean ± SD. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables). 
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Table 2. Cross-sectional analysis between baseline (Phase 1) vitamin D intake and markers of CVD risk1. 
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Total cholesterol       
    Participants, n 114 112 114 112  
    Mean, mmol/L 5.98±1.11 5.99±1.56 5.93±1.08 5.81±0.94  
    Unadjusted Coef.  ref 0.001 -0.053 -0.174 0.254 
    Multivariable-adjusted Coef.2 ref 0.012 -0.025 -0.109 0.487 
    Multivariable-adjusted Coef.3 ref 0.029 -0.007 -0.083 0.588 
HDL-cholesterol      
    Participants, n 112 110 113 111  
    Mean, mmol/L 1.29±0.37 1.32±0.34 1.40±0.40 1.42±0.41  
    Unadjusted Coef.  ref 0.025 0.104 0.122 0.006 
    Multivariable-adjusted Coef.2 ref 0.023 0.129 0.134 0.002 
    Multivariable-adjusted Coef.3 ref 0.020 0.126 0.131 0.003 
Total/HDL-cholesterol*      
    Participants, n 112 110 113 111  
    Mean, mmol/L 5.13±2.40 4.83±1.92 4.53±1.35 4.43±1.42  
    Unadjusted Coef.  ref -0.045 -0.094 -0.120 0.004 
    Multivariable-adjusted Coef.2 ref -0.039 -0.102 -0.112 0.005 
    Multivariable-adjusted Coef.3 ref -0.035 -0.098 -0.107 0.008 
LDL-cholesterol      
    Participants, n 112 108 103 109  
    Mean, mmol/L 4.30±1.12 4.28±1.51 4.21±1.08 4.09±0.98  
    Unadjusted Coef.  ref -0.017 -0.087 -0.202 0.182 
    Multivariable-adjusted Coef.2 ref -0.018 -0.089 -0.159 0.298 
    Multivariable-adjusted Coef.3 ref -0.007 -0.077 -0.142 0.352 
Triacylglycerol*      
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    Participants, n 112 108 113 110  
    Mean, mmol/L 2.06±1.20 1.81±1.21 1.62±0.91 1.56±0.98  
    Unadjusted Coef.  ref -0.130 -0.206 -0.262 <0.001 
    Multivariable-adjusted Coef.1 ref -0.098 -0.163 -0.214 0.003 
    Multivariable-adjusted Coef.2 ref -0.075 -0.138 -0.180 0.013 
Systolic blood pressure      
    Participants, n 114 112 114 112  
    Mean, mmHg 140.5±20.9 139.8±18.1 141.6±20.1 140.6±17.0  
    Unadjusted Coef.  ref -0.678 1.114 0.045 0.810 
    Multivariable-adjusted Coef.1 ref 0.934 2.994 1.123 0.491 
    Multivariable-adjusted Coef.2 ref 1.066 3.136 1.321 0.454 
Diastolic blood pressure      
    Participants, n 114 112 114 112  
    Mean, mmHg 89.4±12.0 90.1±11.7 88.7±12.4 87.4±11.9  
    Unadjusted Coef.  ref 0.615 -0.754 -2.064 0.137 
    Multivariable-adjusted Coef.1 ref 1.237 -0.471 -1.935 0.146 
    Multivariable-adjusted Coef.2 ref 1.567 -0.113 -1.438 0.247 
Pulse Pressure      
    Participants, n 114 112 114 112  
    Mean, mmHg 51.1±14.5 49.8±13.6 53.0±13.2 53.2±13.8  
    Unadjusted Coef.  ref -1.293 1.868 2.109 0.104 
    Multivariable-adjusted Coef.1 ref -0.303 3.465 3.058 0.026 
    Multivariable-adjusted Coef.2 ref -0.501 3.250 2.760 0.040 
* Original data were transformed to natural logarithms for regression model. 
1 All values are mean ± SD. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake.  
3 Additionally adjusted for calcium intake.  
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Table 3. Longitudinal analysis between baseline (Phase 1) vitamin D intake and markers of CVD risk after 5 years of follow-up1. 
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Total cholesterol       
    Participants, n 109 110 111 109  
    Mean, mmol/L 5.67±0.96 5.62±1.08 5.68±0.97 5.60±0.84  
    Unadjusted Coef.  ref -0.045 0.018 -0.068 0.733 
    Multivariable-adjusted Coef.2 ref -0.018 0.042 -0.025 0.976 
    Multivariable-adjusted Coef.3 ref 0.027 0.086 0.038 0.687 
HDL-cholesterol      
    Participants, n 109 110 111 109  
    Mean, mmol/L 0.98±0.26 1.03±0.23 1.06±0.23 1.00±0.26  
    Unadjusted Coef.  ref 0.046 0.078 0.018 0.419 
    Multivariable-adjusted Coef.2 ref 0.034 0.080 0.010 0.464 
    Multivariable-adjusted Coef.3 ref 0.034 0.080 0.011 0.466 
Total/HDL-cholesterol*      
    Participants, n 109 110 111 109  
    Mean, mmol/L 6.23±2.24 5.77±1.75 5.66±1.75 5.98±1.73  
    Unadjusted Coef.  ref -0.070 -0.084 -0.030 0.415 
    Multivariable-adjusted Coef.2 ref -0.051 -0.081 -0.015 0.560 
    Multivariable-adjusted Coef.3 ref -0.044 -0.073 -0.004 0.751 
LDL-cholesterol      
    Participants, n 109 110 111 109  
    Mean, mmol/L 4.23±0.90 4.17±0.99 4.28±0.96 4.24±0.81  
    Unadjusted Coef.  ref -0.062 0.047 0.010 0.722 
    Multivariable-adjusted Coef.2 ref -0.051 -0.081 -0.015 0.560 
    Multivariable-adjusted Coef.3 ref -0.044 -0.073 -0.004 0.751 
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Triacylglycerol*      
    Participants, n 109 110 111 109  
    Mean, mmol/L 2.27±1.66 2.13±1.41 1.74±0.77 1.79±1.05  
    Unadjusted Coef.  ref -0.078 -0.194 -0.197 0.001 
    Multivariable-adjusted Coef.2 ref -0.049 -0.172 -0.173 0.003 
    Multivariable-adjusted Coef.3 ref -0.032 -0.154 -0.148 0.010 
Systolic blood pressure      
    Participants, n 113 109 113 111  
    Mean, mmHg 148.9±26.8 146.8±0.3 144.9±22.6 145.5±21.2  
    Unadjusted Coef.  ref -2.032 -3.973 -3.417 0.206 
    Multivariable-adjusted Coef.2 ref -0.233 -2.185 -2.083 0.403 
    Multivariable-adjusted Coef.3 ref -0.201 -2.150 -2.034 0.419 
Diastolic blood pressure      
    Participants, n 113 109 113 111  
    Mean, mmHg 86.2±12.3 84.3±10.7 84.1±10.9 83.0±11.9  
    Unadjusted Coef.  ref -1.873 -2.133 -3.194 0.042 
    Multivariable-adjusted Coef.2 ref -1.475 -1.865 -2.793 0.080 
    Multivariable-adjusted Coef.3 ref -1.340 -1.718 -2.587 0.112 
Pulse Pressure      
    Participants, n 113 109 113 111  
    Mean, mmHg 62.7±20.0 62.5±16.1 60.8±18.2 62.4±16.0  
    Unadjusted Coef.  ref -0.159 -1.840 -0.222 0.750 
    Multivariable-adjusted Coef.2 ref 1.242 -0.320 0.711 0.938 
    Multivariable-adjusted Coef.3 ref 1.139 -0.432 0.553 0.995 
* Original data were transformed to natural logarithms for regression model. 
1 All values are mean ± SD. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake.  
3 Additionally adjusted for calcium intake.  
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Table 4. Longitudinal analysis between baseline (Phase 1) vitamin D intake and markers of CVD risk after 10 years of follow-up1.
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Table 5. Longitudinal analysis between baseline (Phase 1) vitamin D intake and markers of CVD risk after over 20 years of follow-up1. 
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Mean Arterial Pressure, 
         Participants, n 43 43 47 41  
    Mean, mmHg 96.35±10.19 96.07±14.07 99.63±13.09 95.64±13.70  
    Unadjusted Coef.  ref -0.284 3.279 -0.702 0.824 
    Multivariable-adjusted Coef.2 ref 0.326 3.919 1.000 0.417 
    Multivariable-adjusted Coef.3 ref 0.985 4.556 1.937 0.275 
Pulse wave velocity      
    Participants, n 43 45 47 39  
    Mean, m/s 11.89±2.61 11.40±2.82 11.77±2.71 11.48±2.78  
    Unadjusted Coef.  ref -0.495 -0.123 -0.411 0.663 
    Multivariable-adjusted Coef.2 ref -0.413 0.052 -0.098 0.889 
    Multivariable-adjusted Coef.3 ref -0.339 0.124 0.009 0.756 
Augmentation index      
    Participants, n 43 46 47 41  
    Mean 27.35±8.49 25.30±10.68 27.04±8.81 24.70±9.26  
    Unadjusted Coef.  ref -2.044 -0.306 -2.654 0.355 
    Multivariable-adjusted Coef.2 ref -2.147 -0.370 -4.051 0.097 
    Multivariable-adjusted Coef.3 ref -1.389 0.363 -2.971 0.267 
Systolic blood pressure 
    Participants, n 43 46 47 41  
    Mean, mmHg 143.3±16.2 141.9±18.6 143.7±20.9 139.8±20.3  
    Unadjusted Coef.  ref -1.368 0.379 -3.522 0.519 
    Multivariable-adjusted Coef.2 ref -0.055 1.225 -1.464 0.864 
    Multivariable-adjusted Coef.3 ref 0.971 2.218 -0.003 0.894 
Diastolic blood pressure 
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    Participants, n 43 46 47 41  
    Mean, mmHg 72.3±9.2 72.2±11.5 76.1±10.4 74.3±12.0  
    Unadjusted Coef.  ref -0.128 3.847 1.966 0.170 
    Multivariable-adjusted Coef.2 ref 0.141 4.378 3.574 0.041 
    Multivariable-adjusted Coef.3 ref 0.456 4.683 4.023 0.029 
Pulse pressure* 
    Participants, n 43 46 47 41  
    Mean, mmHg 71.0±15.8 69.8±14.4 67.5±17.1 65.5±17.9  
    Unadjusted Coef.  ref -0.013 -0.055 -0.087 0.064 
    Multivariable-adjusted Coef.2 ref 0.004 -0.047 -0.080 0.075 
    Multivariable-adjusted Coef.3 ref 0.014 -0.037 -0.066 0.130 
* Original data were transformed to natural logarithms for regression model. 
1 All values are mean ± SD. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake, heart rate, vaso-active 
medication. 
3 Additionally adjusted for calcium intake.  
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Table 6. Longitudinal analysis between baseline (Phase 1) vitamin D intake and cardiovascular disease risk after over 20 years of follow-up1.
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Supplemental Table 1. Cross-sectional analysis between baseline (Phase 1) vitamin D intake and plasma glucose and insulin1. 
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Fasting glucose 
         Participants, n 113 113 113 113  
    Mean, mmol/L 4.90±1.02 5.07±1.81 4.86±0.66 4.93±1.17  
    Unadjusted Coef.  ref 0.171 -0.038 0.024 0.794 
    Multivariable-adjusted Coef.2 ref 0.174 -0.022 0.068 0.989 
    Multivariable-adjusted Coef.3 ref 0.176 -0.019 0.071 0.989 
Insulin*      
    Participants, n 92 104 101 104  
    Mean, mmol/L 1.08±2.24 1.09±3.10 1.07±4.32 0.76±0.88  
    Unadjusted Coef.  ref 0.037 -0.128 -0.086 0.233 
    Multivariable-adjusted Coef.2 ref 0.043 -0.124 -0.042 0.406 
    Multivariable-adjusted Coef.3 ref 0.056 -0.109 -0.020 0.520 
*original data is transformed to natural logarithms for regression model. 
1 All values are mean ± SD. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake.  
3 Additionally adjusted for calcium intake.  
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Supplemental Table 2. Longitudinal analysis between baseline (Phase 1) vitamin D intake and plasma glucose and insulin after 5 years of follow-up1. 
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Fasting glucose 
         Participants, n 109 110 111 109 
    Mean, mmol/L 5.39±1.09 5.63±2.03 5.14±0.64 5.35±1.28  
    Unadjusted Coef.  ref 0.243 -0.247 -0.036 0.302 
    Multivariable-adjusted Coef.2 ref 0.307 -0.231 -0.018 0.317 
    Multivariable-adjusted Coef.3 ref 0.322 -0.216 0.004 0.362 
Insulin*      
    Participants, n 49 43 52 47  
    Mean, mmol/L 2.85±2.12 3.70±1.76 3.42±2.99 3.54±2.35  
    Unadjusted Coef.  ref 0.501 0.313 0.361 0.050 
    Multivariable-adjusted Coef.2 ref 0.481 0.280 0.358 0.055 
    Multivariable-adjusted Coef.3 ref 0.463 0.225 0.314 0.126 
*original data is transformed to natural logarithms for regression model. 
1 All values are mean ± SD. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake.  
3 Additionally adjusted for calcium intake.  
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Supplemental Table 3. Longitudinal analysis between baseline (Phase 1) vitamin D intake and plasma glucose after 10 years of follow-up1.  
 
Vitamin D intake from foods (µg/week) 
 
 
0.1-9.9 10-15.1 15.2-27.2 ≥27.3 P for trend 
Fasting glucose 
         Participants, n 86 96 99 99  
    Mean, mmol/L 5.49±1.22 5.73±1.82 5.74±1.98 5.86±1.95  
    Unadjusted Coef.  ref 0.238 0.245 0.372 0.182 
    Multivariable-adjusted Coef.2 ref 0.238 0.241 0.443 0.118 
    Multivariable-adjusted Coef.3 ref 0.246 0.250 0.458 0.112 
1 All values are mean ± SD; Insulin was not available at 10 years examination. 
2 Multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided 
into 3 equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no), food energy intake.  
3 Additionally adjusted for calcium intake.  
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Chapter 4 - Egg consumption and cardiovascular disease events, diabetes 
and all-cause mortality: evidence from Caerphilly Prospective Cohort 
Study (CAPS) and National Diet and Nutritional Survey (NDNS) (Abstract has 
been published at the ‘Nutrition Society’s 2015 summer meeting (Appendix-1)). 
 
The present chapter aims to examine the effect of egg consumption on cardiovascular disease 
(CVD) events and diabetes in epidemiological study- evidence from Caerphilly Cohort. 
 
JAL and DIG designed the research; JG and DAH conducted the research; JG and DAH 
analysed the data with guidance from JEP; JG, DAH, DIG and JAL wrote the paper; PCE and 
JRC contributed expertise on epidemiology and CVD respectively. DIG and JAL had primary 
responsibility for the final content of the manuscript. All authors read and approved the final 
manuscript. All authors critically reviewed and approved. Abstract has been published at the 
‘Nutrition Society’s 2015 summer meeting (Appendices-1). Full paper of the revision version 
has been submitted to journal. 
 
 
 
 
 
 
 
 
 
65 
 
Association between egg consumption and cardiovascular disease events, diabetes and 
all-cause mortality 
 
Jing Guo, Ditte A Hobbs, John R Cockcroft, Peter C Elwood, Janet E Pickering, Julie A 
Lovegrove and David I Givens 
 
1 From the Institute for Food, Nutrition and Health (JG, JEP, JAL, DIG), the Hugh Sinclair 
Unit of Human Nutrition (DAH, JAL) and the Institute for Cardiovascular and Metabolic 
Research (JG, DAH, DIG, JAL) University of Reading, Reading, RG6 6AR, United 
Kingdom; Wales Heart Research Institute (JRC), and Department of Primary Care and Public 
Health (PCE), Cardiff University, United Kingdom. 
2 Address correspondence to Julie A. Lovegrove, Hugh Sinclair Unit of Human Nutrition and 
Institute for Cardiovascular and Metabolic Research, University of Reading, University of 
Reading, Reading, RG6 6AR, United Kingdom. E-mail: j.a.lovegrove@reading.ac.uk. 
3 Supported by the Barham Benevolent Foundation.  
4 Abbreviations used: CVD: cardiovascular disease; MI: myocardial infarction; T2D: type 2 
diabetes; IGT: impaired glucose tolerance; CAPS: Caerphilly prospective cohort study; 
NDNS: national diet and nutrition survey; FFQ: food-frequency questionnaire; RCT: 
randomized controlled trials; SBP: Systolic blood pressure; DBP: diastolic blood pressure; 
TGs: triacylglycerol; CRP: C-reactive protein; HbA1c: glycated haemoglobin; ICD: 
International Classification of Diseases; HR: hazard ratio. 
5 Running title: Egg consumption and diabetes and risk of CVD  
6 Author names for indexing: Guo, Hobbs, Cockcroft, Elwood, Pickering, Lovegrove and 
Givens 
7 Word count: 5564 
8 Conflict of Interest: the authors declare that they have no conflict of interest. 
 
 
66 
 
Abstract 
Purpose The association between egg consumption and cardiovascular disease (CVD) or type 
2 diabetes (T2D) remains controversial. We investigated the association between egg 
consumption and risk of CVD, T2D and mortality in the Caerphilly prospective cohort study 
(CAPS) and National Diet and Nutritional Survey (NDNS).  
Methods CAPS included 2512 men aged 45 to 59 years (1979-1983). Dietary intake, disease 
incidence and mortality were updated at 5-year intervals. NDNS included 754 adults aged 19-
64 years from 2008-2012.  
Results Men free of CVD (n=1781) were followed up for a mean of 22.8 years, new incidence 
of stroke (n=248), MI (n=477), heart failure (n=201), mortality (n=1028) and type 2 diabetes 
(T2D) (n=120) was identified. Egg consumption was not associated with incident of MI, heart 
failure, mortality or T2D. In contrast, increased risk of stroke in subjects with T2D and/or 
impaired glucose tolerance (IGT, fasting plasma glucose ≥6.1 mmol/L), adjusted hazard ratios 
(95% CI) were 1.0 (reference), 1.09 (0.41, 2.88), 0.96 (0.37, 2.50), 1.39 (0.54, 3.56) and 2.87 
(1.13, 7.27) for egg intake (n) of 0≤n≤1, 1<n≤2, 2<n≤3, 3<n<5, and n≥5 eggs/wk, 
respectively (P for trend=0.01). In addition, cross-sectional analyses of CAPS and NDNS 
revealed higher egg consumption was significantly associated with elevated fasting glucose in 
those with T2D and/or IGT (baseline P=0.02; 5-year-later examination P=0.04; NDNS 
P=0.01).  
Conclusions Higher egg consumption was associated with higher blood glucose in men with 
T2D and/or IGT. The markedly increased incidence of stroke with higher egg consumption 
among T2D and/or IGT sub-group warrants further investigation.  
 
Key words eggs, cardiovascular disease, type 2 diabetes, impaired glucose tolerance, all-
cause mortality 
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Introduction 
Cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality, and the 
prevalence of type 2 diabetes mellitus (T2D) is also increasing globally. Diet plays an 
important role in prevention and management of both CVD [1] and T2D [2]. Eggs are a good 
source of a number of nutrients in the UK diet such as vitamin D, selenium, vitamin K and 
choline as well as high quality protein [3]. However, eggs also contain relatively large 
amounts of dietary cholesterol (350 mg/100g) [4], which has been associated with impaired 
glucose metabolism [5] and increased inflammation [6] in animal models and with elevated 
fasting glucose in humans [7]. Meta-analyses of intervention studies have shown that 
increased consumption of dietary cholesterol increases serum total, LDL and HDL cholesterol 
concentrations, as well as the ratio of total to HDL cholesterol [8, 9], although Gray and 
Griffin [10] conclude that these changes are small and are not clinically significant. However, 
findings from randomized controlled trials (RCT) investigating the effects of high egg 
consumption on blood lipid have not been consistent. For example, a recent randomized 
controlled trial of 140 overweight or obese subjects with prediabetes or T2D showed that high 
egg consumption (2 eggs/d for 6 d/wk) did not have an adverse effect on lipid profile of those 
with T2D [11]. Furthermore, Fuller et al [11] reported no effect of egg intake and glycemic 
control in this 3 month RCT in T2D, whereas an inverse association between egg intake and 
fasting plasma glucose was reported in a prospective cohort study [12]. 
Evidence from previous meta-analyses in relation to egg consumption and CVD mortality 
showed inconsistent results. Some studies [13, 14] have shown that consumption of up to one 
egg per day is not associated with increased risk of CVD in the general population, which is 
in contrast to a recent meta-analysis which reported up to one egg per day was associated with 
reduced risk of stroke [15]. Furthermore, inconsistent associations between egg intake and 
CVD in diabetic patients where observed. Shin et al [14] concluded egg consumption up to 
one egg per day was associated with an increased risk of CVD in diabetic patients, whereas 
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Rong et al (13) found egg intake up to one egg per day was associated with a reduced risk of 
hemorrhagic stroke in diabetic patients. 
Therefore, our hypothesis was that a higher egg intake is unlikely to increase the risk of 
CVD events (myocardial infarction (MI), stroke, heart failure), T2D or all-cause mortality in 
the general population, but may have detrimental effects in those suffering from T2D. This 
hypothesis was tested by using evidence from the Caerphilly Prospective Cohort Study 
(CAPS) and years 1-4 of the UK National Diet and Nutrition Survey (NDNS).  
 
Subjects and methods 
Study population of Caerphilly Prospective Cohort Study 
The Caerphilly Prospective Cohort Study (CAPS) was set up between 1979 and 1983 and was 
designed to investigate CVD risk factors, there was follow-up of the men and re-examined at 
5-year intervals (Figure 1). Initially, 2512 men aged 45-59 years old living in Caerphilly, 
Wales, United Kingdom and the adjacent area were recruited onto the study [16]. However, 
561 men were lost through attrition after Phase 1 (1979-1983) and an additional group of 447 
men were recruited for replacement, giving a new total of 2398 men at Phase 2 (1984-1988).  
At 5 years later, a total of 2147 men revisited the clinical centre for the Phase 3 examination 
(1989-1993). The current study did not include data from Phase 1, as there were an 
inconsistent number of subjects between Phase 1 and Phase 2.  
 
Dietary assessment 
Diet was assessed at both Phase 2 and Phase 3 with the use of a semi-quantitative food-
frequency questionnaire (FFQ). Participants were asked to report the number of eggs 
consumed on a weekly basis, with one unit of consumption equivalent to one egg. This FFQ 
was previously validated using a 7-day weighed diet diary in a representative sub-group of 
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665 men, representing 30 % of Phase 1 participants [17]. In order to present the best 
estimation of egg consumption, the mean egg intake at Phase 2 and Phase 3 was used for the 
longitudinal analysis, which also allowed estimation of the effect of the cumulative long-term 
diet. Subjects with pre-existing stroke (n=60), MI (n=98), and those with missing data or 
confounding factors (n=208) were excluded from for the longitudinal CVD analysis, which 
left a total of 1781 men. Subjects with pre-existing stroke, MI were also excluded for cross-
sectional analyses at Phase 2 or Phase 3. 
The mean egg intakes at Phase 2 and Phase 3 were calculated for 1781 subjects who 
reported egg consumption in both phases. As egg consumption was not a continuous variable, 
it was divided into categorical variables for the analysis.  
 
Cardiovascular events, diabetes and all-cause mortality 
The incident of T2D was self-reported from questionnaires in the Caerphilly cohort. 
Identification of vascular disease events and deaths by cause has been described elsewhere 
[18-20]. In brief, subjects were seen in Clinics centre, symptoms and illnesses suggestive of a 
stroke or heart attack were confirmed by the use of the London School of Hygiene chest pain 
questionnaire and the Oxford Stroke Questionnaire, subjects also had an electrocardiogram 
measurement during the visit. Appropriate searches of hospital and general practitioner 
databases were made to extract relevant clinical information. Vascular events (International 
Classification of Diseases (ICD) 121-5, 10th revision) of fatal ischaemic heart disease and 
non-fatal MI and ischaemic stroke (ICD 163-4) were diagnosed by two independent expert 
clinicians and an epidemiologist using all available clinical evidence, including computed 
tomography, radiological and pathological information. Furthermore, the records of all men at 
the National Health Service Central Registry were flagged so that notification of death 
certificate was received directly, and cause of death was defined by ICD-9 Revision.  
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The aim of this analysis was to investigate the relationship between egg intake and CVD or 
mortality in the total population, as well as in a sub-group suffering from T2D. After removal 
of 16 subjects with T2D who had missing dietary or confounding factor data, 94 pre-existing 
T2D subjects remained for inclusion in the analysis. In order to have sufficient numbers for 
the statistical analysis, we combined the men with impaired glucose tolerance (IGT; n=319), 
defined by the WHO as fasting plasma glucose of 6.1 mmol/L or higher [21]. Subjects (n=73) 
who met the inclusion criteria for both T2D and IGT were counted once in the analysis, thus, 
T2D and/or IGT sub-group included 340 subjects which were included in the longitudinal 
analysis of the associations between egg consumption with CVD events or all-cause 
mortality. 
 
Other measurements 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), plasma glucose, insulin, 
triacylglycerol (TGs), total/HDL-cholesterol, fibrinogen, homocysteine and C-reactive protein 
(CRP) were measured in fasting plasma or serum samples at Phase 2. LDL-cholesterol was 
calculated by using TGs, total cholesterol and HDL- cholesterol by the Friedewald formula 
[22]. Pulse pressure was calculated by subtracting DBP from SBP. However, only SBP, DPB, 
glucose, TGs, total cholesterol, fibrinogen were measured at Phase 3 in CAPS.  
 
National Diet and Nutrition Survey 
Data files from the National Diet and Nutrition Survey (NDNS) [23] years 1-4 of the rolling 
programme (2008-2009 to 2011-2012) were obtained from the UK Data Archive (www.data-
archive.ac.uk). The data from 754 adults (males n=322 and females n=432) aged 19-64 years 
old were used to determine association between egg intake (g/day) and fasting blood glucose, 
glycated haemoglobin (HbA1c) and other biochemical measures of cardio-metabolic health, 
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including total-, HDL-, and LDL- cholesterol, the total-/HDL- cholesterol ratio, TGs, SBP, 
DBP, pulse pressure and CRP. Egg consumption was divided into tertiles for the analysis. 
Participants with a previous history of stroke (n=1), heart attack or angina (n=6) were 
excluded from the analysis. In addition, associations between egg consumption and metabolic 
markers were examined in the T2D and/or IGT sub-group, which included men with T2D 
(n=14) or IGT (fasting plasma glucose ≥ 6.1 mmol/L, n=56), subjects (n=11) who met 
inclusion criteria for both T2D and IGT groups were only counted once. Thus, the total 
number in the T2D and/or IGT sub-group was 59 subjects. The egg food group included 
whole eggs and dishes such as omelettes and scrambled eggs. Composite dishes such as egg 
fried rice and quiches were removed from the total egg consumption to fit with the analysis 
conducted on the CAPS.  
 
Statistical analysis  
All data analysis was conducted using STATA (version 13.0; STATA Corporation, 2014) and 
a 2-sided P<0.05 was considered statistically significant. In the longitudinal analysis of 
CAPS, Cox proportional hazard models were used to calculate non-adjusted and multivariate 
adjusted hazard ratios (HR) by comparing the time until onset of disease or mortality in cases 
in higher intake categories of egg consumption with that in the lowest egg group as the 
reference group. The survival time of the Cox proportional hazard models was the date of 
disease diagnosis or the last follow-up visit date. The first multivariate model controlled for a 
number of confounding factors in CAPS. These included the covariates age (years), body 
mass index (weight (kg)/height (m2)), energy intake (kcal/day), alcohol consumption (as 
ethanol, ml/week), smoking (never-smoked, ex-smoked, current smoked), energy expenditure 
(kJ/day), social class (manual worker; non-manual worker), family history of MI (yes or no) 
and T2D (yes or no). The second multivariate model also controlled for sugar intake (<50, 50-
100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption 
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(<7, 8-14, 15-21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or 
>20 g/d). The possibility of an interaction between egg consumption and subgroup of T2D 
and/or IGT with respect to any of the outcomes was investigated by an analysis including an 
interaction term in the regression model.  
In secondary analyses, we examined the association between egg consumption and 
metabolic markers in CAPs and NDNS. For cross-sectional analysis of CAPs, the association 
of egg consumption with a range of metabolic markers have been examined at Phase 2. In the 
sensitivity analyses of cross-sectional analysis, the associations of egg consumption with 
metabolic markers have also been evaluated at Phase 3 in order to test the consistency of the 
findings. Trends associated with increasing egg consumption were investigated using linear 
regression for the continuous variables and logistic regression for categorical variables. For 
cross-sectional analysis of the NDNS, we used confounding factors of age (years), gender 
(men or women), energy intake (kcal/day), alcohol consumption (as ethanol, g/day), T2D (yes 
or no) and smoking habit (smokers or non-smokers). General linear regression was used for 
the continuous variables and the Pearson chi-square test for the categorical variables. Original 
data were transformed to natural logarithms if required. 
 
Results 
CAPS: Baseline characteristics according to egg consumption 
The mean egg intake of 1781 subjects was 2.9 (SD=2.1) eggs per week. Among participants, 
14.4 % subjects consumed 5 eggs or more per week. The baseline characteristics of the 
subjects from the CAPS are shown in Table 1. The men in the highest quantiles of egg 
consumption were significantly more likely to be manual workers, smokers, consume more 
alcohol, have higher energy intake, higher energy expenditure and higher BMI. They also had 
a lower incident of family MI history. After controlling for energy intake from foods, the men 
with the highest egg consumption had a significantly higher intake of total fat, saturated fat 
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and sugar intake, but lower cereal or vegetable fibre, carbohydrate intakes, red meat and fruit 
intake.  
 
CAPS: Egg consumption and CVD events, all-cause mortality and diabetes in longitudinal 
investigation 
During the mean follow up of 22.8 years, incident cases of stroke (n=248), MI (n=477), heart 
failure (n=201) and all-cause mortality (n=1028) were reported in the subjects initially free 
from CVD events (Table 2). In multivariate Cox regression model, egg consumption was not 
associated with incident of MI, heart failure, or all-cause mortality. However, a significant 
trend of higher risk of stroke with increasing egg intake (adjusted model P=0.04) was 
observed, with HR of 1.60 (95% CI: 1.00, 2.57) for the highest (≥5 eggs/wk) vs lowest (0≤ 
eggs/wk ≤1) quantile of egg consumption.  
In stratified analyses, the prevalent of T2D and/or IGT did not influence the association 
between egg consumption and MI, heart failure, or all-cause mortality (data not shown). 
When the subjects of T2D and/or IGT were removed from the analysis of stroke, there was no 
significant increase in risk of stroke across increasing quantiles of egg consumption (Table 3). 
However, when this analysis was performed on the T2D and/or IGT sub-group, a significant 
trend for increased risk of stroke (adjusted model P=0.01) with increasing egg consumption 
was identified, HR for incident stroke was 2.87 (95% CI: 1.13, 7.27) in the highest vs lowest 
quantile of egg consumption (P for interaction between egg consumption and T2D and/or IGT 
= 0.09 in non-adjust model, 0.08 in adjusted Model 1 and 0.07 in adjusted Model 2).  
During the follow-up, a total of 120 new T2D cases were diagnosed for subjects free from 
CVD and T2D events. There was no association between egg consumption and incident T2D 
using either un-adjusted or multiple adjusted model (Table 4). 
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CAPS and NDNS: Associations between egg consumption and cardio-metabolic risk 
factors: cross-sectional analysis.  
In Phase 2 of the CAPS, no associations were found between egg consumption and fasting 
plasma glucose concentration in the subjects free from CVD (Supplemental Table 1). 
However, when the analysis was repeated in a subgroup (n=268) of participants with T2D 
and/or IGT, there was a significant positive association between egg consumption and fasting 
glucose concentration (Supplemental Table 2). In this subgroup analysis subjects consuming 
≥5 eggs/wk had 1.31 mmol/L higher fasting glucose compared with subjects consuming 1 
eggs/wk or less. There were no significant associations between egg consumption and other 
biomarkers of CVD risk in the population as a whole (Supplemental Table 1) and subgroup 
analysis (Supplemental Table 2).      
In Phase 3 of the CAPS there was a significant positive association between egg 
consumption and fasting glucose concentration (Supplemental Table 3). When the subjects 
with T2D and/or IGT were removed from the analysis, there was no association between egg 
consumption and fasting glucose concentration across increasing quantile of egg 
consumption. However, when the analysis was repeated in a subgroup of T2D and/or IGT 
(n=334) there was a significant positive association between egg consumption and fasting 
glucose (Supplemental Table 4). In this subgroup analysis subjects consuming ≥5 eggs per 
week had 0.72 mmol/L higher fasting glucose levels compared with subjects consuming 1 
eggs/wk.  
Cross-sectional analysis in NDNS [23] showed egg consumption was positively associated 
with fasting glucose and HbA1c concentrations (Supplemental Table 5). When the subjects 
with T2D and/or IGT were removed from the analysis, there was no significant increase in 
fasting glucose, but there was a significant positive trend for increased egg consumption and 
HbA1c concentration (P=0.02). In the T2D and/or IGT subgroup, egg consumption was 
significant associated with elevated fasting glucose and HbA1c concentrations (Supplemental 
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Table 6). There were no significant associations between egg consumption and other markers 
of cardiovascular risk (Supplemental Table 5).   
 
Discussion 
No overall associations between weekly egg consumption up to 5 eggs/week and risk of MI, 
heart failure, all-cause mortality and T2D were observed after a mean follow-up of 22.8 years, 
but there was a significant positive trend in stroke risk across the quantiles of egg intake. 
Further sub-group investigation showed that the significant trend disappeared after the men 
with T2D and/or IGT were removed. By investigation of the association of egg intake and risk 
of stroke in the sub-group of T2D and/or IGT only, significant positive associations was 
found. Secondary analyses in both CAPS and NDNS showed increased fasting glucose with 
higher egg intake in the sub-group of T2D and/or IGT. In addition, results of cross-sectional 
analyses of NDNS showed higher egg intake was associated with higher HbA1c in the general 
healthy population across tertiles of egg intake.  
These results are consistent with the previous meta-analyses of prospective studies [13, 
14], which showed no association between egg consumption and CVD events in the general 
population. Very few studies have reported a positive association between egg intake and 
CVD risk. Nevertheless, data from Physicians’ Health Study [24] indicated the HR of heart 
failure was 1.33 (95% CI: 1.04, 1.70) with egg consumption ≥ 7 per week compared with that 
of <1 per week over 20 years of follow-up for physicians free of previous MI. In addition, in 
another analysis of the same cohort there was no association between egg intake and MI and 
stroke, but there was a significant positive association with all-cause mortality [25]. The 
difference in the observed association of egg consumption and heart failure or all-cause 
mortality between the current study and that by Djousse et al [24, 25] may be due to 
differences in the characteristics of the investigated subjects. Physicians were included in the 
study of Djousse et al [24, 25], whereas 64% of the men in the current study were manual 
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workers. An earlier British study in 1997 reported a 2.68 times increased risk of ischaemic 
heart disease deaths in 10,802 subjects reporting higher egg intake (>6/week) compared with 
lower egg consumption (<1 egg/week) after 13.3 years follow-up [26]. In our study we were 
not able to conduct a similar analysis, as the data for mortality resulting from different 
categories of heart disease were not available. 
Our finding of no association between egg intake and risk of stroke in generally healthy 
men is consistent with previous studies [27-29]. However in our sub-group analysis of 340 
men with T2D and/or IGT, we found a significant positive association between egg intake and 
the risk of stroke. To the best of our knowledge, our study is the first to show this association 
in subjects with T2D and/or IGT and needs confirmation in further studies.  
In our secondary cross-sectional analysis of CAPS and NDNS, a positive association 
between egg intake and blood glucose was observed in the T2D and/or IGT subgroup. This 
may indicate that higher egg intake had a detrimental effect on the glucose metabolism in 
subjects with T2D and/or IGT, although this needs confirmation in randomized controlled 
dietary intervention trials. An earlier study also showed that higher egg consumption was 
associated with elevated fasting glucose in 394 middle-aged healthy men [7]. This is also 
supported by another cross-sectional analysis [30] that observed significant positive 
relationships between egg consumption and fasting glucose, insulin or insulin resistance, 
although the difference was very small. However, neither of these studies investigated the 
association in sub-groups with T2D and/or IGT [7, 30].  
The concept of eggs as a cholesterol rich food, which may increase LDL-cholesterol and 
risk of heart disease, has been recognised for a long time. However, in our analysis, we found 
no association between egg intake and blood cholesterol concentrations, in agreement with 
Gray and Griffin [10] who concluded that the effect of dietary cholesterol on LDL-cholesterol 
was negligible compared with the effect of dietary saturated fatty acids. In contrast to our 
findings, a study in a Finnish population showed a reduction in fasting plasma glucose in the 
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highest egg consumption quartile (>45 g/d) at baseline and after a 4-year follow up in 2312 
men [12]. This significant association at baseline only appeared when dietary cholesterol 
intake was included as a covariate. However, controlling for dietary cholesterol may lead to 
bias as this component of eggs could be responsible for the observed effects of eggs on 
plasma glucose [31].  
Lastly, this is the first study to show a strong positive association between higher egg 
intake (>29 g/d) and elevated HbA1c concentration in a population without CVD or known 
T2D. Higher HbA1c is regarded as an important marker for pre-diagnosed T2D and CVD [32, 
33]. There was no evidence in CAPS of any association between egg consumption and the 
development of T2D. The numbers of self-reported T2D cases are relatively small and were 
not validated by clinical diagnosis. However in a larger study, Djousse and colleagues [34] 
showed a significant positive association between egg consumption (≥7 weekly) and risk of 
T2D in two large prospective cohort studies of men (n=20,303) and women (n=36,295) with 
1921 and 2112 cases of T2D incident after a follow up period of 20.0 years for men and 11.7 
years for women, respectively. One possible explanation for the non-significant finding in 
CAPS is the relatively small subject group and low number of T2D (n=120), which may have 
limited the statistical power of the study.  
The potential mechanism by which eggs could increase fasting plasma glucose and 
ischaemic stroke in the T2D and/or IGT subjects is unknown. Findings from a 3 month 
randomized controlled study showed that there was no negative effect of higher egg 
consumption (>12 eggs/week) on blood lipid profile compared with low egg consumption (<2 
eggs/week) in overweight or obese subjects diagnosed with diabetes or prediabetes [11]. 
However, in that study the authors controlled for diabetes or prediabetes drug use which may 
have masked the effect of egg consumption. In the baseline analysis of CAPS subject 
characteristics, higher egg consumption was associated with a relatively unhealthy lifestyle 
including higher alcohol consumption, higher energy intake, more smokers, which may 
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indicate that the positive relationship between egg intake and blood glucose or ischaemic 
stroke in those with compromised glycaemic control, is due to residual confounding factors 
linked to the dietary pattern. Therefore, future research is needed to assess if there is a 
causality effect of egg consumption on blood glucose in prediabetes or diabetes subjects.  
The major strength of the CAPS study is that it has a follow-up of over 20 years, which is 
one of the longest UK prospective cohort studies providing new evidence on the relationship 
between dietary factors and CVD events. Furthermore, in order to prevent chance findings, 
the cross-sectional analyses were repeated in two phases of the CAPS (5-year interval). 
However, egg consumption was only recorded as the weekly egg intake and did not account 
for eggs consumed from composite dishes. Thus, egg intakes may have been underestimated 
or misclassified which may have affected the observed associations. In addition, cooking 
methods and information on how eggs were consumed were not recorded, and this may have 
had effects on health outcomes [35]. In terms of the metabolic markers available in CAPS, 
insulin was only measured in a small proportion of subjects and was not measured in Phase 3, 
thus insulin resistance could not be estimated.  
In conclusion, our study did not show any evidence for adverse effects of egg intake on the 
risk of CVD, T2D and all-cause mortality in healthy men. However, a detrimental association 
of modest egg intake on fasting glucose and risk of ischaemic stroke in T2D and/or IGT 
subjects was observed. The adverse cross-sectional association of egg consumption on 
HbA1C in a generally healthy population needs to be confirmed in future studies. 
Furthermore, cautious interpretation of these results is recommended, due to the limited 
sample size and number of disease and deaths. In addition, Nicklas et al [36] pointed out the 
statistical methods and residual confounding factors may have influenced the health 
outcomes. Therefore, large prospective cohort studies and RCTs are required to verify these 
findings. 
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Table 1 Baseline characteristics of participants from the Caerphilly Prospective Cohort Study according to egg consumption1 
  Egg consumption (n, eggs/wk)   
Characteristics 
1 2 3 4 5 
P-trend2 (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) 
Subjects, n  274 464 469 318 256   
Age, y 61.5 ± 4.6 61.9 ± 4.3 61.7 ± 4.5 61.7 ± 4.5 61.6 ± 4.4 0.93 
BMI, kg/m 26.5 ± 3.5 26.5 ± 3.4 26.7 ± 3.7 26.9 ± 4.0 27.1 ± 4.2 0.03 
Energy expenditure, kJ/d 1440 ± 1557 1421 ±1426 1551 ±1651 1659 ± 1618 1850 ± 2042 0.001 
Manual workers, % 53.3 59.7 63.5 70.8 80.1 <0.001 
Family history of MI, % 43.2 38.6 38.4 30.4 36.7 0.02 
History of hypertension, %  28.8 26.9 29.2 31.1 29.7 0.40 
History of diabetes, % 3.3 1.7 0.9 5.3 3.9 0.07 
Current smokers, % 22.6 26.9 36.2 43.4 48.0 <0.001 
Energy intake, kJ/d 7449 ± 1890 8074 ± 1873 8547 ± 2051 8988 ± 2132 9821 ± 2578 <0.001 
Fat, % of energy 33.9 35.1 35.8 36.5 37.1 <0.001 
Saturated fat, % of energy 14.6 15.0 15.5 15.9 16.1 <0.001 
Protein, % of energy 14.7 14.3 14.3 14.2 14.5 0.19 
Carbohydrates, % of energy 49.3 48.3 47.6 47.1 45.9 <0.001 
Fibre (vegetable sources)3, g/d 11.4 ± 0.5 10.9 ± 0.5 11.1 ± 0.6 11.2 ± 0.6 11.3 ± 0.7 0.02 
Fibre (cereal sources)3, g/d  10.8 ± 1.2 10.3 ± 1.1 10.0 ± 1.3 9.3 ± 1.3 9.2 ± 1.6 <0.001 
Sugar3, g/d 76.8 ± 24.1 82.2 ± 23.9 87.3 ± 26.1 93.6 ± 27.2 104.3 ± 32.9 <0.001 
Fruit3, number/wk 9.3 ± 0.5 8.3 ± 0.5 7.9 ± 0.6 7.4 ± 0.6 7.7 ± 0.7 <0.001 
Vegetable3, times/wk 10.7 ± 4.7 10.0 ± 4.6 10.5 ± 4.7 10.6 ± 4.8 10.3 ± 4.8 0.99 
Red meat3, times/wk 17.4 ± 0.9 14.9 ± 0.9 14.8 ± 1.0 14.3 ± 1.1 14.8 ± 1.3 <0.001 
Alcohol intake, ml/wk 15.6 ± 21.5 16.2 ± 20.3 17.8 ± 22.5 17.3 ± 19.7 20.5 ± 22.8 0.010 
1 All values are mean ± SD. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables). 
3 Energy-adjusted values.     
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Table 2 Longitudinal study of incidence of stroke, myocardial infarction, heart failure and all-cause mortality according to egg consumption of all subjects. 
  Egg consumption (n, eggs/wk)   
 
1 2 3 4 5 
 
Characteristics (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Total subjects, n 274 464 469 318 256 
 
Stroke 
      
     No. of events  33 57 57 48 53 
 
     HR (non-adjust) 1 1.01 (0.66, 1.56) 1.01 (0.66, 1.55) 1.27 (0.82, 1.98) 1.82 (1.18, 2.80) 0.002 
     HR (adjusted Model 1)1 1 0.99 (0.65, 1.53) 0.97 (0.63, 1.50) 1.14 (0.72, 1.81) 1.58 (1.00, 2.52) 0.03 
     HR (adjusted Model 2)2 1 1.01 (0.65, 1.56) 1.00 (0.64, 1.55) 1.15 (0.72, 1.84) 1.60 (1.00, 2.57) 0.04 
Myocardial infarction 
      
     No. of events  73 117 137 86 64 
 
     HR (non-adjust) 1 0.94 (0.70, 1.26) 1.11 (0.83, 1.47) 1.00 (0.73, 1.37) 0.94 (0.67, 1.31) 0.98 
     HR (adjusted Model 1) 1 0.96 (0.71, 1.29) 1.10 (0.83, 1.48) 0.99 (0.71, 1.37) 0.90 (0.63, 1.29) 0.75 
     HR (adjusted Model 2) 1 0.97 (0.72, 1.31) 1.14 (0.85, 1.52) 1.01 (0.72, 1.40) 0.91 (0.64, 1.31) 0.80 
Heart failure 
      
     No. of events  29 33 63 44 32 
 
     HR (non-adjust) 1 0.66 (0.40, 1.09) 1.29 (0.83, 2.00) 1.33 (0.83, 2.13) 1.20 (0.72, 1.98) 0.03 
     HR (adjusted Model 1) 1 0.64 (0.39, 1.06) 1.17 (0.74, 1.83) 1.10 (0.67, 1.79) 0.89 (0.52, 1.52) 0.46 
     HR (adjusted Model 2) 1 0.65 (0.39, 1.08) 1.19 (0.76, 1.88) 1.09 (0.66, 1.81) 0.89 (0.51, 1.53) 0.49 
All-cause mortality 
      
     No. of events  135 249 293 187 164 
 
     HR (non-adjust) 1 1.13 (0.92, 1.40) 1.35 (1.10, 1.66) 1.25 (1.00, 1.56) 1.44 (1.14, 1.80) 0.001 
     HR (adjusted Model 1) 1 1.08 (0.87, 1.33) 1.21 (0.98, 1.49) 1.03 (0.82, 1.30) 1.11 (0.87, 1.42) 0.58 
     HR (adjusted Model 2) 1 1.08 (0.87, 1.34) 1.20 (0.98, 1.49) 1.02 (0.81, 1.29) 1.08 (0.84, 1.38) 0.80 
 
1 Values are hazard ratios (95 % CIs) derived by Cox proportional hazards regression models adjusted for age (continuous), BMI (continuous), energy intake 
(continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class (manual or non-manual), family 
history of myocardial infarction (yes or no), diabetes mellitus (yes or no). 
2 Adjusted as model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d).
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Table 3 Longitudinal analysis of incident of stroke according to egg consumption in subjects with and without type 2 diabetes and/or impaired glucose 
tolerance from the Caerphilly Prospective Cohort study. 
  Egg consumption (n, eggs/wk)   
 
1 2 3 4 5 
 
 
(0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Subjects without T2D and/or IGT1             
     Subjects, n 221 397 378 248 197 
      No. of events  25 47 45 34 31 
      HR (non-adjust) 1 1.05 (0.64, 1.70) 1.05 (0.65, 1.72) 1.23 (0.73, 2.05) 1.45 (0.85, 2.45) 0.12 
     HR (adjusted Model 1)2 1 1.01 (0.62, 1.66) 0.97 (0.59, 1.60) 1.14 (0.67, 1.95) 1.28 (0.73, 2.24) 0.33 
     HR (adjusted Model 2)3 1 1.05 (0.64, 1.71) 1.01 (0.61, 1.66) 1.17 (0.68, 2.02) 1.32 (0.75, 2.34) 0.29 
Subjects with T2D and/or IGT  
           Subjects, n 53 67 91 70 59 
      No. of events  8 10 12 14 22 
      HR (non-adjust) 1 0.96 (0.38, 2.44) 0.86 (0.35, 2.10) 1.35 (0.57, 3.23) 2.71 (1.21, 6.09) 0.003 
     HR (adjusted Model 1) 1 1.10 (0.42, 2.86) 1.02 (0.40, 2.62) 1.35 (0.53, 3.43) 2.83 (1.15, 6.96) 0.01 
     HR (adjusted Model 2) 1 1.09 (0.41, 2.88) 0.96 (0.37, 2.50) 1.39 (0.54, 3.56) 2.87 (1.13, 7.27) 0.01 
1  Impaired glucose tolerance, i.e. fasting glucose ≥ 6.1 mmol/L. 
2 Values are hazard ratios (95 % CIs) derived by Cox proportional hazards regression models adjusted for age (continuous), BMI (continuous), energy intake 
(continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class (manual or non-manual), family 
history of myocardial infarction (yes or no). 
3 Adjusted as model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d).
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Table 4 Longitudinal study of incidence of type 2 diabetes according to egg consumption. 
  Egg consumption (n, eggs/wk)   
 
1 2 3 4 5 
 
 
(0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
     Subjects, n 259 447 453 290 238   
     No. of events  17 31 35 21 16 
      HR (non-adjust) 1 1.17 (0.65, 2.12) 1.24 (0.69, 2.21) 1.20 (0.63, 2.27) 1.22 (0.61, 2.41) 0.59 
     HR (adjusted Model 1)1 1 1.08 (0.59, 1.97) 1.05 (0.57, 1.92) 1.25 (0.64, 2.44) 1.23 (0.60, 2.53) 0.48 
     HR (adjusted Model 2)2 1 1.05 (0.57, 1.93) 1.02 (0.55, 1.88) 1.24 (0.63, 2.45) 1.31 (0.63, 2.73) 0.39 
1 Values are hazard ratios (95 % CIs) derived by Cox proportional hazards regression models adjusted for age (continuous), BMI (continuous), energy intake 
(continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class (manual or non-manual), family 
history of myocardial infarction (yes or no). 
2 Adjusted as model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d). 
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Figure 1 Timeline of the Caerphilly Prospective Cohort Study. 
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Supplemental Table 1 Cross-sectional (Phase 2) analysis of metabolic markers across egg consumption categories of all subjects in Caerphilly Prospective 
Cohort Study1 
  Egg consumption (n, eggs/wk)  
 1 2 3 4 5  
Characteristics (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Glucose4       
    Participants, n 413 562 415 347 421  
    Mean, mmol/L 5.25 (0.84) 5.43 (1.43) 5.36 (1.26) 5.41 (1.24) 5.49 (1.56)  
    Coef. (Std. Err.) non-adjust Reference 0.02 (0.00, 0.05) 0.01 (-0.01, 0.04) 0.02 (-0.00, 0.05) 0.03 (0000, 0.05) 0.05 
    Coef. (Std. Err.) adjusted Model 12 Reference 0.02 (-0.00, 0.04) 0.01 (-0.01, 0.03) 0.02 (-0.00, 0.04) 0.01 (-0.01, 0.03) 0.44 
    Coef. (Std. Err.) adjusted Model 23 Reference 0.02 (-0.00, 0.04) 0.01 (-0.02, 0.03) 0.01 (-0.01, 0.04) 0.01 (-0.02, 0.03) 0.70 
Insulin4       
    Participants, n 200 272 196 169 205  
    Mean, mmol/L 5.28 (22.19) 3.74 (3.75) 3.64 (4.21) 3.17 (2.32) 3.43 (2.86)  
    Coef. (Std. Err.) non-adjust Reference 0.00 (-0.13, 0.13) -0.01 (-0.15, 0.13) -0.09 (-0.24, 0.06) -0.06 (-0.20, 0.08) 0.20 
    Coef. (Std. Err.) adjusted Model 1 Reference -0.01 (-0.14, 0.12) -0.03 (-0.17, 0.11) -0.13 (-0.28, 0.02) -0.09 (-0.24, 0.07) 0.10 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.02 (-0.15, 0.11) -0.03 (-0.17, 0.11) -0.13 (-0.28, 0.03) -0.08 (-0.23, 0.08) 0.15 
Total cholesterol        
    Participants, n 409 564 414 348 424  
    Mean, mmol/L 5.64 (0.99) 5.56 (0.99) 5.62 (1.05) 5.64 (1.02) 5.68 (1.00)  
    Coef. (Std. Err.) non-adjust Reference -0.08 (-0.21, 0.05) -0.02 (-0.16, 0.12) -0.00 (-0.15, 0.14) 0.04 (-0.10, 0.18) 0.26 
    Coef. (Std. Err.) adjusted Model 1 Reference -0.09 (-0.22, 0.04) -0.01 (-0.15, 0.13) -0.00 (-0.15, 0.15) 0.05 (-0.09, 0.20) 0.18 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.09 (-0.22, 0.04) -0.03 (-0.17, 0.11) -0.02 (-0.17, 0.13) 0.03 (-0.11, 0.18) 0.35 
HDL-cholesterol,        
    Participants, n 409 564 414 348 424  
    Mean, mmol/L 1.03 (0.25) 1.01 (0.24) 1.03 (0.24) 1.02 (0.25) 1.04 (0.27)  
    Coef. (Std. Err.) non-adjust Reference -0.02 (-0.06, 0.01) 0.00 (-0.03, 0.03) -0.01 (-0.04, 0.03) 0.01 (-0.03, 0.04) 0.36 
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    Coef. (Std. Err.) adjusted Model 1 Reference -0.02 (-0.05, 0.01) 0.01 (-0.03, 0.04) 0.01 (-0.02, 0.05) 0.02 (-0.01, 0.06) 0.05 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.02 (-0.05, 0.01) 0.00 (-0.03, 0.04) 0.01 (-0.03, 0.04) 0.02 (-0.02, 0.05) 0.08 
LDL-cholesterol4       
    Participants, n 409 564 414 348 424  
    Mean, mmol/L 4.23 (0.94) 4.15 (0.90) 4.22 (0.96) 4.21 (0.96) 4.25 (0.92)  
    Coef. (Std. Err.) non-adjust Reference -0.08 (-0.20, 0.03) -0.01 (-0.14, 0.12) -0.02 (-0.16, 0.11) 0.02 (-0.11, 0.14) 0.43 
    Coef. (Std. Err.) adjusted Model 1 Reference -0.09 (-0.21, 0.02) -0.00 (-0.13, 0.12) -0.03 (-0.16, 0.11) 0.04 (-0.10, 0.17) 0.26 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.09 (-0.21, 0.03) -0.02 (-0.14, 0.11) -0.04 (-0.17, 0.10) 0.03 (-0.11, 0.16) 0.40 
Triglycerides4       
    Participants, n 409 564 414 348 424  
    Mean, mmol/L 1.89 (1.06) 2.04 (1.80) 1.86 (1.11) 2.04 (1.57) 1.98 (1.29)  
    Coef. (Std. Err.) non-adjust Reference 0.03 (-0.03, 0.10) -0.02 (-0.09, 0.05) 0.04 (-0.04, 0.11) 0.03 (-0.04, 0.10) 0.55 
    Coef. (Std. Err.) adjusted Model 1 Reference 0.01 (-0.05, 0.08) -0.03 (-0.10, 0.03) -0.01 (-0.08, 0.07) -0.03 (-0.10, 0.04) 0.30 
    Coef. (Std. Err.) adjusted Model 2 Reference 0.01 (-0.05, 0.07) -0.04 (-0.11, 0.03) -0.01 (-0.09,0.06) -0.04 (-0.11, 0.03) 0.18 
Fibrinogen4       
    Participants, n 252 340 280 236 253  
    Mean, g/L 3.03 (0.78) 3.09 (0.85) 3.07 (0.85) 3.09 (0.89) 3.14 (0.83)  
    Coef. (Std. Err.) non-adjust Reference 0.02 (-0.02, 0.06) 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.06) 0.03 (-0.01, 0.08) 0.23 
    Coef. (Std. Err.) adjusted Model 1 Reference 0.00 (-0.04, 0.04) -0.00 (-0.04, 0.04) -0.01 (-0.06, 0.03) 0.02 (-0.02, 0.07) 0.55 
    Coef. (Std. Err.) adjusted Model 2 Reference 0.01 (-0.03, 0.04) -0.00 (-0.06, 0.03) -0.01 (-0.06, 0.03) 0.02 (-0.03, 0.06) 0.77 
Homocysteine       
    Participants, n 412 560 408 346 424  
    Mean, mmol/L 12.65 (4.91) 12.28 (5.07) 12.59 (4.77) 11.91 (4.81) 12.37 (5.52)  
    Coef. (Std. Err.) non-adjust Reference -0.36 (-1.00, 0.28) -0.05 (-0.74, 0.64) -0.73 (-1.45, -0.01) -0.28 (-0.96, 0.40) 0.30 
    Coef. (Std. Err.) adjusted Model 1 Reference -0.37 (-1.01, 0.27) -0.12 (-0.80, 0.57) -0.74 (-1.47, -0.02) -0.35 (-1.07, 0.36) 0.24 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.41 (-1.04, 0.22) -0.21 (-1.55, 0.47) -0.83 (-1.55, -0.10) -0.61 (-1.33, 0.11) 0.06 
C-reactive protein4       
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    Participants, n 280 395 285 242 288  
    Mean, mg/L 2.42 (2.78) 3.29 (5.30) 2.94 (4.91) 2.96 (4.00) 3.22 (4.35)  
    Coef. (Std. Err.) non-adjust Reference 0.18 (0.02, 0.33) 0.10 (-0.07, 0.27) 0.16 (-0.02, 0.34) 0.17 (0.00, 0.34) 0.13 
    Coef. (Std. Err.) adjusted Model 1 Reference 0.10 (-0.05, 0.25) 0.06 (-0.10, 0.22) 0.03 (-0.14, 0.20) 0.04 (-0.13, 0.21) 0.98 
    Coef. (Std. Err.) adjusted Model 2 Reference 0.0 (-0.05, 0.24) 0.04 (-0.12, 0.20) 0.02 (-0.15, 0.19) -0.01 (-0.18, 0.16) 0.54 
Systolic blood pressure4       
    Participants, n 427 577 427 356 433  
    Mean, mmHg 147.0 (22.1) 146.5 (22.2) 144.8 (23.4) 148.1 (23.5) 146.1 (22.6)  
    Coef. (Std. Err.) non-adjust Reference -0.00 (-0.02, 0.02) -0.02 (-0.04, 0.00) 0.01 (-0.01, 0.03) -0.01 (-0.03, 0.01) 0.85 
    Coef. (Std. Err.) adjusted Model 1 Reference -0.01 (-0.03, 0.01) -0.02 (-0.04, -0.00) -0.00 (-0.02, 0.02) -0.02 (-0.04, 0.00) 0.19 
    Coef. (Std. Err.) adjusted Model 2 Reference -0.01 (-0.03, 0.01) -0.02 (-0.04, -0.00) -0.00 (-0.02, 0.02) -0.02 (-0.04, -0.00) 0.14 
Diastolic blood pressure       
    Participants, n 426 577 427 356 433  
    Mean, mmHg 84.7 (11.3) 85.3 (11.7) 83.9 (12.0) 85.5 (12.4) 85.0 (13.3)  
    Coef. (Std. Err.) non-adjust Reference 0.59 (-0.93, 2.11) -0.75 (-2.38, 0.87) 0.83 (-0.88, 2.53) 0.30 (-1.33, 1.92) 0.75 
    Coef. (Std. Err.) adjusted Model 1 Reference 0.44 (-1.04, 1.93) -0.80 (-2.39, 0.79) 0.49 (-1.21, 2.19) -0.09 (-1.77, 1.60) 0.83 
    Coef. (Std. Err.) adjusted Model 2 Reference 0.48 (-1.00, 1.97) -0.77 (-2.37, 0.82) 0.54 (-1.16, 2.25) -0.34 (-2.03, 1.35) 0.64 
1 All values are mean ± SD. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables), adjusted for age (continuous), BMI 
(continuous), energy intake (continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class 
(manual or non-manual), family history of myocardial infarction (yes or no), diabetes mellitus (yes or no). 
3Adjusted as model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d).  
4 Original data were transformed to natural logarithms for regression model. 
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Supplemental Table 2 Cross-sectional (Phase 2) analysis of metabolic markers across egg consumption in subjects type 2 diabetes and/or impaired glucose 
tolerance from the Caerphilly Prospective Cohort study1 
  Egg consumption (n, eggs/wk)  
 1 2 3 4 5  
Characteristics (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Glucose4       
    Participants, n 42 72 46 46 62  
    Fasting glucose, mmol/L 6.89 (1.38) 7.88 (2.83) 7.73 (2.60) 7.45 (2.37) 8.20 (2.62)  
    Coef.± Std. Err. (non-adjust) Reference 0.10 (0.00, 0.21) 0.09 (-0.02, 0.20) 0.06 (-0.05, 0.20) 0.15 (0.05, 0.26) 0.04 
    Coef ± Std. Err. (adjusted Model 1)2 Reference 0.12 (0.02, 0.22) 0.11 (0.00, 0.23) 0.07 (-0.04, 0.18) 0.19 (0.08, 0.30) 0.008 
    Coef ± Std. Err. (adjusted Model 2)3 Reference 0.14 (0.03, 0.24) 0.11 (-0.00, 0.22) 0.05 (-0.06, 0.17) 0.16 (0.05, 0.27) 0.02 
Insulin4       
    Participants, n 22 39 21 21 28  
    Mean, mmol/L 3.78 (2.60) 3.79 (3.49) 3.60 (1.65) 2.95 (1.54) 3.06 (1.97)  
    Coef.± Std. Err. (non-adjust) Reference 0.02 (-0.37, 0.41) 0.10 (-0.35, 0.54) -0.16 (-0.35, 0.54) -0.08 (-0.49, 0.34) 0.46 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.05 (-0.37, 0.47) 0.10(-0.36, 0.57) -0.19 (-0.67, 0.29) -0.15 (-0.60, 0.30) 0.29 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.04 (-0.43, 0.52) 0.07 (-0.47, 0.60) -0.31 (-0.86, 0.25) -0.21 (-0.70, 0.29) 0.17 
Total cholesterol        
    Participants, n 42 72 45 45 62  
    Mean, mmol/L 5.43 (0.75) 5.69 (1.37) 5.37 (0.98) 5.61 (1.03) 5.54 (1.15)  
    Coef.± Std. Err. (non-adjust) Reference 0.26 (-0.17, 0.69) -0.06 (-0.53, 0.42) 0.18 (-0.29, 0.66) 0.11 (-0.33, 0.55) 0.94 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.23 (-0.19, 0.65) 0.00 (-0.46, 0.46) 0.27 (-0.20, 0.74) 0.19 (-0.25, 0.64) 0.50 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.22 (-0.21, 0.66) 0.02 (-0.46, 0.50) 0.25 (-0.24, 0.74) 0.15 (-0.31, 0.60) 0.65 
HDL-cholesterol,        
    Participants, n 42 72 45 45 62  
    Mean, mmol/L 1.05 (0.24) 0.91 (0.23) 0.95 (0.24) 1.00 (0.26) 0.99 (0.26)  
    Coef.± Std. Err. (non-adjust) Reference -0.15 (-0.24, -0.05) -0.10 (-0.21, 0.00) -0.05 (-0.16, 0.05) -0.07 (-0.16, 0.03) 0.82 
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    Coef ± Std. Err. (adjusted Model 1) Reference -0.18 (-0.27, -0.08) -0.11 (-0.21, -0.01) -0.03 (-0.13, 0.07) -0.04 (-0.14, 0.06) 0.24 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.18 (-0.27, -0.09) -0.12 (-0.22, -0.12) -0.04 (-0.14, 0.07) -0.05 (-0.14, 0.05) 0.33 
LDL-cholesterol4       
    Participants, n 42 72 45 45 62  
    Mean, mmol/L 4.00 (0.73) 4.18 (1.10) 3.95 (0.85) 4.18 (1.01) 1.08 (1.00)  
    Coef.± Std. Err. (non-adjust) Reference 0.18 (-0.19, 0.55) -0.04 (-0.45, 0.37) 0.18 (-0.23, 0.59) 0.09 (-0.29, 0.47) 0.83 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.18 (-0.18, 0.54) 0.01 (-0.38, 0.41) 0.28 (-0.13, 0.69) 0.19 (-0.19, 0.57) 0.34 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.17 (-0.21, 0.54) 0.17 (-0.20, 0.54) 0.05 (-0.36, 0.46) 0.16 (-0.23, 0.55) 0.39 
Triglycerides4       
    Participants, n 42 72 45 45 62  
    Mean, mmol/L 1.89 (0.86) 3.04 (3.91) 2.34 (1.61) 2.16 (1.20) 2.35 (2.05)  
    Coef.± Std. Err. (non-adjust) Reference 0.30 (0.08, 0.52) 0.14 (-0.10, 0.38) 0.07 (-0.17, 0.32) 0.10 (-0.13, 0.33) 0.57 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.31 (0.10, 0.52) 0.17 (-0.06, 0.40) 0.07 (-0.16, 0.31) 0.06 (-0.16, 0.28) 0.37 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.32 (0.11, 0.53) 0.16 (-0.07, 0.39) 0.02 (-0.21, 0.26) 0.05 (-0.17, 0.27) 0.23 
Fibrinogen4       
    Participants, n 31 44 28 31 29  
    Mean, g/L 3.12 (0.96) 3.18 (0.98) 2.89 (0.80) 2.89 (0.71) 3.47 (1.02)  
    Coef.± Std. Err. (non-adjust) Reference 0.01 (-0.11, 0.14) -0.08 (-0.22, 0.06) -0.06 (-0.20, 0.07) 0.11 (-0.03, 0.25) 0.45 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.03 (-0.09, 0.15) -0.07 (-0.21, 0.06) -0.07 (-0.20, 0.06) 0.12 (-0.02, 0.03) 0.52 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.03 (-0.11, 0.16) -0.06 (-0.21, 0.08) -0.07 (-0.21, 0.07) 0.12 (-0.03, 0.26) 0.51 
Homocysteine4       
    Participants, n 43 71 44 46 62  
    Mean, mmol/L 12.43 (4.45) 11.40 (3.45) 12.40 (6.57) 10.94 (3.10) 11.63 (6.48)  
    Coef.± Std. Err. (non-adjust) Reference -1.03 (-2.93, 0.87) -0.02 (-2.13, 2.09) -1.49 (-3.57, 0.60) -0.79 (-2.74, 1.16) 0.47 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.83 (-2.72, 1.06) -0.42 (-2.52, 1.69) -1.78 (-3.90, 0.33) -1.07 (-3.08, 0.94) 0.23 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.74 (-2.68, 1.20) -0.08 (-2.24, 2.08) -1.47 (-3.66, 0.72) -1.04 (-3.07, 1.00) 0.26 
C-reactive protein4       
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    Participants, n 28 53 32 27 42  
    Mean, mg/L 2.69 (2.64) 3.04 (4.34) 2.63 (1.70) 1.98 (1.58) 4.94 (5.90)  
    Coef.± Std. Err. (non-adjust) Reference -0.05 (-0.48, 0.38) 0.05 (-0.43, 0.53) -0.25 (-0.75, 0.53) 0.31 (-0.14, 0.76) 0.22 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.03 (-0.46, 0.40) 0.03 (-0.44, 0.50) -0.37 (-0.87, 0.13) 0.24 (-0.22, 0.69) 0.54 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.05 (-0.40, 0.50) 0.07 (-0.42, 0.56) -0.34 (-0.87, 0.18) 0.24 (-0.24, 0.71) 0.67 
Systolic blood pressure4       
    Participants, n 45 70 45 47 61  
    Mean, mmHg 156.4 (25.3) 154.9 (20.2) 153.1 (26.7) 156.5 (25.4) 152.8 (25.3)  
    Coef.± Std. Err. (non-adjust) Reference -0.01 (-0.06, 0.05) -0.02 (-0.096, 0.04) 0.00 (-0.06, 0.07) -0.02 (-0.08, 0.04) 0.53 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.01 (-0.07, 0.04) -0.02 (-0.09, 0.04) 0.01 (-0.06, 0.07) -0.04 (-0.10, 0.02) 0.36 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.01 (-0.07, 0.05) -0.01 (-0.07, 0.06) 0.02 (-0.05, 0.09) -0.04 (-0.10, 0.03) 0.47 
Diastolic blood pressure       
    Participants, n 45 70 45 47 61  
    Mean, mmHg 87.7 (10.4) 87.4 (11.4) 87.6 (14.7) 86.1 (14.5) 86.7 (13.8)  
    Coef.± Std. Err. (non-adjust) Reference -0.32 (-5.20, 4.56) -0.09 (-5.48, 5.30) -1.54 (-6.87, 3.79) -0.97 (-5.99, 4.05) 0.59 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.87 (-5.66, 3.92) -0.56 (-5.86, 4.75) -0.99 (-6.33, 4.35) -2.78 (-7.89, 2.34) 0.31 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.08 (-4.87, 5.03) 1.09 (-4.42, 6.59) 0.36 (-5.20, 5.93) -2.05 (-7.26, 3.17) 0.43 
1 All values are mean ± SD; Impaired glucose tolerance, i.e.  fasting glucose ≥ 6.1 mmol/L. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables), adjusted for age (continuous), BMI 
(continuous), energy intake (continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class 
(manual or non-manual), family history of myocardial infarction (yes or no). 
3Adjusted as model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d).  
4 Original data were transformed to natural logarithms for regression model. 
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Supplemental Table 3 Cross-sectional (Phase 3) analysis of metabolic markers across egg consumption categories of all subjects in Caerphilly Prospective 
Cohort Study1 
  Egg consumption (n, eggs/wk)  
 1 2 3 4 5  
Characteristics (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Glucose4       
    Participants, n 450 505 301 230 229  
    Fasting glucose, mmol/L 5.62 (1.48) 5.59 (1.45) 5.75 (1.77) 5.82 (1.98) 6.09 (2.17)  
    Coef.± Std. Err. (non-adjust) Reference -0.00 (-0.03, 0.02) 0.01 (-0.02, 0.05) 0.02 (-0.01, 0.05) 0.06 (-0.01, 0.05) <0.001 
    Coef ± Std. Err. (adjusted Model 1)2 Reference -0.01 (-0.03, 0.02) 0.01 (-0.02, 0.04) 0.01 (-0.03, 0.04) 0.04 (0.01, 0.08) 0.03 
    Coef ± Std. Err. (adjusted Model 2)3 Reference -0.01 (-0.03, 0.02) 0.01 (-0.02, 0.04) 0.01 (-0.03, 0.04) 0.04 (0.00, 0.07) 0.04 
Total cholesterol        
    Participants, n 453 503 303 267 192  
    Mean, mmol/L 6.30 (1.24) 6.17 (1.17) 6.25 (1.17) 6.31 (1.04) 6.26 (1.14)  
    Coef.± Std. Err. (non-adjust) Reference -0.13 (-0.27, 0.02) -0.05 (-0.22, 0.11) 0.01 (-0.17, 0.19) -0.04 (-0.22, 0.14) 0.85 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.18 (-0.35, -0.02) -0.08 (-0.28, 0.11) 0.05 (-0.16, 0.26) -0.07 (-0.29, 0.15) 0.72 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.20 (-0.37, 0.03) -0.09 (-0.29, 0.10) 0.04 (-0.17, 0.25) -0.09 (-0.31, 0.13) 0.84 
Triglycerides4       
    Participants, n 453 503 303 229 230  
    Mean, mmol/L 1.98 (1.23) 1.84 (1.08) 1.86 (1.08) 1.90 (1.15) 2.02 (1.43)  
    Coef.± Std. Err. (non-adjust) Reference -0.07 (-0.13, -0.00) -0.05 (-0.13, 0.02) -0.05 (-0.13, 0.04) -0.02 (-0.10, 0.07) 0.71 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.09 (-0.17, -0.02) -0.09 (-0.17, -0.00) -0.11 (-0.20, -0.02) -0.09 (-0.19, 0.01) 0.05 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.10 (-0.17, -0.03) -0.09 (-0.18, -0.01) -0.12 (-0.21, -0.03) -0.10 (-0.19, -0.00) 0.05 
Fibrinogen4       
    Participants, n 444 498 302 227 227  
    Mean, g/L 4.17 (0.95) 4.24 (0.80) 4.24 (0.80) 4.21 (0.92) 4.13 (0.83)  
    Coef.± Std. Err. (non-adjust) Reference 0.03 (0.00, 0.05) 0.05 (0.02, 0.08) 0.04 (0.01, 0.07) 0.02 (-0.01, 0.06) 0.03 
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    Coef ± Std. Err. (adjusted Model 1) Reference 0.01 (-0.02, 0.04) 0.04 (0.00, 0.07) 0.03 (-0.01, 0.06) 0.02 (-0.02, 0.06) 0.18 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.01 (-0.02, 0.04) 0.04 (0.00, 0.07) 0.03 (-0.01, 0.06) 0.02 (-0.02, 0.06) 0.17 
Systolic blood pressure       
    Participants, n 466 520 313 238 236  
    Mean, mmHg 144.2 (21.9) 142.5 (20.8) 144.4 (23.2) 146.7 (20.4) 147.0 (23.8)  
    Coef.± Std. Err. (non-adjust) Reference -1.73 (-4.48, 1.01) 0.19 (-2.95, 3.33) 2.47 (-0.95, 5.90) 2.85 (-0.59, 6.28) 0.02 
    Coef ± Std. Err. (adjusted Model 1) Reference 2.12 (-5.21, 0.97) 0.01 (-3.59, 3.60) 1.34 (-2.51, 5.19) 2.47 (-1.59, 6.53) 0.08 
    Coef ± Std. Err. (adjusted Model 2) Reference -1.99 (-5.11, 1.12) 0.10 (-3.52, 3.72) 1.46 (-2.41, 5.34) 2.44 (-1.65, 6.53) 0.08 
Diastolic blood pressure       
    Participants, n 466 520 313 238 236  
    Mean, mmHg 81.1 (11.8) 81.5 (12.1) 80.7 (12.2) 81.38 (12.0) 82.5 (11.9)  
    Coef.± Std. Err. (non-adjust) Reference 0.43 (-1.07, 1.93) -0.36 (-2.08, 1.36) 0.29 (-1.58, 2.17) 1.43 (-0.45, 3.31) 0.28 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.15 (-1.55, 1.84) -0.46 (-2.43, 1.52) -0.25 (-2.36, 1.86) 1.17 (-1.06, 3.40) 0.57 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.30 (-1.41, 2.01) -0.38 (-2.37, 1.61) -0.15 (-2.27, 1.98) 1.28 (-0.97, 3.53) 0.52 
1 All values are mean ± SD. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables), adjusted for age (continuous), BMI 
(continuous), energy intake (continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class 
(manual or non-manual), family history of myocardial infarction (yes or no), diabetes mellitus (yes or no). 
3 Adjustd as  model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d). 
4 Original data were transformed to natural logarithms for regression model. 
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Supplemental Table 4 Cross-sectional (Phase 3) analysis of metabolic markers across egg consumption in subjects type 2 diabetes and/or impaired glucose 
tolerance from the Caerphilly Prospective Cohort study1 
  Egg consumption (n, eggs/wk)   
 1 2 3 4 5  
Characteristics (0≤ n ≤1) (1< n ≤2) (2< n ≤3) (3< n <5) (n ≥5) P-trend 
Glucose4       
    Participants, n 76 91 61 44 62  
    Fasting glucose, mmol/L 7.74 (2.60) 7.54 (2.49) 8.20 (2.68) 8.51 (3.25) 8.46 (3.05)  
    Coef.± Std. Err. (non-adjust) Reference -0.02 (-0.11, 0.06) 0.06 (-0.04, 0.15) 0.08 (-0.03, 0.19) 0.08 (-0.02, 0.17) 0.02 
    Coef ± Std. Err. (adjusted Model 1)2 Reference 0.01 (-0.09, 0.11) 0.09 (-0.02, 0.21) 0.13 (-0.00, 0.26) 0.11 (-0.01, 0.23) 0.02 
    Coef ± Std. Err. (adjusted Model 2)3 Reference 0.01 (-0.10, 0.12) 0.09 (-0.03, 0.21) 0.13 (-0.01, 0.27) 0.09 (-0.03, 0.22) 0.04 
Total cholesterol        
    Participants, n 76 90 61 44 62  
    Mean, mmol/L 6.31 (1.13) 6.19 (1.08) 6.15 (1.19) 6.19 (1.19) 6.13 (1.00)  
    Coef.± Std. Err. (non-adjust) Reference -0.12 (-0.46, 0.22) -0.15 (-0.53, 0.22) -0.12 (-0.53, 0.30) -0.18 (-0.55, 0.20) 0.40 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.17 (-0.57, 0.24) -0.14 (-0.59, 0.31) 0.17 (-0.34, 0.68) -0.03 (-0.50, 0.44) 0.67 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.25 (-0.68, 0.18) -0.19 (-0.67, 0.28) 0.10 (-0.44, 0.65) -0.08 (-0.57, 0.41) 0.76 
Triglycerides4       
    Participants, n 76 90 61 44 62  
    Mean, mmol/L 2.35 (1.53) 2.06 (1.42) 2.08 (0.97) 2.66 (1.71) 2.18 (1.45)  
    Coef.± Std. Err. (non-adjust) Reference -0.12 (-0.29, 0.05) -0.05 (-0.24, 0.13) 0.11 (-0.09, 0.32) -0.09 (-0.28, 0.10) 0.92 
    Coef ± Std. Err. (adjusted Model 1) Reference -0.08 (-0.28, 0.11) -0.00 (-0.22, 0.22) 0.10 (-0.14, 0.35) -0.07 (-0.29, 0.16) 0.90 
    Coef ± Std. Err. (adjusted Model 2) Reference -0.09 (-0.30, 0.12) -0.03 (-0.26, 0.20) 0.11 (-0.15, 0.38) -0.07 (-0.31, 0.16) 0.92 
Fibrinogen4       
    Participants, n 74 90 61 44 61  
    Mean, g/L 4.08 (0.78) 4.20 (1.16) 4.23 (0.78) 4.38 (0.91) 4.26 (0.93)  
    Coef.± Std. Err. (non-adjust) Reference 0.01 (-0.05, 0.08) 0.04 (-0.03, 0.11) 0.07 (-0.01, 0.15) 0.04 (-0.03, 0.11) 0.12 
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    Coef ± Std. Err. (adjusted Model 1) Reference 0.02 (-0.06, 0.09) 0.04 (-0.05, 0.13) 0.05 (-0.06, 0.15) 0.04 (-0.05, 0.14) 0.30 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.01 (-0.08, 0.10) 0.04 (-0.06, 0.13) 0.04 (-0.07, 0.15) 0.05 (-0.05, 0.14) 0.28 
Systolic blood pressure       
    Participants, n 75 92 61 46 62  
    Mean, mmHg 118.3 (22.3) 142.9 (20.1) 149.3 (23.1) 150.3 (20.7) 151.2 (22.9)  
    Coef.± Std. Err. (non-adjust) Reference -5.43 (-12.09, 1.23) 0.99 (-6.39, 8.37) 1.98 (-6.04, 9.99) 2.90 (-4.45, 10.25) 0.11 
    Coef ± Std. Err. (adjusted Model 1) Reference -3.31 (-10.91, 4.29) 0.74 (-7.84, 9.32) 5.69 (-3.74, 15.13) 5.32 (-3.62, 14.25) 0.05 
    Coef ± Std. Err. (adjusted Model 2) Reference -5.35 (-13.30, 2.59) -1.23 (-10.09, 7.62) 3.81 (-6.15, 13.76) 4.57 (-4.57, 13.72) 0.07 
Diastolic blood pressure       
    Participants, n 75 92 61 46 62  
    Mean, mmHg 82.2 (12.1) 82.2 (10.3) 83.8 (11.6) 82.2 (12.1) 84.2 (10.9)  
    Coef.± Std. Err. (non-adjust) Reference -0.00 (-3.47, 3.46) 1.57 (-2.27, 5.41) -0.03 (-4.20, 4.14) 2.01 (-1.81, 5.83) 0.32 
    Coef ± Std. Err. (adjusted Model 1) Reference 0.59 (-3.37, 4.56) 0.99 (-3.48, 5.46) 1.83 (-3.09, 6.75) 3.18 (-1.48, 7.84) 0.15 
    Coef ± Std. Err. (adjusted Model 2) Reference 0.22 (-4.01, 4.45) 0.65 (-4.07, 5.36) 1.57 (-3.73, 6.87) 3.27 (-1.60, 8.14) 0.15 
1 All values are mean ± SD; Impaired glucose tolerance, i.e.  fasting glucose ≥ 6.1 mmol/L. 
2 P-trend was assessed by linear regression (continuous variables) or by logistic regression (categorical variables), adjusted for age (continuous), BMI 
(continuous), energy intake (continuous), alcohol consumption (quartiles), smoking (never, past or current), energy expenditure (quartiles), social class 
(manual or non-manual), family history of myocardial infarction (yes or no). 
3 Adjustd as  model 1 plus sugar intake (<50, 50-100, >100 g/d), fruit consumption (<7, 8-14, 15-21, or >21 times/wk), red meat consumption (<7, 8-14, 15-
21, or >21 times/wk) and fibre (cereal and vegetable sources) (<10, 10-20, or >20 g/d). 
4 Original data were transformed to natural logarithms for regression model. 
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Supplemental Table 5 Cross-sectional analysis metabolic markers of adult males (19-64 y) across tertiles of egg consumption from the National Diet and 
Nutrition Survey (2009/10-2011/12)1 
 Egg consumption (n) 
 1 2 3  
Characteristics (n = 0 g/d) (0< n ≤ 29 g/d) (> 29 g/d) P-trend 
Fasting glucose     
    Participants, n 356 204 187  
    Mean, mmol/L 5.08 ± 0.80 5.17 ± 0.98 5.35 ± 1.70  
    Coef.± Std. Err. (non-adjust) Reference 0.10 (-0.10, 0.29) 0.27 (0.07, 0.47) 0.01 
    Coef ± Std. Err. (adjusted)2 Reference 0.12 (-0.04, 0.28) 0.21 (0.05, 0.39) 0.01 
HbA1c     
    Subjects, n 338 188 183  
    HbA1c, mmol/L 5.45 ± 0.43 5.48 ± 0.47 5.65 ± 0.77  
    Coef.± Std. Err. (non-adjust) Reference 0.04 (-0.06, 0.13) 0.20 (0.10, 0.30) <0.001 
    Coef ± Std. Err. (adjusted) Reference 0.06 (-0.02, 0.14) 0.16 (0.08, 0.24) <0.001 
Total cholesterol      
    Participants, n 345 194 185  
    Mean, mmol/L 5.21 ± 1.06 5.37 ± 1.10 5.35 ± 1.15  
    Coef.± Std. Err. (non-adjust) Reference 0.15 (-0.04, 0.35) 0.14 (-0.05. 0.34) 0.12 
    Coef ± Std. Err. (adjusted) Reference 0.09 (-0.10, 0.27) 0.05 (-0.14, 0.23) 0.53 
Triglycerides     
    Participants, n 345 194 185  
    Mean, mmol/L 1.43 ± 1.25 1.30 ± 0.86 1.35 ± 0.83  
    Coef.± Std. Err. (non-adjust) Reference -0.05 (-0.15, 0.05) -0.01 (-0.11, 0.09) 0.71 
    Coef ± Std. Err. (adjusted) Reference -0.03 (-0.12, 0.66) -0.06 (-0.16, 0.04) 0.22 
HDL-cholesterol3     
    Participants, n 345 194 185  
    Mean, mmol/L 1.48 ± 0.43 1.56 ± 0.44 1.51 ± 0.45  
    Coef.± Std. Err. (non-adjust) Reference 0.06 (0.01, 0.11) 0.02 (-0.03, 0.07) 0.27 
    Coef ± Std. Err. (adjusted) Reference 0.03 (-0.02, 0.07) 0.03 (-0.02, 0.08) 0.18 
LDL-cholesterol     
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    Participants, n 334 190 183  
    Mean, mmol/L 3.16 ± 0.92 3.27 ± 0.95 3.28 ± 1.02  
    Coef.± Std. Err. (non-adjust) Reference 0.11 (-0.06, 0.28) 0.13 (-0.05, 0.30) 0.12 
    Coef ± Std. Err. (adjusted) Reference 0.07 (-0.09, 0.23) 0.04 (-0.13, 0.20) 0.57 
Diastolic blood pressure     
    Participants, n 354 202 187  
    Mean, mmol/L 74.75 ± 11.71 74.93 ± 10.23 75.43 ± 10.26  
    Coef.± Std. Err. (non-adjust) Reference 0.17 (-1.73, 2.07) 0.68 (-1.27, 2.62) 0.51 
    Coef ± Std. Err. (adjusted) Reference 0.12 (-1.72, 1.97) 0.21 (-1.68, 2.11) 0.82 
Systolic blood pressure     
    Participants, n 354 202 187  
    Mean, mmol/L 124.43 ± 15.78 124.46 ± 14.87 127.16 ± 15.22  
    Coef.± Std. Err. (non-adjust) Reference 0.03 (-2.64, 2.69) 2.73 (-0.00, 5.46) 0.07 
    Coef ± Std. Err. (adjusted) Reference -0.01 (-2.42, 2.40) 0.81 (-1.67, 3.29) 0.56 
Total/HDL ratio3     
    Participants, n 345 194 185  
    Mean, mmol/L 3.75 ± 1.36 3.61 ± 1.15 3.76 ± 1.25  
    Coef.± Std. Err. (non-adjust) Reference -0.03 (-0.09, 0.03) 0.01 (-0.05, 0.06) 0.96 
    Coef ± Std. Err. (adjusted) Reference -0.01 (-0.06, 0.04) -0.02 (-0.07, 0.03) 0.43 
Pulse Pressure     
    Participants, n 354 202 187  
    Mean, mmol/L 71.30 ± 10.89 70.00 ± 9.77 70.51 ± 11.42  
    Coef.± Std. Err. (non-adjust) Reference -1.30 (-3.16, 0.56) -0.79 (-2.70, 1.11) 0.32 
    Coef ± Std. Err. (adjusted) Reference -0.76 (-2.60, 1.09) -0.29 (-2.19, 1.60) 0.70 
C-reactive protein     
    Participants, n 345 194 185  
    Mean, mmol/L 1.70 ± 1.01 1.66 ± 1.08 1.74 ± 1.06 0.50 
1 All values are mean ± SD. 
2 P-trend was assessed by linear regression (continuous variables) or by Pearson chi-square test (categorical variables), adjusted for age (continuous), food 
energy (continuous), alcohol consumption (tertiles), smoking (yes or no), sex (men or women), and incident of diabetes (yes or no).    
3 Original data were transformed to natural logarithms for regression model. 
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Supplemental Table 6 Cross-sectional analysis of metabolic markers across egg consumption in subjects with subjects type 2 diabetes and/or impaired 
glucose tolerance from the National Diet and Nutrition Survey (2009/10-2011/12)1 
 Egg consumption (n) 
 1 2 3  
Characteristics (n = 0 g/d) (0< n ≤ 29 g/d) (> 29 g/d) P-trend 
Fasting glucose     
    Participants, n 25 18 16  
    Mean, mmol/L 7.01± 1.53 7.20 ± 2.11 8.89 ± 4.34  
    Coef.± Std. Err. (non-adjust) Reference 0.19 (-1.50, 1.88) 1.88 (0.14, 3.63) 0.04 
    Coef ± Std. Err. (adjusted)2 Reference 0.51 (-1.24, 2.25) 2.25 (0.55, 3.95) 0.01 
HbA1c     
    Subjects, n 24 17 16  
    HbA1c, mmol/L 6.15 ± 0.65 6.37 ± 0.75 7.01 ± 1.92  
    Coef.± Std. Err. (non-adjust) Reference 0.22 (-0.52, 0.97) 0.87 (0.11, 1.62) 0.03 
    Coef ± Std. Err. (adjusted) Reference 0.36 (-0.38, 1.11) 1.10 (0.37, 1.83) 0.004 
Total cholesterol      
    Participants, n 25 17 16  
    Mean, mmol/L 5.24 ± 1.51 4.98 ± 0.94 5.16 ± 1.04  
    Coef.± Std. Err. (non-adjust) Reference -0.26 (-1.04, 0.52) -0.07 (-0.87, 0.72) 0.79 
    Coef ± Std. Err. (adjusted) Reference -0.37 (-1.24, 0.50) -0.26 (-1.10, 0.59) 0.51 
Triglycerides     
    Participants, n 25 17 16  
    Mean, mmol/L 3.15 ± 3.03 1.78 ± 1.21 2.13 ± 1.29  
    Coef.± Std. Err. (non-adjust) Reference -0.43 (-0.86, 0.00) -0.20 (-0.64, 0.24) 0.28 
    Coef ± Std. Err. (adjusted) Reference -0.28 (-0.75, 0.19) -0.19 (-0.65, 0.26) 0.37 
HDL-cholesterol3     
    Participants, n 25 17 16  
    Mean, mmol/L 4.96 ± 2.34 3.99 ± 1.41 4.29 ± 1.19  
    Coef.± Std. Err. (non-adjust) Reference -0.18 (-0.43, 0.06) -0.08 (-0.34, 0.17) 0.42 
    Coef ± Std. Err. (adjusted) Reference -0.10 (-0.36, 0.17) -0.08 (-0.33, 0.18) 0.52 
LDL-cholesterol     
    Participants, n 19 16 15  
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    Mean, mmol/L 2.92 ± 1.29 2.89 ± 0.82 3.06 ± 0.88  
    Coef.± Std. Err. (non-adjust) Reference -0.03 (-0.74, 0.69) 0.15 (-0.58, 0.87) 0.70 
    Coef ± Std. Err. (adjusted) Reference -0.25 (-1.06, 0.55) -0.05 (-0.84, 0.75) 0.91 
Diastolic blood pressure     
    Participants, n 24 18 16  
    Mean, mmol/L 78.92 ± 10.88 77.17 ± 8.03 75.75 ± 7.46  
    Coef.± Std. Err. (non-adjust) Reference -1.75 (-7.50, 4.00) -3.17 (-9.12, 2.78) 0.28 
    Coef ± Std. Err. (adjusted) Reference -0.08 (-6.14, 5.98) -2.53 (-8.39, 3.32) 0.40 
Systolic blood pressure     
    Participants, n 24 18 16  
    Mean, mmol/L 132.83 ± 16.24 129.22 ± 9.13 128.31 ± 8.33  
    Coef.± Std. Err. (non-adjust) Reference -3.61 (-11.39, 4.17) -4.52 (-12.57, 3.53) 0.24 
    Coef ± Std. Err. (adjusted) Reference -0.60 (-9.04, 7.84) -3.53 (-11.69, 4.63) 0.39 
Total/HDL ratio3     
    Participants, n 25 17 16  
    Mean, mmol/L 4.96 ± 2.34 3.99 ± 1.41 4.29 ± 1.19  
    Coef.± Std. Err. (non-adjust) Reference -0.18 (-0.43, 0.06) -0.08 (-0.34, 0.17) 0.42 
    Coef ± Std. Err. (adjusted) Reference -0.10 (-0.36, 0.17) -0.08 (-0.33, 0.18) 0.52 
Pulse Pressure     
    Participants, n 24 18 16  
    Mean, mmol/L 73.79 ± 10.45 73.22 ± 9.84 73.31 ± 11.39  
    Coef.± Std. Err. (non-adjust) Reference -0.57 (-7.15, 6.01) -0.48 (-7.29, 6.34) 0.88 
    Coef ± Std. Err. (adjusted) Reference 1.30 (-6.05, 8.65) 0.66 (-6.44, 7.77) 0.84 
C-reactive protein     
    Participants, n 25 17 16  
    Mean, mmol/L 2.16 ± 0.90 1.88 ± 0.93 1.56 ± 0.73 0.13 
1 All values are mean ± SD; Impaired glucose tolerance, i.e.  fasting glucose ≥ 6.1 mmol/L. 
2 P-trend was assessed by linear regression (continuous variables) or by Pearson chi-square test (categorical variables), adjusted for age (continuous), food 
energy (continuous), alcohol consumption (tertiles), smoking (yes or no), sex (men or women).    
3 Original data were transformed to natural logarithms for regression model. 
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Chapter 5 - Effect of production system, supermarket and purchase date on 
the vitamin D content of eggs at retail (Published: Food Chemistry 2016; 221:1021-
5) 
The present chapter aims to examine the vitamin D content (vitamin D3 and 25(OH) D3) of 
retail eggs in the UK, and possible effect of production system (indoor vs outdoor), 
supermarket and purchase date. 
 
DIG designed the study. JG conducted the research with help from students Sarah Barnsley 
and Sophie Franks who collected the samples. JG wrote the manuscript. All authors read and 
approved the final manuscript. 
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Chapter 6 - Milk and dairy consumption and risk of cardiovascular 
diseases and all-cause mortality: dose-response meta-analysis of prospective 
cohort studies (Published: European Journal of Epidemiology 2017 (doi:10.1007/s10654-
017-0243-1)). 
 
The present chapter aims to to examine linear and non-linear dose-response associations 
between milk and dairy products with CHD, CVD events and all-cause mortality using 
existing prospective cohort studies of adequate quality. 
 
JG, AA, DIG, JAL, and SSSM designed the research. JG performed the literature search, 
extracted data. JG, SSSM checked data. JG performed the analyses and drafted the paper.  
AA, DIG, JAL, SSSM critically reviewed and improved it. JG is guarantor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
 
 
 
 
 112 
 
  
 113 
 
  
 114 
 
  
 115 
 
  
 116 
 
  
 117 
 
  
 118 
 
  
 119 
 
  
 120 
 
  
 121 
 
  
 122 
 
  
 123 
 
  
 124 
 
  
 125 
 
  
 126 
 
  
 127 
 
  
 128 
 
  
 129 
 
  
 130 
 
Online Supporting Material  
CONTENT 
Supplemental Methods  
 Search strategy. 
 Newcastle-OTTAWA quality assessment scale to determine quality of prospective 
cohort studies. 
Supplemental Tables 
 Supplemental Table 1. Quality assessment of prospective cohort studies on dairy 
intake, risk of CHD, CVD and all-cause mortality. 
 Supplemental Table 2. Definition of dairy products as described in original 29 
prospective cohort studies included in the meta-analysis. 
 Supplemental Table 3. Association between dairy foods and all-cause mortality by 
subgroups. 
 Supplemental Table 4. Association between dairy foods and CHD by subgroups. 
 Supplemental Table 5. Association between dairy foods and CVD by subgroups 
Supplemental Figures 
 Supplemental Figure 1. Forest plot for the association between total dairy intake and 
all-cause mortality. 
 Supplemental Figure 2. Forest plot for the association between total dairy intake and 
CHD. 
 Supplemental Figure 3. Forest plot for the association between total dairy intake and 
CVD. 
 Supplemental Figure 4. Forest plot for the association between high-fat dairy intake 
and all-cause mortality. 
 Supplemental Figure 5. Forest plot for the association between high-fat dairy intake 
and CHD. 
 Supplemental Figure 6. Forest plot for the association between high-fat dairy intake 
and CVD. 
 Supplemental Figure 7. Forest plot for the association between low-fat dairy intake 
and all-cause mortality. 
 Supplemental Figure 8. Forest plot for the association between low-fat dairy intake 
and CHD. 
 Supplemental Figure 9. Forest plot for the association between low-fat dairy intake 
and CVD. 
 Supplemental Figure 10. Forest plot for the association between milk intake and all-
cause mortality. 
 Supplemental Figure 11. Forest plot for the association between milk intake and CHD. 
 131 
 
 Supplemental Figure 12. Forest plot for the association between milk intake and CVD. 
 Supplemental Figure 13. Forest plot for the association between total fermented dairy 
intake and CHD. 
 Supplemental Figure 14. Forest plot for the association between cheese intake and all-
cause mortality. 
 Supplemental Figure 15. Forest plot for the association between cheese intake and 
CHD. 
 Supplemental Figure 16. Forest plot for the association between yogurt intake and all-
cause mortality. 
 Supplemental Figure 17. Forest plot for the association between yogurt intake and 
CHD. 
 Supplemental Figure 18. Forest plot for the association between yogurt intake and 
CVD. 
 Supplemental Figure 19. Funnel plot for studies of the association between total dairy 
intake and all-cause mortality. 
 Supplemental Figure 20. Funnel plot for studies of the association between total dairy 
intake and CHD. 
 Supplemental Figure 21. Funnel plot for studies of the association between low-fat 
dairy intake and CHD. 
 Supplemental Figure 22. Funnel plot for studies of the association between milk intake 
and all-cause mortality. 
 Supplemental Figure 23. Funnel plot for studies of the association between milk intake 
and CHD. 
 Supplemental Figure 24. Funnel plot for studies of the association between milk intake 
and CVD. 
 Supplemental Figure 25. Funnel plot for studies of the association between fermented 
dairy intake and CHD. 
 Supplemental Figure 26. Funnel plot for studies of the association between cheese 
intake and all-cause mortality. 
 Supplemental Figure 27. Funnel plot for studies of the association between cheese 
intake and CHD. 
 Supplemental Figure 28. Ding’s Spaghetti plot for the association between total dairy 
intake and all-cause mortality. 
 
 
 
 
 
 
 
 
 
 132 
 
Supplemental Methods 
Search strategy (PubMed) – updated until Sep 2016 
EMBASE (http://www.embase.com) and SCOPUS (http://www.scopus.com) search strategies 
were based on the PubMed (http://www.ncbi.nlm.nih.gov/pubmed) query syntax which is 
shown below. 
 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed)  
Action 1 Determinants  
#1 dairy [Title/Abstract]) OR milk*[Title/Abstract]) OR cheese*[Title/Abstract]) OR 
yogurt*[Title/Abstract]) OR yogurt*[Title/Abstract]) OR butter [Title/Abstract]) OR 
buttermilk [Title/Abstract]) OR dietary pattern*[Title/Abstract] 
#2 dairy products [MeSH Terms]) OR milk [MeSH Terms]) OR cheese [MeSH Terms]) OR 
yogurt[MeSH Terms]) OR butter[MeSH Terms]) OR cultured milk products[MeSH Terms] 
#3 custard*[Title/Abstract]) OR pudding*[Title/Abstract]) OR cream*[Title/Abstract]) OR 
cream[Title/Abstract]) OR ice cream[Title/Abstract]) OR ice-cream[Title/Abstract]) OR 
curd*[Title/Abstract]) OR porridge[Title/Abstract] 
#4 diet[Title/Abstract]) OR diets[Title/Abstract]) OR dietary[Title/Abstract]) OR 
intake*[Title/Abstract]) OR suppl*[Title/Abstract]) OR consumption[Title/Abstract]) OR 
food*[Title/Abstract]) OR drink*[Title/Abstract]) OR meal[Title/Abstract]) OR 
nutrition[Title/Abstract]) OR nutrient*[Title/Abstract]) OR products[Title/Abstract] 
#5 [(#1 OR #2 OR #3) AND #4] 
Action 2 Outcome 
#6 diet[Title/Abstract]) OR diets[Title/Abstract]) OR dietary[Title/Abstract]) OR 
intake*[Title/Abstract]) OR suppl*[Title/Abstract]) OR consumption[Title/Abstract]) OR 
food*[Title/Abstract]) OR drink*[Title/Abstract]) OR meal[Title/Abstract]) OR 
nutrition[Title/Abstract]) OR nutrient*[Title/Abstract]) OR products[Title/Abstract] 
#7 cardiovascular [Title/Abstract]) OR vascular [Title/Abstract]) OR CVD [Title/Abstract]) 
OR Cardiovascular Diseases [Mesh:NoExp] 
#8 coronary[Title/Abstract]) OR cardiac[Title/Abstract]) OR heart[Title/Abstract]) OR 
infarction*[Title/Abstract]) OR infarct*[Title/Abstract]) OR ischaemic[Title/Abstract]) OR 
ischemic[Title/Abstract]) OR ischaemia[Title/Abstract]) OR ischemia[Title/Abstract]) OR 
CHD[Title/Abstract]) OR CAD[Title/Abstract]) OR MI[Title/Abstract]) OR 
myocard*[Title/Abstract]) OR Coronary Artery Disease[Mesh:NoExp]) OR coronary 
disease[Mesh:NoExp] 
#9 cerebrovascular*[Title/Abstract]) OR stroke[Title/Abstract]) OR CVA[Title/Abstract]) OR 
Cerebrovascular disease[Mesh:NoExp]) OR stroke[Mesh:NoExp] 
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#10 (#6 OR #7 OR #8 OR #9) 
Action 3 Combine exposure and outcome 
#11 (#5 AND #10) 
Action 4 Limits 
#12 Rats[Mesh:NoExp]) OR Mice[Mesh:NoExp]) OR rat[Title/Abstract]) OR 
rats[Title/Abstract]) OR mouse[Title/Abstract]) OR mice[Title/Abstract]) OR 
vivo[Title/Abstract]) OR vitro[Title/Abstract]) 
#13 (#11 NOT #12) 
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NEWCASTLE – OTTAWA QUALITY ASSESSMENT SCALE 
COHORT STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability.  
Selection  
1) Representativeness of the exposed cohort  
a) truly representative of the average healthy adults in the community   
b) somewhat representative of the average healthy adults in the community  
c) selected group of users e.g. nurses, volunteers, vegetarian 
d) no description of the derivation of the cohort  
2) Selection of the non-exposed cohort  
a) drawn from the same community as the exposed cohort   
b) drawn from a different source  
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure  
a) secure record (e.g. 7 day food diary)   
b) structured interview/≥ 2 dietary recalls/diet history/ food frequency questionnaire validated 
for dairy components   
c) written self-report (e.g. <2 dietary recalls/non-validated food frequency questionnaire or 
not reported whether food frequency questionnaire was validated)  
d) no description  
4) Demonstration that outcome of interest was not present at start of study  
a) yes  
b) no  
 
Comparability  
1) Comparability of cohorts on the basis of the design or analysis  
a) study controls for age, sex, smoking, total energy intake, and body mass index  
b) study controls for any additional factor (e.g. physical activity, alcohol intake, family history 
of diabetes, dietary factors)  
 
Outcome  
1) Assessment of outcome  
a) independent blind assessment (e.g. clinical diagnosis/complete medical information 
available).  
b) record linkage/medical record or validated self-report  
c) non-validated self-report 
d) no description  
2) Was follow-up long enough for outcomes to occur  
a) yes/ follow up period for outcome of interest is 10 years or over  
b) no  
3) Adequacy of follow-up of cohorts  
a) complete follow-up - all subjects accounted for   
b) subjects lost to follow-up unlikely to introduce bias - small number lost ≤20% follow-up, 
or description provided of those lost  
c) follow-up rate <80% or no description of those lost  
d) no statement
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Supplemental Table 1. Quality assessment of cohorts studies on dairy intake, risk of CHD, CVD or all-cause mortality. 
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Kahn et al, 1984 [1] B  A  C B - B  A  B  5 
Mann et al, 1997 [2] C A  C A  - B  A  D 4 
Hu et al, 1999 [3] C A  B  A  A       B  B  A  B  8 
Appleby et al, 1999 [4] C A  B  B - B  A  B  6 
Bostick et al, 1999 [5] C A  B  A  A       B  B  B B  9 
Fortes et al,  2000 [6] C A  B  A  - B  B B  6 
Ness et al, 2001 [7] B  A  D A  - B  A  D 5 
Al-Delaimy et al, 2003 [8] C A  B  A  A       B  B  A  B  8 
Elwood et al, 2004 [9] B  A  A  A  A       B  A  A  B  8 
Knoops et al, 2006 [10] B  A  B  A  - D A  D 5 
Paganini-Hill et al, 2007 [11] B  A  C A  - B  A  B  6 
Panagiotakos et al, 2009 [12] B  A  B  A  - B  B C 5 
Engberink et al, 2009 [13] A  A  B  A  A       B  A  A  D 8 
Bonthuis et al. 2010 [14] B  A  B  A  A       B  B  A  B  8 
Goldbohm et al. 2011 [15] A  A  B  A  A       B  B  A  B  9 
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Sonestedt et al. 2011 [16] B  A  A  A  A       B  A  A  A  9 
Kondo et al. 2012 [17] A  A  B  A  A       B  B  A  B  9 
Dalmeijer et al, 2012 [18] A  A  B  A  A       B  B  A  B  9 
Patterson et al. 2013 [19] B  A  B  A  - B  A  C 6 
Soedamah-Muthu et al. 2013 [20] C A  B  A  A       B  A  A  D 7 
Louie et al. 2013 [21] C A  B  A  A       B  B  A  B  9 
von Ruesten et al, 2013 [22] A  A  B  A  A       B  B  B  A  8 
Van Aerde et al, 2013 [23] B  A  B  A  A       B  B  A  B  9 
Michaelsson et al. 2014 [24] 
 -Swedish Mammography Cohort  B  A  A  A  A       B  B  A  C 8 
-The Cohort of Swedish Men  B  A  A  A  A       B  B  A  C 8 
Praagman et al. 2014 (Rotterdam) [25] A  A  B  A  A       B  A  A  B  8 
Haring et al, 2014 [26] B  A  C A  A       B  B  A  C 7 
Huang et al. 2015 [27] A  A  B  A  - B  A  D 6 
Bergholdt et al, 2015 [28] A  A  B  A  - A  B  B  6 
Praagman et al. 2015 [29] B  A  B  A  A       B  A  A  B  9 
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Wang et al. 2015 [30] B  A  C A  - B  A  A  6 
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Supplemental Table 2. Definition of dairy products as described in the paper of 29 prospective cohort studies included in the meta-analysis. 
Exposure category in original paper Exposure category  
in meta-analysis 
Definition (if available) 
Kahn et al, 1984 [1]   
Milk Milk Not further defined 
Cheese Cheese Not further defined 
Mann et al, 1997 [2]     
Milk Milk  Not further defined 
Cheese Cheese Cheese (excluding cottage) 
Hu et al, 1999 [3]     
Total dairy Total dairy Not further defined 
High-fat dairy High-fat dairy Whole milk, hard or cream cheese, ice cream, and butter 
Low-fat dairy Low-fat dairy Skim or low-fat milk, yogurt, and cottage cheese 
Milk Milk Not further defined 
Appleby et al, 1999 [4]     
Milk Milk Not further defined 
Cheese Cheese Not further defined 
Bostick et al, 1999 [5]     
Total dairy Total dairy Milk products excluding butter 
Fat-containing dairy intake High-fat dairy Milk products other than butter containing fat (exclude skim milk) 
Fortes et al, 2000 [6]     
Cheese Cheese Not further defined 
Ness et al, 2001 [7]     
Milk Milk Milk  
Al-Delaimy et al, 2003 [8]     
Total dairy Total dairy Not further defined 
High-fat dairy High-fat dairy Not further defined 
Low-fat dairy Low-fat dairy Not further defined 
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Milk Milk Not further defined 
Elwood et al, 2004 [9]     
Milk Milk Liquid milk, not milk used in food preparation 
Knoops et al, 2006 [10]   
Milk and milk products Total dairy Not further defined 
Paganini-Hill et al, 2007 [11]     
Milk Milk Milk  
Panagiotakos et al, 2009 [12]     
Dairy products Total dairy Not further defined 
Cheese Cheese Not further defined 
Yogurt Yogurt Not further defined 
Milk Milk Not further defined 
Bonthuis et al. 2010 [14]     
Total dairy  Total dairy  Skim milk, low-fat milk, low-fat yogurt, cottage or ricotta cheese, whole 
milk, cream, ice cream, yogurt, full-fat cheese and custard 
Low-fat dairy Low-fat dairy Skim milk, low-fat milk, low-fat yogurt, cottage or ricotta cheese 
Full-fat dairy Full-fat dairy Whole milk, cream, ice cream, yogurt, full-fat cheese and custard 
Milk Milk Whole milk, skimmed and low-fat milk 
Yogurt Yogurt Not further defined 
Full-fat cheese Full-fat cheese Not further defined 
Goldbohm et al. 2011 [15]     
Milk products  Total dairy  Milk, yogurt, buttermilk, quark, and dishes in which these foods were used 
Nonfermented full-fat milk High-fat dairy Whole milk (3.7% fat), cream (36%, 20% fat), condensed whole milk, 
whole-milk cocoa, pudding, and ice cream 
Nonfermented low-fat milk Low-fat dairy Low-fat milk (1.5% fat), skim milk (0.1% fat), condensed low-fat milk, and 
low-fat and skim cocoa 
Fermented full-fat milk High-fat fermented dairy  Yogurt (3.5% fat), full-fat quark (fresh cheese), and sour cream 
Fermented low-fat milk Low-fat fermented dairy Buttermilk, skim yogurt (0.1% fat), and non-fat quark (fresh cheese) 
Cheese Cheese Not further defined 
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butter Butter Not further defined 
Low-fat dairy Low-fat dairy Not further defined 
Sonestedt et al. 2011 [16]     
Total dairy Total dairy Milk, cheese (>10% fat), cream, butter (including the milk-based spread 
Bregott) 
Milk Milk products Fermented (yogurt and processed sour milk), non-fermented milk products 
Fermented milk Fermented dairy Yogurt and processed sour milk 
Low-fat milk Low-fat dairy Milk and milk products≤2.4% fat 
high-fat milk High-fat dairy Milk and milk products>2.4% fat 
cheese Cheese  Cheese>10% fat 
Kondo et al. 2012 [17]   
Milk and dairy product 
consumption 
Milk 93% was in the form of milk 
Dalmeijer et al, 2012 [18]   
Total dairy intake Total dairy intake All dairy food products except for butter and ice cream.  
High-fat dairy High-fat dairy Milk and milk products with a fat content ≥2 g/100 g (whole milk products) 
or cheese products with a fat content ≥20 g/100 g.  
Low-fat dairy Low-fat dairy Milk and milk products with a fat content<2 g/100 g (skimmed or semi-
skimmed milk products) or cheese with a fat content< 20 g/100 g 
Cheese Cheese All types of cheese except for curd 
Fermented dairy Fermented dairy Buttermilk, yogurts, and cheese 
Patterson et al. 2013 [19]     
Total dairy foods Total dairy Total dairy intake was the sum of milk [full-fat (≥3.0% fat), semi-skimmed 
(≤1.5% fat), skimmed (0.5% fat), and pancakes], cultured milk/yogurt [full-
fat (≥3.0% fat) and low-fat (≤1.5% fat)], cheese [full-fat (>17% fat), low-fat 
(≤17% fat), and cottage cheese/quark], cream and crème fraiche (full-fat and 
low-fat) intakes. 
Milk  Milk Full-fat (≥3.0% fat), semi-skimmed (≤1.5% fat), skimmed (0.5% fat), and 
pancakes (A serving of pancakes contributed one serving of total milk) 
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Low-fat milk Low-fat milk Semi-skimmed (≤1.5% fat) and skimmed (0.5% fat) 
Full-fat milk Full-fat  milk Milk (≥3.0% fat) 
Cultured milk /yogurt Fermented dairy Not further defined 
Low-fat cultured milk/ yogurt Low-fat fermented dairy Cultured milk/yogurt (≤1.5% fat) 
Full-fat cultured milk/yogurt High-fat fermented dairy Cultured milk/yogurt (≥3.0% fat) 
Cheese cheese Full-fat (>17% fat), low-fat (≤17% fat), and cottage cheese/quark 
Low-fat cheese Low-fat cheese Low-fat varieties (10–17%) and excluded very-low-fat cheese (i.e., cottage 
cheese/quark (4% fat)) 
High-fat cheese Full-fat cheese Cheese (>17% fat) 
Soedamah-Muthu et al. 2013 [20]     
Total dairy Total dairy All dairy products, except butter and ice cream 
High-fat dairy High-fat dairy Full-fat cheese, yogurt, milk puddings, whole and Channel Islands milk 
Low-fat dairy Low-fat dairy Cottage cheese, semi-skimmed, skimmed milk and milk-based hot drinks 
Total milk Total milk Whole and low-fat milk 
Fermented dairy Fermented dairy Yogurt and total cheese 
Cheese Cheese Full-fat cheese and cottage 
Yogurt Yogurt Not further defined 
Louie et al. 2013 [21]     
Total dairy Total dairy  Whole fat milk, reduced fat/skim milk, low fat cheese, whole fat cheese, 
reduced fat dairy dessert (e.g., low fat yogurt), and medium fat dairy dessert 
(e.g., custard and whole fat yogurt). 
Low/reduced fat dairy Low-fat dairy Reduce fat/ skim milk, reduced fat dairy dessert and low fat cheese 
Whole fat dairy Full-fat dairy Whole fat milk, whole fat cheese and medium fat dairy dessert 
von Ruesten et al, 2013 [22]     
Low-fat dairy Low-fat dairy Fat-reduced variants of: milk/milkshake (1.5% fat or less), yogurt, fruit 
yogurt (1.5% fat or less), soured milk/kefir, curd/curd with herbs 
High-fat dairy High-fat dairy Normal- or high-fat variants of: milk/milkshake, yogurt, fruit yogurt, soured 
milk/kefir, curd/curd with herbs 
Low-fat cheese Low-fat cheese Fat-reduced variants of: Cream cheese, hard cheese (for example, gouda, 
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Emmental cheese, Tilsiter cheese), soft cheese (for example, camembert, 
brie, gorgonzola) 
High-fat cheese High-fat cheese Normal- or high-fat variants of: Cream cheese, processed cheese, hard cheese 
(for example, gouda, Emmental cheese, Tilsiter cheese), soft cheese (for 
example, camembert, brie, gorgonzola), whipped cream 
Van Aerde et al, 2013 [23]     
Total dairy Total dairy Includes all dairy products, except butter 
High-fat dairy High-fat dairy All milk products with a fat content>2.0/100 g or cheese products with a fat 
content>20 g/100 g 
Low-fat dairy Low-fat dairy All milk products with a fat content<2.0/100 g or cheese products with a fat 
content<20/100 g 
Milk Milk All milk: skimmed, semi-skimmed, and whole milk 
Fermented dairy Fermented dairy All fermented products, such as yogurt, buttermilk, curds, and cheese 
products 
Cheese Cheese Soft cheese and hard cheese (both low-fat and high-fat) 
Michaelsson et al. 2014 [24]     
Milk Milk Not further defined 
Cheese Cheese Not further defined 
Fermented milk products Fermented dairy Yogurt and other soured milk products 
Praagman et al. 2014 [25] and Engberink et al. 2009 [13]   
Total dairy Total dairy Milk, buttermilk, yogurt, coffee creamer, curd, pudding, porridge, custard, 
whipped cream, ice cream, and cheese, but not butter 
Low-fat dairy Low-fat dairy Milk and milk products with a fat content <2.0/100 g and cheese products 
with a fat content <20/100 g 
High-fat dairy High-fat dairy Milk and milk products with a fat content ≥2.0/100 g and cheese products 
with a fat content >20/100 g 
Fermented dairy Fermented dairy All types of buttermilk, yogurt, curd and cheese 
Cheese Cheese All types of cheese, excluding curd 
Yogurt Yogurt Not further defined 
Haring et al, 2014 [26]     
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Total dairy intake Total dairy intake Not further defined 
High-fat dairy High-fat dairy Not further defined 
Low-fat dairy Low-fat dairy Not further defined 
Huang et al. 2015 [27]     
Total dairy Total dairy Liquid milk and fat-free, low-fat, high-fat, and flavoured dairy products 
Bergholdt et al, 2015 [28]     
Milk Milk whole milk (3.5% fat), semi-skimmed (0.5-1.5% fat) and skimmed milk (0.1-
0.3% fat) 
Praagman et al. 2015 [29]     
Fermented dairy foods Fermented dairy Butter milk, yogurt (fat and skim), yogurt drink, curd 
Yogurt Yogurt Not further defined 
Cheese Cheese Cheese 'Goudse', cheese 'Edammer' 40+, cheese 'Leidse', cheese 'brie' 50+, 
cheese 'Trenta', cheese on pizza 
Wang et al. 2015 [30]     
Milk  Milk Not further defined 
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Supplemental Table 3. Association between dairy foods and all-cause mortality by 
subgroups1. 
Dairy food Subgroup 
No. study 
populations 
Relative risk  Heterogeneity test 
(95% CI)2 I² (%) P-value 
Total dairy Overall 10 0.99 (0.96, 1.03) 62.2 0.005 
Per 200 g/d Age (y) 
    
 
≤50  3 0.90 (0.73, 1.11) 62.4 0.070 
 
>50  7 0.99 (0.96, 1.04) 67.4 0.005 
 
Follow-up time (y) 
    
 
≤10  5 1.02 (0.99, 1.05) 51.6 0.083 
 
>10 5 0.93 (0.87, 1.01) 54.0 0.069 
 
Gender 
    
 
Men 1 1.01 (0.99, 1.03) 
  
 
Women 1 1.02 (0.99, 1.06) 
  
 
Men and Women 8 0.96 (0.90, 1.03) 65.5 0.005 
 
Continent 
    
 
Europe 8 1.00 (0.97, 1.03) 62.0 0.010 
 
Australia 1 0.80 (0.65, 1.00) 
 
 
Asia 1 0.69 (0.35, 1.33) 
 
 
Confounding factors2 
 
Yes 6 0.99 (0.96, 1.03) 61.3 0.024 
 
No 4 0.95 (0.76, 1.21) 70.1 0.018 
 
BMI 
    
 
≤25 3 1.01 (1.00, 1.03) 0.0 0.458 
 
>25 6 0.95 (0.89, 1.01) 65.5 0.013 
 
Newcastle-Ottawa quality score 
   
 
<7 3 0.78 (0.42, 1.45) 76.9 0.013 
 
≥7 7 0.99 (0.96, 1.02) 57.9 0.027 
Low-fat dairy Overall 7 1.01 (0.99, 1.03) 0.0 0.734 
Per 200 g/d Age (y) 
    
 
≤50  2 1.01 (0.95, 1.08) 0.0 0.753 
 
>50 5 1.01 (0.99, 1.03) 0.0 0.483 
 
Follow-up time (y) 
    
 
≤10  3 1.02 (0.99, 1.04) 0.0 0.813 
 
>10 4 0.97 (0.93, 1.02) 0.0 0.896 
 
Gender 
    
 
Men 1 1.01 (0.98, 1.04) 
  
 
Women 1 1.03 (0.99, 1.06) 
  
 
Men and Women 5 0.99 (0.95, 1.02) 0.0 0.823 
 
Continent 
    
 
Europe 6 1.01 (0.99, 1.03) 0.0 0.624 
 
Australia 1 0.97 (0.74, 1.27) 
  
 
Confounding factors2 
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Yes 6 1.01 (0.99,1.03) 0.0 0.816 
 
No 1 0.98 (0.92, 1.03) 
  
 
BMI 
    
 
≤25 2 1.02 (0.99, 1.04) 0.0 0.522 
 
>25 5 0.99 (0.95, 1.02) 0.0 0.823 
 
Newcastle-Ottawa quality score 
   
 
<7 0 
   
 
≥7 7 1.01 (0.99, 1.03) 0.0 0.734 
Milk  Overall 12 1.00 (0.93, 1.07) 97.4 <0.001 
Per 244 g/d Age (y) 
    
 
≤50  3 0.95 (0.92, 0.98) 0.0 0.479 
 
>50 8 1.02 (0.93, 1.11) 97.8 <0.001 
 
Follow-up time (y) 
    
 
≤10  0 
 
 
>10 12 1.00 (0.93, 1.07) 97.4 <0.001 
 
Gender 
    
 
Men 4 0.99 (0.94, 1.04) 85.9 <0.001 
 
Women 2 1.09 (0.83, 1.43) 98.6 <0.001 
 
Men and Women 6 0.99 (0.96, 1.03) 43.4 0.116 
 
Continent 
    
 
Europe 7 1.01 (0.91, 1.13) 98.2 <0.001 
 
Australia 1 0.91 (0.68, 1.22) 
 
 
Asia 2 0.95 (0.91, 0.99) 0.0 0.934 
 
USA 2 1.01 (0.98, 1.05) 70.9 0.064 
 
Confounding factors2 
 
Yes 5 1.03 (0.93, 1.07) 98.3 <0.001 
 
No 7 0.98 (0.95, 1.01) 71.2 0.002 
 
BMI 
    
 
≤25 5 1.01 (0.88, 1.16) 98.3 <0.001 
 
>25 6 0.99 (0.94, 1.04) 71.8 0.003 
 
Newcastle-Ottawa quality score 
   
 
<7 6 0.97 (0.94, 1.01) 74.7 0.001 
 
≥7 6 1.04 (0.92,1.17) 97.9 <0.001 
Total fermented dairy Overall 19 0.98 (0.97, 0.99) 94.4 <0.001 
Per 20 g/d Age (y) 
    
 
≤50  6 1.00 (0.99, 1.00) 0.0 0.816 
 
>50 12 0.97 (0.96, 0.99) 96.5 <0.001 
 
Follow-up time (y) 
    
 
≤10  6 0.99 (0.99, 1.00) 59.7 0.030 
 
>10 13 0.97 (0.96, 0.99) 96.1 <0.001 
 
Gender 
    
 
Men 4 0.99 (0.98, 1.00) 72.0 0.013 
 
Women 4 0.96 (0.92, 1.00) 99.0 <0.001 
 
Men and Women 11 0.99 (0.99, 1.00) 20.3 0.250 
 
Continent 
    
 
Europe 16 0.98 (0.97, 0.99) 95.3 <0.001 
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Australia 2 1.06 (0.95, 1.18) 0.0 0.389 
 
USA 1 0.99 (0.94, 1.04) 
 
 
Confounding factors2 
 
Yes 15 0.98 (0.97, 0.99) 95.6 <0.001 
 
No 4 0.97 (0.94, 1.01) 0.0 0.609 
 
BMI 
    
 
≤25 7 0.97 (0.95, 1.00) 98.0 <0.001 
 
>25 11 0.99 (0.99, 1.00) 42.2 0.068 
 
Newcastle-Ottawa quality score 
   
 
<7 3 0.99 (0.95, 1.04) 0.0 0.805 
 
≥7 16 0.98 (0.97, 0.99) 95.3 <0.001 
Cheese Overall 13 0.99 (0.96, 1.01) 93.3 <0.001 
Per 10 g/d Age (y) 
    
 
≤50  4 1.00 (0.98, 1.02) 0.0 0.784 
 
>50 8 0.98 (0.95, 1.01) 95.8 <0.001 
 
Follow-up time (y) 
    
 
≤10  4 1.00 (0.99, 1.02) 21.1 0.284 
 
>10 9 0.98 (0.96, 1.01) 93.4 <0.001 
 
Gender 
    
 
Men 2 1.00 (0.98, 1.02) 88.5 0.003 
 
Women 2 0.96 (0.91, 1.02) 97.5 <0.001 
 
Men and Women 9 0.99 (0.98, 1.00) 0.0 0.918 
 
Continent 
    
 
Europe 11 0.99 (0.96, 1.01) 94.3 <0.001 
 
Australia 1 0.96 (0.83, 1.13) 
  
 
USA 1 0.99 (0.97, 1.02) 
  
 
Confounding factors2 
 
Yes 9 0.99 (0.96, 1.01) 95.4 <0.001 
 
No 4 0.99 (0.97, 1.00) 0.0 0.600 
 
BMI 
    
 
≤25 4 0.99 (0.94, 1.03) 97.8 <0.001 
 
>25 8 0.99 (0.98, 1.00) 0.0 0.906 
 
Newcastle-Ottawa quality score 
   
 
<7 2 0.99 (0.97, 1.02) 0.0 0.675 
  ≥7 11 0.99 (0.96, 1.01) 94.3 <0.001 
1 Insufficient studies to split results for high-fat dairy and yogurt.  
2 Confounding factors adjusted for age, sex, BMI, smoking, alcohol, leisure activity and total 
energy intake. 
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Supplemental Table 4. Association between dairy foods and CHD by subgroups1. 
Dairy food Subgroup 
No. study 
populations 
Relative risk  Heterogeneity test 
(95% CI)2 I² (%) P-value 
Total dairy Overall 12 0.99 (0.96, 1.02) 38.9 0.081 
Per 200 g/d Age (y) 
    
 
≤50  4 1.02 (0.98, 1.06) 33.1 0.214 
 
>50 8 0.97 (0.94, 1.00) 16.5 0.300 
 
Follow-up time (y) 
    
 
≤10  5 0.99 (0.96, 1.02) 0.0 0.733 
 
>10 7 0.99 (0.94, 1.03) 62.4 0.014 
 
Gender 
    
 
Men 2 0.99 (0.95, 1.03) 0.0 0.403 
 
Women 4 1.00 (0.94, 1.06) 70.2 0.018 
 
Men and Women 6 0.98 (0.94, 1.02) 21.6 0.272 
 
Continent 
    
 
Europe 7 0.98 (0.95, 1.02) 14.9 0.317 
 
Australia 1 0.87 (0.77, 0.98) 
 
 
USA 4 1.01 (0.97, 1.04) 30.8 0.227 
 
Confounding factors2 
 
Yes 9 1.01 (0.98, 1.03) 3.4 0.406 
 
No 3 0.94 (0.88, 1.00) 37.7 0.201 
 
BMI 
    
 
≤25 2 0.99 (0.89, 1.10) 88.8 0.003 
 
>25 10 0.99 (0.96, 1.01) 0.0 0.487 
 
Newcastle-Ottawa quality score 
   
 
<7 1 0.94 (0.89, 0.99) 
  
 
≥7 11 1.00 (0.97, 1.03) 25.8 0.198 
High-fat dairy Overall 9 0.99 (0.93, 1.05) 22.9 0.240 
Per 200 g/d Age (y) 
    
 
≤50  2 0.89 (0.61, 1.29) 76.1 0.041 
 
>50 7 0.98 (0.92, 1.05) 0.0 0.474 
 
Follow-up time (y) 
    
 
≤10  3 0.94 (0.77, 1.14) 39.1 0.194 
 
>10 6 1.00 (0.93, 1.07) 25.0 0.246 
 
Gender 
    
 
Men 1 0.98 (0.88, 1.09) 
  
 
Women 2 1.03 (0.97, 1.10) 0.0 0.800 
 
Men and Women 6 0.92 (0.80, 1.06) 40.3 0.137 
 
Continent 
    
 
Europe 4 0.86 (0.68, 1.08) 30.9 0.227 
 
Australia 1 0.86 (0.70, 1.05) 
  
 
USA 4 1.02 (0.97, 1.08) 0.0 0.793 
 
Confounding factors2 
 
Yes 7 1.00 (0.94, 1.07) 25.5 0.235 
 
No 2 0.89 (0.75, 1.07) 0.0 0.451 
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BMI 
    
 
≤25 1 1.04 (0.97, 1.11) 
  
 
>25 8 0.97 (0.89, 1.05) 19.7 0.274 
 
Newcastle-Ottawa quality score 
   
 
≥7 9 0.99 (0.93, 1.05) 22.9 0.240 
Low-fat dairy Overall 10 1.00 (0.97, 1.03) 27.3 0.193 
Per 200 g/d Age (y) 
    
 
≤50  2 0.97 (0.91, 1.04) 38.3 0.203 
 
>50 8 1.01 (0.97, 1.05) 26.8 0.215 
 
Follow-up time (y) 
    
 
≤10  4 1.00 (0.96, 1.06) 14.5 0.320 
 
>10 6 1.00 (0.95, 1.05) 43.5 0.115 
 
Gender 
    
 
Men 2 1.01 (0.97, 1.05) 0.0 0.848 
 
Women 2 1.00 (0.87, 1.15) 75.1 0.045 
 
Men and Women 6 1.00 (0.95, 1.05) 35.7 0.169 
 
Continent 
    
 
Europe 6 1.02 (0.97, 1.08) 32.7 0.191 
 
Australia 1 0.94 (0.73, 1.21) 
  
 
USA 3 0.98 (0.93, 1.03) 39.6 0.191 
 
Confounding factors2 
 
Yes 8 0.99 (0.96, 1.03) 34.4 0.154 
 
No 2 1.04 (0.96, 1.12) 0.0 0.407 
 
BMI 
    
 
≤25 3 1.00 (0.92, 1.09) 54.0 0.114 
 
>25 7 1.00 (0.97, 1.04) 24.9 0.239 
 
Newcastle-Ottawa quality score 
   
 
≥7 10 1.00 (0.97, 1.03) 27.3 0.193 
Milk  Overall 12 1.01 (0.96, 1.06) 45.5 0.043 
Per 244 g/d Age (y) 
    
 
≤50  4 1.02 (0.94, 1.12) 54.6 0.086 
 
>50 8 1.00 (0.94, 1.07) 48.5 0.059 
 
Follow-up time (y) 
    
 
≤10  2 0.97 (0.91, 1.04) 0.0 0.676 
 
>10 10 1.02 (0.60, 1.08) 53.1 0.024 
 
Gender 
    
 
Men 4 0.98 (0.93, 1.04) 34.4 0.206 
 
Women 3 1.04 (0.93, 1.17) 64.2 0.061 
 
Men and Women 5 1.00 (0.93, 1.08) 9.0 0.355 
 
Continent 
    
 
Europe 8 1.00 (0.95, 1.04) 25.4 0.227 
 
Asia 2 0.99 (0.19, 5.05) 87.2 0.005 
 
USA 2 1.03 (0.97, 1.08) 23.1 0.254 
 
Confounding factors2 
 
Yes 4 1.02 (0.97, 1.08) 20.3 0.288 
 
No 8 1.00 (0.93, 1.08) 54.3 0.032 
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BMI 
    
 
≤25 6 1.08 (0.97, 1.20) 46.0 0.099 
 
>25 5 0.98 (0.94, 1.01) 0.0 0.537 
 
Newcastle-Ottawa quality score 
   
 
<7 5 1.01 (0.95, 1.07) 43.3 0.133 
 
≥7 7 1.00 (0.93, 1.09) 52.6 0.049 
Total fermented 
dairy Overall 14 0.99 (0.98, 1.01) 44.6 0.037 
Per 20 g/d Age (y) 
    
 
≤50  5 1.00 (0.97, 1.04) 65.7 0.020 
 
>50 9 0.99 (0.98, 1.00) 21.9 0.249 
 
Follow-up time (y) 
    
 
≤10  6 1.00 (0.98, 1.02) 9.6 0.355 
 
>10 8 0.99 (0.98, 1.01) 53.3 0.036 
 
Gender 
    
 
Men 2 0.92 (0.77, 1.10) 57.3 0.126 
 
Women 4 0.99 (0.97, 1.01) 53.7 0.090 
 
Men and Women 8 1.00 (0.98, 1.02) 41.3 0.103 
 
Continent 
    
 
Europe 14 0.99 (0.98, 1.01) 44.6 0.037 
 
Confounding factors2 
 
Yes 9 1.00 (0.99, 1.01) 0.0 0.447 
 
No 5 0.99 (0.97, 1.02) 72.5 0.006 
 
BMI 
    
 
≤25 8 0.99 (0.96, 1.02) 63.2 0.008 
 
>25 6 1.00 (0.99, 1.01) 0.0 0.727 
 
Newcastle-Ottawa quality score 
   
 
<7 4 0.99 (0.96, 1.03) 78.5 0.003 
 
≥7 10 1.00 (0.99, 1.01) 0.0 0.535 
Cheese Overall 10 0.99 (0.97, 1.02) 40.3 0.089 
Per 10 g/d Age (y) 
    
 
≤50  4 1.06 (0.98, 1.15) 61.7 0.05 
 
>50 6 0.99 (0.98, 0.99) 0.0 0.809 
 
Follow-up time (y) 
    
 
≤10  4 0.99 (0.95, 1.02) 27.1 0.249 
 
>10 6 1.01 (0.97, 1.05) 54.4 0.052 
 
Gender 
    
 
Men 1 0.97 (0.93, 1.02) 
  
 
Women 2 0.99 (0.98. 1.00) 0.0 0.648 
 
Men and Women 7 1.01 (0.97, 1.06) 48.9 0.068 
 
Continent 
    
 
Europe 10 0.99 (0.97, 1.02) 40.3 0.089 
 
Confounding factors2 
 
Yes 6 0.99 (0.96, 1.01) 0.0 0.461 
 
No 4 1.03 (0.97, 1.10) 71.2 0.015 
 
BMI 
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≤25 5 1.00 (0.95, 1.05) 63.3 0.028 
 
>25 5 1.00 (0.97, 1.03) 0.0 0.543 
 
Newcastle-Ottawa quality score 
   
 
<7 3 1.14 (0.93, 1.40) 80.3 0.006 
 
≥7 7 0.99 (0.97, 1.01) 0.0 0.561 
1 Insufficient studies to split results for high-fat dairy and yogurt.  
2 Confounding factors adjusted for age, sex, BMI, smoking, alcohol, leisure activity and total 
energy intake. 
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Supplemental Table 5. Association between dairy foods and CVD by subgroups1. 
Dairy food Subgroup 
No. study 
populations 
Relative risk  Heterogeneity test 
(95% CI)2 I² (%) P-value 
Total dairy Overall 8 0.97 (0.91, 1.02) 59.9 0.015 
Per 200 g/d Age (y) 
    
 
≤50  3 0.68 (0.39, 1.19) 77.5 0.012 
 
>50 5 0.97 (0.91, 1.04) 52.6 0.077 
 
Follow-up time (y) 
    
 
≤10  2 1.08 (0.81, 1.44) 59.4 0.116 
 
>10 6 0.95 (0.87, 1.03) 64.9 0.014 
 
Gender 
    
 
Men and Women 8 0.97 (0.91, 1.02) 59.9 0.015 
 
Continent 
    
 
Europe 5 0.98 (0.94, 1.02) 36.5 0.178 
 
Australia 2 0.81 (0.60, 1.09) 52.1 0.149 
 
Asia 1 0.19 (0.04, 0.76) 
 
 
Confounding factors2 
 
Yes 4 0.98 (0.92, 1.03) 58.3 0.066 
 
No 4 0.95 (0.80, 1.12) 68.1 0.024 
 
BMI 
    
 
≤25 1 0.19 (0.04, 0.76) 
  
 
>25 7 0.97 (0.92, 1.01) 50.9 0.057 
 
Newcastle-Ottawa quality score 
   
 
<7 2 0.56 (0.91, 1.02) 59.9 0.015 
 
≥7 6 0.96 (0.92, 1.01) 47.7 0.088 
High-fat dairy Overall 7 0.93 (0.84, 1.03) 37.4 0.143 
Per 200 g/d Age (y) 
    
 
≤50  3 0.76 (0.59, 0.97) 31.5 0.232 
 
>50 4 0.99 (0.93, 1.04) 0.0 0.797 
 
Follow-up time (y) 
    
 
≤10  2 0.82 (0.67, 1.01) 0.0 0.570 
 
>10 5 0.96 (0.86, 1.07) 39.4 0.159 
 
Gender 
    
 
Men and Women 7 0.93 (0.84, 1.03) 37.4 0.143 
 
Continent 
    
 
Europe 5 0.98 (0.93, 1.04) 0.0 0.450 
 
Australia 2 0.72 (0.41, 1.28) 75.1 0.045 
 
Confounding factors2 
 
Yes 5 0.88 (0.74, 1.04) 53.9 0.070 
 
No 2 0.97 (0.85, 1.11) 0.0 0.338 
 
BMI 
    
 
≤25 1 0.86 (0.66, 1.13) 
 
 
>25 6 0.94 (0.83, 1.05) 43.6 0.115 
 
Newcastle-Ottawa quality score 
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≥7 7 0.93 (0.84, 1.03) 37.4 0.143 
Low-fat dairy Overall 7 0.98 (0.95, 1.01) 0.0 0.769 
Per 200 g/d Age (y) 
    
 
≤50  3 0.99 (0.94, 1.04) 0.0 0.577 
 
>50 4 0.97 (0.93, 1.01) 0.0 0.584 
 
Follow-up time (y) 
    
 
≤10  2 0.98 (0.94, 1.03) 0.0 0.599 
 
>10 5 0.97 (0.94, 1.01) 0.0 0.579 
 
Gender 
    
 
Men and Women 7 0.98 (0.95, 1.01) 0.0 0.769 
 
Continent 
    
 
Europe 5 0.98 (0.95, 1.01) 0.0 0.888 
 
Australia 2 0.96 (0.69, 1.35) 43.8 0.182 
 
Confounding factors2 
 
Yes 5 0.98 (0.95, 1.01) 0.0 0.742 
 
No 2 0.95 (0.86, 1.04) 0.0 0.345 
 
BMI 
    
 
>25 6 0.97 (0.94, 1.00) 0.0 0.715 
 
Newcastle-Ottawa quality score 
   
 
≥7 7 0.98 (0.95, 1.01) 0.0 0.769 
Milk  Overall 12 1.01 (0.93, 1.10) 92.4 <0.001 
Per 244 g/d Age (y) 
    
 
≤50  2 0.96 (0.92, 1.01) 0.0 0.399 
 
>50 10 1.03 (0.93, 1.13) 92.5 <0.001 
 
Follow-up time (y) 
    
 
≤10  1 1.67 (0.75, 3.72) 
  
 
>10 11 1.01 (0.92, 1.09) 93.0 <0.001 
 
Gender 
    
 
Men 5 0.97 (0.91, 1.05) 80.2 <0.001 
 
Women 2 0.99 (0.76, 1.28) 93.4 <0.001 
 
Men and Women 4 1.11 (0.84, 1.47) 91.2 0.052 
 
Continent 
    
 
Europe 7 1.06 (0.96, 1.17) 95.0 <0.001 
 
Australia 1 0.77 (0.46, 1.29) 
  
 
Asia 4 0.91 (0.82, 1.02) 39.8 0.173 
 
Confounding factors2 
 
Yes 5 1.10 (0.98-1.25) 95.3 <0.001 
 
No 7 0.94 (0.89-0.99) 28.6 0.210 
 
BMI 
    
 
≤25 5 0.99 (0.80, 1.22) 93.5 <0.001 
 
>25 7 1.00 (0.94, 1.06) 70.9 0.002 
 
Newcastle-Ottawa quality score 
   
 
<7 4 0.95 (0.90, 1.00) 22.1 0.278 
 
≥7 8 1.05 (0.94, 1.16) 93.0 <0.001 
Total fermented dairy Overall 17 0.98 (0.97, 0.99) 87.5 <0.001 
Per 20 g/d Age (y) 
    
 
≤50  7 1.00 (0.99, 1.01) 0.0 0.541 
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>50 10 0.98 (0.96, 0.99) 92.5 <0.001 
 
Follow-up time (y) 
    
 
≤10  5 1.00 (0.99, 1.01) 0.0 0.659 
 
>10 12 0.97 (0.96, 0.99) 91.1 <0.001 
 
Gender 
    
 
Men 2 0.99 (0.96, 1.01) 77.3 0.036 
 
Women 2 0.93 (0.81, 1.06) 99.0 <0.001 
 
Men and Women 13 0.99 (0.99, 1.00) 0.0 0.476 
 
Continent 
    
 
Europe 15 0.98 (0.97, 0.99) 88.9 <0.001 
 
Australia 2 0.89 (0.72, 1.10) 0.0 0.510 
 
Confounding factors2 
 
Yes 14 0.98 (0.97, 0.99) 89.5 <0.001 
 
No 3 1.02 (0.98, 1.06) 0.0 0.593 
 
BMI 
    
 
≤25 2 0.93 (0.81, 1.06) 99.0 <0.001 
 
>25 13 0.99 (0.99, 1.00) 25.0 0.191 
 
Newcastle-Ottawa quality score 
   
 
<7 2 1.02 (0.97, 1.08) 4.1 0.307 
 
≥7 15 0.98 (0.97, 0.99) 88.8 <0.001 
Cheese Overall 11 0.98 (0.95, 1.00) 82.6 <0.001 
Per 10 g/d Age (y) 
    
 
≤50  5 0.98 (0.96, 1.01) 0.0 0.528 
 
>50 6 0.98 (0.94, 1.01) 90.5 <0.001 
 
Follow-up time (y) 
    
 
≤10  4 1.00 (0.96, 1.04) 0.0 0.853 
 
>10 7 0.97 (0.85, 1.00) 88.7 <0.001 
 
Gender 
    
 
Men 1 0.99 (0.97, 1.00) 
  
 
Women 1 0.93 (0.92, 0.94) 
  
 
Men and Women 9 0.99 (0.97, 1.00) 0.0 0.764 
 
Continent 
    
 
Europe 10 0.98 (0.95, 1.00) 84.1 <0.001 
 
Australia 1 0.86 (0.65, 1.15) 
  
 
Confounding factors2 
 
Yes 9 0.98 (0.95, 1.00) 85.2 <0.001 
 
No 2 1.00 (0.96, 1.05) 0.0 0.354 
 
BMI 
    
 
≤25 1 0.93 (0.92, 0.94) 
  
 
>25 8 0.99 (0.98, 0.99) 0.0 0.679 
 
Newcastle-Ottawa quality score 
   
 
<7 1 0.95 (0.83, 1.08) 
    ≥7 10 0.98 (0.95, 1.01) 84.3 <0.001 
1 Insufficient studies to split results for high-fat dairy and yogurt. 2 Confounding factors 
adjusted for age, sex, BMI, smoking, alcohol, leisure activity and total energy intake. 
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Supplemental Figure 1. Forest plot for the association between total dairy intake and all-cause 
mortality. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
total dairy and all-cause mortality (per increment of 200 g/d), including 10 populations 
(n=175,063 individuals). Heterogeneity (I2) of between-study variations is 62.2%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 62.2%, p = 0.005)
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Supplemental Figure 2. Forest plot for the association between total dairy intake and CHD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between total dairy and 
CHD (per increment of 200 g/d), including 12 populations (n=330,350 individuals). 
Heterogeneity (I2) of between-study variations is 38.9%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 38.9%, p = 0.081)
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Supplemental Figure 3. Forest plot for the association between total dairy intake and CVD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between total dairy and 
CVD (per increment of 200 g/d), including 8 populations (n=76,207 individuals). 
Heterogeneity (I2) of between-study variations is 59.9%. 
 
NOTE: Weights are from random effects analysis
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Supplemental Figure 4. Forest plot for the association between high-fat dairy intake and all-
cause mortality. Squares represent study-specific RRs. Square areas are proportional to the 
overall specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
high-fat dairy and all-cause mortality (per increment of 200 g/d), including 5 populations 
(n=47,126 individuals). Heterogeneity (I2) of between-study variations is 0%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 5. Forest plot for the association between high-fat dairy intake and 
CHD. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
high-fat dairy and CHD (per increment of 200 g/d), including 9 populations (n=171,627 
individuals). Heterogeneity (I2) of between-study variations is 22.9%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 6. Forest plot for the association between high-fat dairy intake and 
CVD. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
high-fat dairy and CVD (per increment of 200 g/d), including 7 populations (n=95,242 
individuals). Heterogeneity (I2) of between-study variations is 37.4%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 7. Forest plot for the association between low-fat dairy intake and all-
cause mortality. Squares represent study-specific RRs. Square areas are proportional to the 
overall specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
low-fat dairy and all-cause mortality (per increment of 200 g/d), including 7 populations 
(n=167,978 individuals). Heterogeneity (I2) of between-study variations is 0%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 8. Forest plot for the association between low-fat dairy intake and CHD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between low-fat dairy 
and CHD (per increment of 200 g/d), including 10 populations (n=262,228 individuals). 
Heterogeneity (I2) of between-study variations is 27.3%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 9. Forest plot for the association between low-fat dairy intake and CVD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between low-fat dairy 
and CVD (per increment of 200 g/d), including 7 populations (n=95,242 individuals). 
Heterogeneity (I2) of between-study variations is 0%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 10. Forest plot for the association between milk intake and all-cause 
mortality. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
milk and all-cause mortality (per increment of 244 g/d), including 12 populations (n=268,570 
individuals). Heterogeneity (I2) of between-study variations is 97.4%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 11. Forest plot for the association between milk intake and CHD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between milk and CHD 
(per increment of 244 g/d), including 12 populations (n=230,621 individuals). Heterogeneity 
(I2) of between-study variations is 45.5%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 12. Forest plot for the association between milk intake and CVD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between milk and CVD 
(per increment of 244 g/d), including 12 populations (n=249,779 individuals). Heterogeneity 
(I2) of between-study variations is 92.4%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 13. Forest plot for the association between total fermented dairy intake 
and CHD. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
total fermented dairy and CHD (per increment of 20 g/d), including 14 populations 
(n=256,091 individuals). Heterogeneity (I2) of between-study variations is 44.6%. 
NOTE: Weights are from random effects analysis
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Supplemental Figure 14. Forest plot for the association between cheese intake and all-cause 
mortality. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
cheese and all-cause mortality (per increment of 10 g/d), including 13 populations (n=342,120 
individuals). Heterogeneity (I2) of between-study variations is 93.3%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 93.3%, p = 0.000)
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6.11
7.36
11.41
11.38
1.78
10.23
10.03
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Relative risk
 168 
 
 
Supplemental Figure 15. Forest plot for the association between cheese intake and CHD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between cheese and 
CHD (per increment of 10 g/d), including 10 populations (n=256,091 individuals). 
Heterogeneity (I2) of between-study variations is 40.3%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 40.3%, p = 0.089)
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0.94 (0.86, 1.04)
0.99 (0.98, 1.00)
0.93 (0.78, 1.11)
Relative
0.97 (0.93, 1.02)
1.02 (0.98, 1.07)
1.25 (1.02, 1.52)
0.97 (0.90, 1.04)
100.00
0.96
9.29
13.36
Weight
5.42
31.03
1.66
%
14.54
14.36
1.32
8.06
  
10.7 1.8
Relative risk
 169 
 
 
Supplemental Figure 16. Forest plot for the association between yogurt intake and all-cause 
mortality. Squares represent study-specific RRs. Square areas are proportional to the overall 
specific-study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. 
Diamonds represent the pooled relative risk and 95% CIs. Overall no association between 
yogurt and all-cause mortality (per increment of 50 g/d), including 3 populations (n=40,460 
individuals). Heterogeneity (I2) of between-study variations is 65.8%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 65.8%, p = 0.054)
Praagman
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%
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Supplemental Figure 17. Forest plot for the association between yogurt intake and CHD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between yogurt and 
CHD (per increment of 50 g/d), including 3 populations (n=98,936 individuals). 
Heterogeneity (I2) of between-study variations is 0%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.685)
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1.03 (0.95, 1.11)
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Weight
%
21.04
26.13
52.83
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Relative risk
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Supplemental Figure 18. Forest plot for the association between yogurt intake and CVD. 
Squares represent study-specific RRs. Square areas are proportional to the overall specific-
study weight to the overall meta-analysis. Horizontal lines represent 95% CIs. Diamonds 
represent the pooled relative risk and 95% CIs. Overall no association between yogurt and 
CVD (per increment of 50 g/d), including 3 populations (n=36,624individuals). Heterogeneity 
(I2) of between-study variations is 0%. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.499)
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Supplemental Figure 19. Funnel plot for studies of the association between total dairy intake 
and all-cause mortality based on linear dose-response slopes (no. of cases=21,222; total 
n=175,063). Each dot indicates a study population with its relative risk (RR). The y-axis 
represents the SEs of the log (RR). Test for publication bias: Egger’s test P = 0.086, 
symmetry indicates no evidence of publication bias. 
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Supplemental Figure 20. Funnel plot for studies of the association between total dairy intake 
and CHD based on linear dose-response slopes (no. of cases=8,298; total n=330,350). Each 
dot indicates a study population with its relative risk (RR). The y-axis represents the SEs of 
the log (RR). Test for publication bias: Egger’s test P = 1.000, symmetry indicates no 
evidence of publication bias. 
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Supplemental Figure 21. Funnel plot for studies of the association between low-fat dairy 
intake and CHD based on linear dose-response slopes (no. of cases=6,244; total n=262,228). 
Each dot indicates a study population with its relative risk (RR). The y-axis represents the SEs 
of the log (RR). Test for publication bias: Egger’s test P = 0.747, symmetry indicates no 
evidence of publication bias. 
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Supplemental Figure 22. Funnel plot for studies of the association between milk intake and 
all-cause mortality based on linear dose-response slopes (no. of cases=69,355; total 
n=268,570). Each dot indicates a study population with its relative risk (RR). The y-axis 
represents the SEs of the log (RR).Test for publication bias: Egger’s test P = 0.254, symmetry 
indicates no evidence of publication bias. 
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Supplemental Figure 23. Funnel plot for studies of the association between milk intake and 
CHD based on linear dose-response slopes (no. of cases=8,612; total n=230,621). Each dot 
indicates a study population with its relative risk (RR). The y-axis represents the SEs of the 
log (RR). Test for publication bias: Egger’s test P = 0.397, symmetry indicates no evidence of 
publication bias. 
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Supplemental Figure 24. Funnel plot for studies of the association between milk intake and 
CVD based on linear dose-response slopes (no. of cases=21,580; total n=249,779). Each dot 
indicates a study population with its relative risk (RR). The y-axis represents the SEs of the 
log (RR). Test for publication bias: Egger’s test P = 0.449, symmetry indicates no evidence of 
publication bias. 
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Supplemental Figure 25. Funnel plot for studies of the association between fermented dairy 
intake and CHD based on linear dose-response slopes (no. of cases=5,667; total n=256,091). 
Each dot indicates a study population with its relative risk (RR). The y-axis represents the SEs 
of the log (RR). Test for publication bias: Egger’s test P = 0.726, symmetry indicates no 
evidence of publication bias. 
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Supplemental Figure 26. Funnel plot for studies of the association between cheese intake and 
all-cause mortality based on linear dose-response slopes (no. of cases=54,125; total 
n=342,120). Each dot indicates a study population with its relative risk (RR). The y-axis 
represents the SEs of the log (RR). Test for publication bias: Egger’s test P = 0.310, 
symmetry indicates no evidence of publication bias. 
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Supplemental Figure 27. Funnel plot for studies of the association between cheese intake and 
CHD based on linear dose-response slopes (no. of cases=4,022; total n=256,091). Each dot 
indicates a study population with its relative risk (RR). The y-axis represents the SEs of the 
log (RR). Test for publication bias: Egger’s test P = 0.273, symmetry indicates no evidence of 
publication bias. 
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Supplemental Figure 28. Spaghetti plot for the association between total dairy intake and all-
cause mortality. Each light blue line represents a study population. Circles are placed at the 
study-specific RRs that are related to the corresponding quantity of the intake. Circles area is 
proportional to the study-specific overall weight. Solid red line represents the pooled RR at 
each quantity of intake and the two dashed dark blue lines are the corresponding 95% CI.
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Chapter 7 - Effect of dietary vitamin D3 and 25(OH) D3 on concentrations 
of 25(OH) D3 in blood plasma and milk of dairy cows 
 
The present chapter aims to investigate the effect of feeding cows different rates and forms of 
vitamin D on vitamin D forms and concentration in milk. 
 
DIG, BJ and JAL designed the study, technicians in CEDAR of University of Reading 
conducted the research. JG received statistics training from KEK. JG analysed the data and 
wrote the manuscript.  
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Abstract 
Milk enriched with vitamin D by supplementing dairy cow diets could provide a valuable 
dietary source of vitamin D, but information on the feasibility of this approach is limited. In 
the current study, the effect of supplementing dairy cows with either vitamin D3 or 25(OH) D3 
over the transition/early lactation period on plasma and milk vitamin D concentrations were 
compared. Sixty dairy cows were randomly allocated to one of four dietary treatments from 
14 days before calving to early lactation (56 days): a control diet (Control) for both transition 
and early lactation containing 0.625 mg Vitamin D3; HyD pre-calving had same diet with 
Control at early lactation, but the transition diet supplemented with 6 mg 25(OH) D3 during 
pre-calving in addition to Control diet; HyD post-calving had same transition diet with 
Control, but early lactation diet included 1.5 mg 25(OH) D3 supplements in addition to 
Control; D3max had same transition diet with Control, but with supplemented 2 mg vitamin 
D3 in addition to Control diet. The results showed no treatment effect on milk yield, 
composition or 25(OH) D3 concentration. However there was an interaction of treatment and 
time for plasma 25(OH) D3 concentration; this increased within two weeks of 
supplementation for the HyD pre-calving group (peaking just after calving, 202 ng/ml), 
whereas that of the HyD post-calving group had a slower response following 
supplementation, continuing to increase at 56 days. There were correlations between plasma 
and milk 25(OH) D3 concentrations at days 4 and 14 of lactation, but not at later sampling 
points. The D3max treatment group did not increase 25(OH) D3 concentration in plasma or 
milk. Overall, results from this study indicate that supplemental 25(OH) D3 is an effective 
means of enhancing dairy cow plasma 25(OH) D3 concentrations than vitamin D3 
supplementation. However, vitamin D content of typical milk consumption (200 ml) would 
contribute 0.02 to 0.66 µg, which was not sufficient to achieve dietary recommended levels. 
Key words: vitamin D3, 25(OH) D3, milk, enrichment. 
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Introduction 
Vitamin D is important for bone health, and mounting evidence demonstrates that vitamin D 
status is inversely associated with risk of chronic disease, such as cardiovascular disease, 
diabetes and cancers (Borradale and Kimlin, 2009; Holick and Chen, 2008). There is 
increasing evidence that vitamin D deficiency is prevalent through the world, including UK 
(Hilger et al., 2014; Cashman and Kiely, 2016), mainly due to lifestyle changes over time 
(Holick, 1995; Tsiaras and Weinstock, 2011). Dietary sources have therefore become more 
important in sustaining adequate vitamin D status (Spiro and Buttriss, 2014). However, few 
types of foods are naturally high in vitamin D (Schmid and Walther, 2013). Therefore, 
vitamin D food fortification has been recommended as a strategy to increase vitamin D intake 
across the population (Cashman, 2015). 
Vitamin D concentrations of milk and dairy products are naturally low (McDermott et al., 
1985). However, because milk and dairy products are widely consumed, a fortification 
programme has been instigated in some countries. Different food standard policies prevent 
fortification in other countries (Samaniego-Vaesken et al., 2012), so increasing milk vitamin 
D concentration via supplementation of dairy cow diets is an alternative strategy.  
In practice, vitamin D3 is the form of vitamin D usually used for fortification. However, it 
is now clear the metabolically-active form, 25(OH) D3, is more effective in raising serum 25 
(OH) D3 concentrations than vitamin D3, and also may be absorbed faster than vitamin D3 
from the human digestive tract (Barger-Lux et al., 1998; Cashman et al., 2012; Jetter et al., 
2013). Previous studies investigating the effect of supplementing dairy cow diets with vitamin 
D3 (Hollis et al., 1981; McDermott et al., 1985; Thompson, 1983) suggest concentrations in 
milk following supplementation remain relatively low compared with the RNI of vitamin D 
(SACN, 2016). To date, only a few studies (Weiss et al., 2015; Wilkens et al., 2012) have 
examined the effect of supplementing cow diets with 25(OH) D3 on plasma or milk vitamin D 
 190 
 
concentration. However, the main hypotheses of these studies were focused around reducing 
prevalence of hypocalcaemia in the cow. 
The main objective of the present study was to investigate the effect of supplemental 
vitamin D3 or 25(OH) D3 in dairy cow diets on the 25(OH) D3 concentration of both plasma 
and milk over the transition period. Vitamin D3 was included as a measurement in the milk as 
it is the precursor form of 25(OH) D3 (McDermott et al., 1985). We hypothesized that 
supplementing cows with 25(OH) D3 would be more efficient at increasing 25(OH) D3 
concentrations of plasma and milk than vitamin D3 supplementation. As hypocalcaemia in 
dairy cows frequently occurs after the initiation of milk production (DeGaris et al., 2008),  the 
secondary objective of the study was to investigate the effect of supplemental 25(OH) D3 
during the pre-calving period on plasm calcium concentration during the periparturient and 
milk initiation production periods. Furthermore, as hypocalcaemia is often accompanied by 
decreased plasma phosphorus and magnesium concentrations (Klimiene et al., 2005), the 
balance between these is crucial during the calving period (Reinhardt et al., 1988), thus, the 
effects of treatments on plasma and milk phosphorus and magnesium concentrations in cows 
were also studied. 
 
Materials and methods 
Animals and management 
All licensed procedures were conducted according to Scientific Procedures Act 1986 under 
the authority of Home Office Project Licence 70/7727. Sixty non-lactating (parity 2 or 
greater) Holstein-Friesian dairy cows with previous lactation yield (305 d) of 10,141 kg 
(SE=177) and initial weight of 725kg (SE=7.5) at the start of the study were randomly 
allocated to 1 of 4 experimental diets using a continuous design, at 14 days prior to calving 
(average duration of the pre-calving period was 14 days (SE=0.5)). When not restrained for 
measurements, cows were loose-housed in a straw yard in the late gestation phase and in a 
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cubicle yard with washed sand bedding and automatic alley scrapers during the lactation 
phase. For the period immediately around parturition, cows were housed in straw-bedded 
maternity pens.  
Cows were group fed during the pre-calving period and for the first week post-calving. 
From day 7 of lactation onwards all cows were fed individually using Calan gates (Calan 
Broadbent Feeding System, American Calan) for the remainder of the study. Cows were 
milked twice daily in the morning and afternoon at unequal intervals (0500 and 1500 h) 
through a 50-point Dairymaster rotary parlour. All cows were housed at the University of 
Reading’s Centre for Dairy Research during the winter period of October 2013 to March 2014 
to avoid the confounding factor of in vivo vitamin D synthesis due to ultraviolet radiation.  
 
Treatment diets, experimental design and blocking 
The four treatment diets were as follows: The control group (Control) was fed a basal 
transition cow diet from 14 days before calving, and a basal early lactation diet until 56 days 
post-calving (Table 1), both supplemented with 0.625 mg vitamin D3 (DSM Nutritional 
Products, Basel, Switzerland) per cow per day (Table 2; NRC, 2001). Treatment “HyD pre-
calving” received an additional 6 mg 25(OH) D3 per cow per day (ROVIMIX® HyD®, DSM 
Nutritional Products, Basel, Switzerland) to the transition diet, and the lactating diet remained 
the same. Treatments “HyD post-calving” and “D3 max” received the basal transition diet up 
to calving. HyD post-calving then received an additional 1.5 mg 25(OH) D3 (ROVIMIX® 
HyD® 1.25%, DSM Nutritional Products, Basel, Switzerland) per cow per day, and D3max 
received 2 mg vitamin D3 (maximum permitted EU level, EC, 2004) post-calving until 56 
days (Table 2).  
All supplements were formulated to provide daily required dose of vitamin D3 and/or 
25(OH) D3 within 250 g ground wheat. Each group was blocked in group four according to 
expected calving date. Within each group and block, cows were allocated at random to the 
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treatments. The composition and estimated nutritive value of the transition and early lactation 
basal diets are described in Table 1. All of diets were formulated to meet animal nutritional 
requirements as determined using the UK Feed into Milk model (Thomas, 2004). Both diets 
were fed as total mixed rations (TMR) and were offered ad libitum to achieve 5% refusals. 
The non-forage component of each diet was combined into a concentrate blend (Table 1). 
Oven DM (temperature and time in oven?) of the TMR, silages and concentrate blend were 
measured three times and once (for concentrate) per week. Feed offered were adjusted once 
per week according to the mean of the last three forage DM results. Diet was prepared daily 
and feed was dispensed between 0730 h and 0900 h. Milk yield were recorded daily through 
the whole study.  
 
Experimental sampling 
Blood samples were collected from tail-vein of each cow on day 14 and 7 before expected 
calving date, on the day of calving (within the first 24 hour after parturition) and days 4, 7, 14, 
21, 28, 35 and 42 of lactation. Two samples were collected in 10 ml vacutainers containing 
EDTA (Beckton Dickinson?) from each cow at each sampling time. Each collected sample 
was immediately centrifuged at 3,000 rpm for 15 minutes at 15 °C to separate plasma, and 
plasma then stored at -80 °C. 
Milk samples were collected on days 4, 14, 28, 35 and 42 of lactation and analysed for 
vitamin D concentrations (Vitamin D3 and 25(OH) D3). Two milk samples (am and pm) were 
pooled (100 ml) and then were split into 2 × 50 ml samples and immediately frozen at -80 °C. 
In addition, two milk samples (am and pm) were collected at each day of 4, 28 and 42 and 
were pooled for mineral analysis).  
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Chemical analysis 
Analysis of plasma and milk vitamin D3 and 25 (OH) D3 analyses were conducted by DSM 
Nutritional Products Ltd (Basel, Switzerland). Food and Drug Administration (FDA; 2013) 
and European Medicines Agency (EMEA; 2011) bioanalytical guidelines were used to 
validate the method.  
In brief, for plasma vitamin D3 and 25(OH) D3, after the addition of a deuterated internal 
standard solution, proteins were precipitated with a mixture of tetrahydrofuran, acetonitrile 
and methanol. The supernatant was evaporated and the residue reconstituted with acetonitrile-
methanol solution after centrifugation. An aliquot of plasma sample was injected on the LC-
MS/MS system.  
For milk vitamin D3 quantification, after addition of internal standard solution, 
saponification with methanol, ethanol and potassium hydroxide was conducted. Water was 
added and vitamin D3 was extracted by liquid/liquid extraction twice successively with 
cyclohexane. The cyclohexane phase was evaporated to dryness under a stream of nitrogen. 
The residue was reconstituted in methanol and acetonitrile solution. After the final extraction 
was filtered, an aliquot was injected on the LC-MS/MS system. 
For milk 25 (OH) D3 quantification, after addition of internal standard solution, a 
saponification is performed with adding methanol and potassium hydroxide, a liquid/liquid 
extraction with tert-butyl methyl ether is used to extract 25(OH) D3. After evaporation of the 
extract, the sample is cleaned by solid phase extraction technique. With elution with a mixture 
of acetonitrile and methanol, the eluate is evaporated until dryness under a gentle stream of 
nitrogen. Final residue is reconstituted in methanol/acetonitrile solvent and filtrated before 
injection into the LC-MS/MS system. 
Concentrations of vitamin D3 and 25(OH)D3 in all samples were determined by LC-
MS/MS system (Agilent 1290) using reverse phase column, coupled with APPI source 
(ABSciex 4000) using an atmospheric pressure photospray ionization (APPI) source in 
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positive mode. The detection of the specific fragment ions is performed by using multiple 
reactions monitoring mode (MRM). 
To assess the daily and long-term laboratory performance of the method, dedicated 
standard and quality control samples were analyzed daily with the unknown samples to ensure 
accuracy and precision. Data acquisition of extracted ion chromatograms, integration and 
quantification were performed by Analyst® software from ABSciex.  
Analysis of milk for calcium, phosphate and magnesium in milk were measured by 
National Milk Laboratories, UK. Milk samples are homogenized by vigorous shaking, 10 g of 
the milk sample is transferred into a 50 ml polypropylene digestion vessel. By adding 30 ml 
of nitric acid (Romilk High Purity SpA), the samples are placed in a hotblock at 110°C for 4 
hours, after cool to room temperature, each sample is mixed with deionized water and cap to 
make up 50 ml for the further a 10 times dilution with deionized water before ICP-MS 
analysis.  
Analysis of concentrations of calcium, phosphate and magnesium in plasma were 
measured by Veterinary Laboratories Agency, UK with using Olympus AU 400 analyzer by 
using standard kits with appropriate quality control by Animal and Plant Health Agency in the 
UK.  
Milk composition measurements including fat, protein, lactose, casein, urea and somatic 
cell count were analysed by infrared spectroscopy (Foss Electric Ltd., York, UK), the method 
as described elsewhere (Reynolds et al., 2014) and the analyses was conducted by National 
Milk Laboratories, UK.  
 
Statistical analysis 
Results were averaged for each cow and sampling period, and were analysed using mixed 
procedure of SAS (Statistical Analysis System software package version 9.4, SAS Institute, 
Cary, NC, USA), including fixed effects of dietary treatments and time, and random effects of 
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cow, with time (day) being the repeated measure within cows. Milk yield and composition 
were only analysed for the post-calving period, whereas other data were analysed for the 
whole study. Compound symmetry, heterogeneous compound symmetry, first-order 
autoregressive or a heterogeneous first-order regressive covariance structure were used for 
repeated measures analysis based on goodness of the fit criteria for each analysed variable. 
Orthogonal contrasts were applied to investigate the difference between treatments: control vs 
all other diets; HyD pre-calving vs HyD post-calving; D3max vs HyDpost-calving. Least 
square means (SEMs) were reported, and treatment effects were considered significant at 
P<0.05.  
Area under curve (AUC) for plasma and milk vitamin D concentrations over time were 
calculated according to trapezium rule as the summation measure for each treatment, which 
was analysed by one-way ANOVA in STATA (version 13.0; STATA Corporation, 2014), 
Bonferroni correction was used subsequently to compute the multiple pairwise comparisons if 
there was significant effect of the investigated variables between treatments. Furthermore, in 
order to assess transfer of 25(OH) D3, calcium, phosphorus or magnesium from plasma to 
milk at each time point, correlation of 25(OH) D3, calcium, phosphorus and magnesium of 
plasma and milk were conducted (across all treatments) by using general linear regression 
model in STATA.  
 
Results 
Characteristics of dairy cows, and mineral of plasma and milk 
There was no interaction effect of treatment and time on milk yield, milk composition, or 
characteristics of the cow (Table 4). In addition, there was no interaction effect of treatment 
and time on mineral concentrations of calcium, phosphorus and magnesium in both plasma 
and milk (Table 5).  
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There was no interaction effect of treatment and time on milk yield, milk composition, or 
characteristics of the cow (Table 4). In addition, there was no interaction effect of treatment 
and time on mineral concentrations of calcium, phosphorus and magnesium in both plasma 
and milk (Table 5).  
 
Vitamin D in plasma 
The HyD pre-calving treatment resulted in a greater (P<0.001) mean concentration of 25(OH) 
D3 in plasma across the whole study (Table 4; Figure 1). The peak 25(OH) D3 concentration 
of 202 ng/ml was achieved by day 1 of lactation, before decreasing gradually. In comparison, 
HyD3 post-calving resulted in an increase in plasma 25(OH) D3 concentration following 14 
days of  supplementation, and at day 56 reached 179 ng/ml. There was a difference (P<0.001) 
between treatment on summary exposure Area Under Curve (AUC). AUC-14 to 56 days of HyD 
pre-calving (8274 ± 630 ng/mL) and HyD3 post-calving (6806 ± 356 ng/mL) was significant 
higher than Control (2964 ± 304 ng/mL) and D3max post-calving (2619 ± 207 ng/mL) 
treatments. There was no difference between treatments of HyD pre-calving and HyD post-
calving, or between Control and D3max. 
 
Vitamin D in milk 
There was no overall effect of treatment on 25(OH) D3 concentration in milk, but there was 
an effect of time (P=0.004) and a treatment by time interaction (P<0.001) (Table 5; Figure 2). 
In addition, 25(OH) D3 concentrations in the milk of HyD pre-calving had a decreasing trend 
(Figure 2). Vitamin D3 was measured in milk but 87% of values were below limit of 
quantification of 60 ng/kg, so data analysis could not be conducted. There was no difference 
(P=0.14) of treatment effect on AUC4-42 days. AUC4-42 days of Control, HyD pre-calving, D3 
max and HyD post-calving were (33.7 ± 3.7) × 103, (42.8 ± 3.7) × 103, (31.3 ± 3.3) × 103 and 
(34.8 ± 4.9) × 103 ng/kg, respectively. 
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Nutrient correlations of plasma and milk 
Concentrations of 25(OH) D3 in plasma and in milk were correlated at day 4 (R
2=0.25; 
P=0.009) and 14 (R2=0.24; P=0.01) of lactation, but not at day 28, 35 or 42 (Figure 3). There 
was no correlation between concentrations of calcium, phosphorus or magnesium in plasma 
and milk (P>0.05). 
 
Discussion 
Vitamin D metabolite form of 25(OH) D3 is more effective than vitamin D3 in raising human 
serum 25(OH) D3 concentrations (Barger-Lux et al., 1998; Cashman et al., 2012; Jetter et al., 
2013). To our knowledge, the current study is the first study to compare the effect of 
supplementing cows of both pre-calving and post-calving with 25(OH) D3 and vitamin D3 on 
25(OH) D3 concentrations in plasma and milk. The current study demonstrated that a daily 
oral supplementation of 6 mg 25(OH) D3 during two weeks pre-calving or 1.5 mg 25(OH) D3 
during 8 weeks after-calving is more effective in raising plasma 25(OH) D3 concentrations 
than vitamin D3 supplementation.  
Supplementing cows with 25(OH) D3 for two weeks pre-calving increased plasma  25(OH) 
D3 concentration, which reached a peak just after calving (day 1; 202 ng/ml) when 
supplementation stopped. This result is consistent with previous studies (Wilkins et al., 2012; 
Weiss et al. 2015) who reported that pre-calving 25(OH) D3 supplementation is effective at 
increasing plasma concentrations, peaking at the same time. The daily 25(OH) D3 
supplementation dose (6 mg) in the current study was the same as that used by Weiss et al. 
(2015), and yet the earlier study resulted in a higher peak concentration (274 ng/ml). Wilkens 
et al. (2012) supplemented with less 25(OH) D3 (3 mg/day) but the peak plasma concentration 
was similar to that of the current study (198 ng/ml). One possible reason may due to the 
influence of vitamin D-binding protein (DBP), previous study (Powe et al., 2013) showed 
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DBP has influence on 25(OH) D level. Unfortunately, DBP concentrations were not measured 
in the current study or studies of Weiss et al. (2015) and Wilkens et al. (2012).  
Supplementation of vitamin D3 up to 2 mg /day after-calving for 8 week did not increase 
plasma 25(OH) D3 concentration compared with control with 0.625 mg/d. McDermott et al., 
(1985) compared three daily doses of vitamin D3 supplements (0.25 mg, 1.25 mg or 6.25 mg) 
to dairy cows for 14 weeks, and results demonstrated that only the 6.25 mg dose significantly 
enhanced plasma 25(OH) D3 concentration. Therefore it is perhaps not surprising that the 
supplementation level of 2 mg/day used in the current study did not increase plasma 25(OH) 
D3 concentrations.  
Vitamin D (vitamin D3 and 25(OH) D3) concentrations in milk were not affected by 
treatments, and the mean concentration of 25(OH) D3 concentration in milk through whole 
study was 8.75×10-4 mg/L. Hollis et al., (1981) has fed cows with daily 0.1 mg or 10 mg 
vitamin D3, but this 10-fold elevated supplementation level only resulted in a 2-fold increase 
in milk 25(OH) D3 concentration (from 3.72×10
-4 mg/L increased to 6.85×10-4 mg/L). 
McDermott et al., (1985) supplemented cow diets with a higher daily dose of vitamin D3 (1.25 
mg or 6.25 mg) for 14 weeks, and reported that milk 25(OH) D3 concentration only slightly 
increased from 7.5×10-4 mg/L to 9.25×10-4 mg/L. In agreement with Weiss et al. (2015), the 
current study demonstrated that milk concentrations of 25(OH) D3 were highest earlier in 
lactation compared with later. Furthermore, the current study found a correlation between 
plasma and milk 25(OH) D3 concentrations up to 14 days post-calving but not after, which is 
also in agreement with earlier study of Weiss et al., (2015). This may due to colostrum 
containing greater concentrations of vitamin D binding protein than milk later in lactation, 
which facilitates greater transfer of 25(OH) D3 from the plasma to milk in early lactation 
(Larson and Jorgensen, 1974).  
Concentrations of 25(OH) D3 in milk from the current study ranged from 0.1 to 3.3 µg/kg, 
which, for a typical milk serving of 200 ml (FSA, 2005) would contribute 0.02 to 0.66 µg, 
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well below the current UK recommended intake level of 10 µg/day (SACN, 2016). 
Nevertheless, supplementing cow diets with 25(OH) D3 is more effective than supplementing 
with vitamin D3 in raising plasma 25(OH) D3 concentrations in dairy cows, and the plasma 
25(OH) D3 concentrations of all treatments in current study are within the physiological range 
(Horst et al., 1981). Therefore, the higher effective in raising plasma 25(OH) D3 may resulted 
in which can be used as a better food additive than vitamin D3 to dairy cows in the future.   
Mineral concentrations of calcium, phosphorous and magnesium were not stimulated by 
vitamin D3 or 25(OH) D3 supplementations in the current study. Study Okura et al., (2004) 
shown mineral concentrations is associated with vitamin D biologically form 1,25(OH)2 D3 
which is produced in kidney (Okura et al., 2004). Thus, the possible reason maybe because 
the 1,25(OH)2D3 was not significant affected by dietary vitamin D3 or 25(OH) D3 
supplementation in current study. Unfortunately, 1, 25(OH)2 D3 was not measured in current 
study, which needs further exploration. Furthermore, because the limitation of the vitamin D 
concentration in the diets were not tested, thus, it is unknown the actual vitamin D dose that 
dairy cows received, which should be enhanced in the future studies. 
 
 
Conclusions 
Supplementing dairy cows with 25(OH) D3 was a successful strategy for increasing 
circulating concentrations of 25(OH) D3 in the cow. Transfer of this into milk appeared to be 
greater during early lactation (0-14 days). Therefore, supplementation of cow diets at this 
supplementation level may not be an effective dietary strategy for increasing 25(OH) D3 
content of milk in order to address vitamin D deficiency within the general population. 
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Table 1. Composition and estimated nutritive value of basal transition and early lactation cow diet. 
 
Basal transition diet Basal early lactation diet 
Ingredient, g/kg   
     Grass silage 244 224 
     Maize silage 344 242 
     Wheat straw 160 18 
     Grass hay - 39 
     Megalac - 12 
     Minerals1 14 10 
     Sodium chloride  - 4 
     Ammonium chloride 14 - 
     Magnesium chloride 14 - 
     Concentrate blend2 210 458 
Estimated nutritive value 
       Crude protein, g/kg 144 173 
     Metabolisable energy, MJ/kg 10.2 11.8 
     Starch, g/kg 169 203 
     Neutral detergent fibre, g/kg 450 351 
     Oil, g/kg 44 58 
     Ash 109 83 
     Water-soluble carbohydrate 25 48 
1Containing (mg/kg) Calcium 270,000; Phosphorus 40,000; Magnesium 60,000; Sodium 40,000; Selenium (sodium selenite) 30; Cobalt (cobalt carbonate) 
50; Iodine (calcium iodate) 500; Manganese (manganese oxide) 4,000; Zinc (zinc oxide) 5,000; Copper (cupric sulphate) 1,500; Vitamin A (retinyl acetate) 
12.5; Vitamin E (di-alpha tocopheryl acetate) 0.01. 
2Containing (g/kg Dry Matter) Rolled wheat 313; Hipro soyabean meal 159; Soya hulls 60; Palm kernel meal 120; Rapeseed meal 170; Wheatfeed 129; 
Megalac 16; Molasses 33. 
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Table 2. Details of experimental treatments. 
    Daily feeding for each cow 
Treatment  Cow no. 14 days of pre-calving until calving Feeding from calving to early lactation of 56 days 
Control 15 Basal transition cow diet1 plus vitamin D supplementation: Basal early lactation diet1 plus vitamin D supplementation: 
  
0.625 mg vitamin D3 0.625 mg vitamin D3 
  
no 25(OH) D3 no 25(OH) D3 
    HyD pre-calving  15 Basal transition cow diet plus vitamin D supplementation: Basal early lactation diet plus vitamin D supplementation: 
  
0.625 mg vitamin D3 0.625 mg vitamin D3 
  
6 mg 25(OH) D3 no 25(OH) D3 
    D3max 15 Basal transition cow diet plus vitamin D supplementation: Basal early lactation diet plus vitamin D supplementation: 
  
0.625 mg vitamin D3 2 mg vitamin D3 
  
no 25(OH) D3 no 25(OH) D3 
    HyD post-calving 15 Basal transition cow diet plus vitamin D supplementation: Basal early lactation diet plus vitamin D supplementation: 
  
0.625 mg vitamin D3 0.625 mg vitamin D3 
    no 25(OH) D3 1.5 mg 25(OH) D3 
1 Composition and estimated nutritive value of basal transition and early lactation cow diet described in Table 1. 
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Table 3. Effect of supplements on milk yield, milk composition and dry matter intake of cows (least square means). 
  Treatment 
 
P2 
 
Contrast P3 
Characteristics Control 
HyD pre-
calving D3max 
HyD post-
calving SEM1 Treatment Time 
Treatment 
× time 
 
1 2 3 
Milk yield 
                 Milk yield (kg/d) 43.0 42.4 42.3 44.2 1.39 0.735 <0.001 0.320 
 
0.993 0.355 0.311 
     Fat-corrected milk  (kg/d) 46.5 44.3 45.7 46.6 1.71 0.718 0.024 0.183 
 
0.604 0.313 0.680 
     Energy-corrected milk (kg/d) 45.2 43.2 44.4 45.4 1.60 0.745 0.071 0.210 
 
0.629 0.328 0.634 
     Fat (g/d) 1722 1587 1689 1697 74.6 0.625 0.001 0.182 
 
0.447 0.332 0.937 
     Protein (g/d) 1292 1267 1266 1311 42.2 0.841 0.601 0.645 
 
0.819 0.457 0.441 
     Lactose (g/d) 1926 1895 1901 1979 62.2 0.747 <0.001 0.313 
 
0.993 0.324 0.358 
Milk composition 
                 Fat (%) 4.03 3.73 4.01 3.85 0.116 0.187 <0.001 0.055 
 
0.198 0.479 0.290 
     Protein  (%) 3.02 3.01 2.99 2.97 0.042 0.842 <0.001 0.439 
 
0.582 0.476 0.814 
     Lactose (%) 4.48 4.47 4.49 4.48 0.025 0.946 0.001 0.779 
 
0.916 0.784 0.755 
     Casein (%) 2.29 2.29 2.30 2.27 0.045 0.946 <0.001 0.613 
 
0.844 0.569 0.764 
Urea (mg/l) 244 239 231 244 13.1 0.762 0.389 0.618 
 
0.620 0.728 0.352 
Somatic cell count 
(×10000/ml) 4.2 7.5 5.5 8.8 0.1 0.293 <0.001 0.257 
 
0.120 0.679 0.249 
Dry matter intake (kg/d) 25.0 24.5 24.9 25.5 0.93 0.803 <0.001 0.734 
 
0.975 0.332 0.542 
1 Standard error of the mean for n=15 measurements. 
2 Probability corresponding to the effect of treatment, time, or treatment by time interaction 
3 Where 1=Control vs all other diets, 2=HyD pre-calving vs HyD post-calving, 3=D3max vs post-calving
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Table 4. Effect of supplements on milk and plasma 25-hydroxyvitamin D3 or mineral concentrations (least square means). 
  Treatment 
 
P2 
 
Contrast P3 
Measurements Control 
HyD pre-
calving D3max 
HyD post-
calving SEM2 Treatment Time 
Treatment × 
time 
 
1 2 3 
Plasma (whole study)             
     25(OH) D3 (ng/ml) 43.0 122.7 39.5 87.1 5.11 <0.0001 <0.001 <0.001  <0.001 <0.001 <0.001 
     Calcium (mmol/l) 2.38 2.34 2.35 2.33 0.028 0.399 <0.001 0.715  0.118 0.593 0.515 
     Phosphorus (mmol/l) 1.64 1.73 1.72 1.77 0.053 0.130 <0.001 0.717  0.030 0.482 0.344 
     Magnesium(mmol/l)  0.98 0.97 0.98 0.97 0.021 0.933 <0.001 0.379  0.733 0.875 0.875 
Milk  
                 25(OH) D3 (ng/kg) 869 1132 889 1001 130.7 0.193 0.004 <0.001 
 
0.214 0.339 0.412 
     Calcium (mg/kg) 1105 1064 1085 1133 26.9 0.111 <0.001 0.782 
 
0.644 0.020 0.111 
     Phosphorus (mg/kg) 896 923 880 930 24.4 0.215 <0.001 0.240 
 
0.484 0.789 0.065 
     Magnesium (mg/kg) 95.8 96.3 93.9 98.2 2.95 0.591 <0.001 0.906 
 
0.901 0.554 0.175 
1 Standard error of the mean for n=15 measurements. 
2 Provability corresponding to the effect of treatment, time, or treatment by time interaction 
3 Where 1=Control vs all other diets, 2=HyD pre-calving vs HyD post-calving, 3=D3max vs post-calving
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Figure 1. Effect of treatments on 25(OH) D3 concentrations in plasma. Control for both transition and early lactation containing 0.625 mg Vitamin D3; HyD 
pre-calving had same diet with Control at early lactation, but the transition diet supplemented with 6 mg 25(OH) D3 during pre-calving in addition to Control 
diet; HyD post-calving had same transition diet with Control, but early lactation diet included 1.5 mg 25(OH) D3 supplements in addition to Control; D3max 
had same transition diet with Control, but with supplemented 2 mg vitamin D3 in addition to Control diet. Least squares means ± s.e.m. for 15 measurements.
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Figure 2. Effect of treatments on 25(OH) D3 concentrations in milk. Control for both transition and early lactation containing 0.625 mg Vitamin D3; HyD 
pre-calving had same diet with Control at early lactation, but the transition diet supplemented with 6 mg 25(OH) D3 during pre-calving in addition to Control 
diet; HyD post-calving had same transition diet with Control, but early lactation diet included 1.5 mg 25(OH) D3 supplements in addition to Control; D3max 
had same transition diet with Control, but with supplemented 2 mg vitamin D3 in addition to Control diet. Least squares means ± s.e.m. for 15 measurements. 
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Figure 3. Corrections between 25-hydroxyvitamin D3 in plasma and in milk. 
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Chapter 8 - Differential effect of 25-hydroxyvitamin D3 and vitamin D3 
fortified dairy drinks on postprandial markers of vitamin D status and 
cardiovascular disease risk markers in men with sub-optimal vitamin D 
status. 
 
The present chapter aims to compare the acute effect of a dairy drink enriched with vitamin 
D3 or 25(OH) D3 on vitamin D status and markers of CVD risk in humans. 
 
JAL, DIG, KGJ and JG designed the study; JG conducted the research. JG analysed the data, 
JG wrote the manuscript.
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Abstract 
Background: One strategy for improving vitamin D status in the population is the 
consumption of vitamin D fortified foods. However, the effects of dairy products fortified 
with different vitamin D isoforms on vitamin D status and metabolic outcomes have not been 
addressed. 
Objective: We investigated whether a dairy drink fortified with either 25-hydroxyvitamin D3 
(25(OH) D3) or vitamin D3 had differential effects on 24 h circulating plasma 25(OH) D3 
concentrations (marker of vitamin D status) and cardiometabolic risk markers. 
Design: A randomised, controlled, cross-over, double-blind postprandial study was conducted 
in 17 men of sub-optimal vitamin D status. They were randomised to three different test meals 
which contained either a non-fortified dairy drink (control), 20 µg 25(OH) D3 fortified or 20 
µg vitamin D3 fortified dairy drinks on separate occasions, separated by 2 weeks. Plasma 
25(OH) D3 and cardiometabolic risk markers (including vascular function) were measured 
frequently up to 8 h postprandially, and at 24 h after the dairy drink was consumed.  
Results: Plasma 25(OH) D3 was significantly higher following 25(OH) D3 compared with 
vitamin D3 fortified dairy drink and control (P=0.019), reflected in the 1.5-fold and 1.8-fold 
greater incremental area under the curve for the 0-8 h response, respectively. Change in 
plasma 25(OH) D3 from baseline to 24 h for the 25(OH) D3 fortified dairy drink was also 
significantly higher than the vitamin D3 fortified and control (P<0.0001) dairy drinks. There 
was no significant effect of the test meals on the cardiometabolic risk markers. 
Conclusion: A 25(OH) D3 fortified dairy drink was more effective at raising plasma 25 (OH) 
D3 concentrations postprandially than the vitamin D3 fortified drink. The long-term effect of 
25(OH) D3 dairy drink consumption on vitamin D status and cardiometabolic risk markers 
should be investigated. 
Key words: vitamin D3, 25(OH) D3, dairy drink, milk, butter, vascular function, 
augmentation index, vitamin D status.
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Introduction 
Vitamin D deficiency has been reported to be associated with an increased risk of many 
common and chronic diseases, including cardiovascular disease, some cancers and diabetes 
(1). Circulating 25-hydroxyvitamin D (25(OH) D) concentration is commonly used as the 
measure of vitamin D status (2). The Institute of Medicine reported circulating concentrations 
of 50 nmol/L or above as adequate for sustaining musculoskeletal health outcomes (3). 
Hypovitaminosis D is now prevalent in the general European population (4) with 23% of UK 
adults presenting with a vitamin D status below 25 nmol/L (5). Due to diet and lifestyle 
changes and the frequent use of sunscreen, many individuals do not endogenously synthesise 
sufficient vitamin D from sunlight exposure (6). Therefore, vitamin D from dietary sources 
has become more important for maintenance of adequate vitamin D status. However there are 
only a few foods naturally rich in vitamin D such as egg yolk and oily fish (7). Thus, one 
strategy used in some countries, including USA and Canada, to improve population vitamin D 
status is fortification of milk with vitamin D, which has resulted in milk being the major 
contributor to vitamin D intake in these countries (8).    
The relative efficacy of 25(OH) D3 and vitamin D3 for improving vitamin D status is 
inconsistent between studies (9-14), yet it is generally found that 25(OH) D3 supplementation 
can increase vitamin D status more effectively than vitamin D3 after chronic supplementation. 
To our knowledge, there are no human studies which have compared the efficacy of foods 
fortified with these two forms of vitamin D3 to increase postprandial circulating 25(OH) D3 
concentrations, or their differential effects on chronic disease risk markers in the short term. 
Therefore, our study aimed to address this knowledge gap by comparing the acute effect of 
consuming test meals containing dairy drinks which have been fortified with either 20 µg 
vitamin D3 or 20 µg 25(OH) D3 on changes in postprandial plasma vitamin D3 and 25(OH) 
D3, cardiometabolic risk markers including vascular reactivity, blood pressure (BP), lipid 
profile, indexes of insulin resistance, inflammatory and vascular biomarkers. In addition, 
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whole blood culture cytokine production was examined as a real-time measure of 
inflammatory status.  
 
Methods 
Subjects 
The study was conducted according to the Declaration of Helsinki and approved by the 
University of Reading Research Ethics Committee (approval no. 15/15), and was registered at 
www.clinicaltrials.gov (NCT02535910). Non-smoking men (n=18) aged 30-65 years with a 
body mass index (BMI) between 20-35 kg/m2 with sub-optimal vitamin D status (plasma 
25(OH) D ≤ 50 nmol/l) were recruited from the population in Reading, UK and the 
surrounding areas, from May to October 2015 by email, internet, poster or newspaper 
advertisements. Subjects who expressed an interest in the study were asked to complete a 
medical, lifestyle and ethnicity questionnaire. The key exclusion criteria included: women, 
cardiovascular, renal, gastrointestinal, respiratory and endocrine diseases, diabetes or cancer; 
hypertension; use of nutritional supplements; on long-term medication; milk 
allergy/intolerance or lactose intolerance; outdoor workers and those who used tanning beds; 
overseas holidays two months before or during the study period; vigorous exercise (>3 times 
of 30 min aerobic exercise/week) and excessive alcohol intake (>14 units/week). Those who 
complied with the inclusion criteria were invited to attend a screening visit following a 12-
hour overnight fast consuming nothing but water during this time. All subjects provided 
written informed consent. Blood samples were taken by venipuncture for determination of the 
full blood count at the Royal Berkshire Hospital (Reading UK), men who had anemia 
(haemoglobin < 125 g/L) were excluded. Blood samples were also collected for measuring 
vitamin D status (performed at the Royal Berkshire Hospital) and fasting serum glucose, total 
cholesterol, triacylglycerol (TAG), markers of liver and kidney function using an automated 
clinical chemistry analyser (ILAB 600, Werfen UK Limited). Furthermore, static BP was 
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measured during the screening visit to exclude subjects with abnormal blood pressure. 
Normal blood pressure was considered to be a systolic blood pressure (SBP) of 90-120 mmHg 
and a diastolic blood pressure (DBP) between 60-80 mmHg.  
 
Study design 
This study was an acute, randomised, controlled, 3-way-crossover, double-blinded study 
conducted between October 2015 and February 2016. After participants were accepted onto 
the study, they were invited to the clinical unit of the Hugh Sinclair Unit of Human Nutrition 
at the University of Reading for a familiarisation visit to be acquainted with the clinical 
facilities and vascular function study measurements. Before the first study visit, the 
participants were asked to complete a 4-day diet diary (including 3 weekdays and 1 weekend 
day within the same week) and Dietplan 6.6 software was used to assess habitual dietary 
intake including dietary vitamin D. The first study day was performed 2-weeks after the 
familiarisation visit and there was a 2-week washout period between the 3 study visits (see 
Supplemental Figure 1). The participants were randomly assigned to the study interventions 
by web-based random letter sequence generator (https://www.randomizer.org/). A double-
blinded protocol was maintained throughout the study until all of the statistical analysis was 
completed. Throughout the study, participants were asked to maintain their normal diet and 
lifestyle, to avoid taking any dietary supplements and to minimize sun exposure.  
Participants were asked to avoid alcohol, caffeine or any vigorous physical activity for 24 
h before each visit and to consume a standard low-fat evening meal provided by the 
researchers. In addition, no foods that were fortified or high in vitamin D were permitted for 
the 24 h study period and low-nitrate water (The Buxton Mineral Water Company Ltd) was 
provided to the subjects to consume the day before the study visit and throughout the 
postprandial day until the 24 h time point. 
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For each study visit, participants arrived at the clinical unit of the Hugh Sinclair Unit of 
Human Nutrition at approximately 8.00 am after a 12 h overnight fast. Height, weight, waist 
and hip circumferences were measured before a cannula was inserted into the antecubital vein 
of the dominant arm. BP and vascular reactivity measurements were performed after a 30 min 
rest in a temperature controlled (23±1 °C) clinical room before a fasting blood sample was 
taken. After the baseline measurements were completed, the test meal was provided and 
consumed within 15 minutes. Ten postprandial blood samples, four BP and four vascular 
reactivity measurements were performed up to 8 h after the test meal (see Supplemental 
Figure 1). Subjects remained in the clinical unit for the duration of the 8 h study visit and no 
additional food was consumed during the postprandial study period. A standard controlled 
evening meal (Marks and Spencer Ltd) was consumed at the end of study visit (no vitamin D 
enriched or fortified foods), after which the participants fasted overnight. The following 
morning, they returned to the clinical unit for their 24 h assessment in which a fasting blood 
sample was collected, and BP and vascular reactivity were measured.  
 
Acute test meals 
Vitamin D3 and 25(OH) D3 supplements (Dishman Netherlands B.V.) were dissolved in 
refined olive oil (Sainsbury’s Supermarkets Ltd) to achieve a concentration of 1 µg/100 µl 
vitamin D3 or 25(OH) D3 stock fortified oil. Aliquots of vitamin D3 test oil (containing 20 µg 
vitamin D3), 25(OH) D3 test oil (containing 20 µg 25(OH) D3), and control (olive oil) were 
assigned a random code and store at -20 °C.  
On the morning of each study visit, the dairy drink was prepared from 300 ml full fat milk 
(Co-operative Limited), 32 g unsalted butter (Co-operative Ltd) and 25 g Askeys Treat 
Strawberry sauce (The Silver Spoon Ltd). Milk and strawberry sauce were warmed and mixed 
with melted butter using a hand blender (Sainsbury’s Supermarkets Ltd), before 2 ml of the 
defrosted test/control oil was added into the warm dairy drink and homogenised well.  
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Subjects were given a test breakfast which included the dairy drink, 3 slices (120 g) of 
white toast (Hovis Ltd) with 40 g strawberry jam (Sainsbury’s Supermarkets Ltd) and 15 g 
unsalted butter (Co-operative Ltd). Each of the test meals contained 51 g fat, 125 g 
carbohydrate, 23 g protein and 4.54 MJ. The nutrient compositions of the foods were obtained 
from the product labels. 
 
Assessment of vascular function, blood pressure and anthropometric measures 
Height and weight was measured using a wall-mounted stadiometer and Tanita BC-418 
digital scale (Tanita Europe BV) respectively. BP was measured on the upper left arm using a 
BP monitor (TM-2430; A&D Ltd) in triplicate after a minimum of 10 min rest in a supine 
position at baseline (0 min) and at 1.5, 3, 6 and 8 h after breakfast and also at the 24 h visit. 
An Endo-PAT 2000 device (Itamar Medical Ltd) was used to assess the peripheral artery 
tonometry at baseline (before breakfast) and at the 24 h visit as described elsewhere (15). In 
brief, after the subjects had rested in a supine position for 20 min, the occlusion cuff was 
placed on the non-dominant upper arm, and fingertip probes were secured to the index finger 
of both hands. Measurements were taken for 5 min baseline, 5 min occlusion (cuff was 
inflated to 60 mm Hg above the subjects’ SBP (between 200 and 300 mmHg)) and 5 min 
post-occlusion after deflation of the cuff. Pulse wave amplitude (PWA) was recorded 
automatically by the EndoPAT software (EndoPATTM 2000). From the PWA recordings, 
reactive hyperemia index (RHI), Framingham reactive hyperemia index (F-RHI), 
augmentation index (AI), and AI adjusted for a heart rate of 75 beats/min (AI@75) were 
automatically calculated (16). In addition, digital volume pulse (DVP) photoplethysmography 
(Pulse Trace; Micro Medical) was measured at baseline (0 min) and 1.5, 3, 6 and 8 h after 
breakfast and also at the 24 h visit to determine arterial stiffness index (SI), reflection index 
(RI), peak-to-peak time (PPT) and heart rate (HR) (17).  
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Plasma collection and analysis  
Blood samples collected from the cannula were placed into serum separating tubes (for the 
analysis of blood lipids, apolipoprotein B (apoB), C-reactive protein (CRP), glucose and 
insulin); lithium heparin tubes (for the analysis of total nitrates and nitrites (NOx)); and 
K3EDTA-coated tubes (for the analysis of tumor necrosis factor alpha (TNF-α), Interleukin 6 
(IL-6), vitamin D3 and 25(OH)D3). After blood collection, the serum separating tubes were 
stored at room temperature for 15 min, whereas those containing anticoagulant were stored on 
ice. All blood samples were centrifuged within 30 min at 1700 × g for 15 min at room 
temperature (serum) or 4 °C (plasma). After centrifugation, the serum or plasma were 
aliquoted and stored at -20 °C until analysis. 
Analysis of plasma vitamin D3 and 25(OH) D3 (as sum of 25(OH) D3 and 3-epi-25(OH) 
D3) was conducted by DSM Nutritional Products Ltd using a method validated according to 
Food and Drug Administration (18) and European Medicines Agency (19) bioanalytical 
guidelines. In brief, after addition of a deuterated internal standard solution, a protein 
precipitation was performed with a mixture of tetrahydrofuran, acetonitrile and methanol. 
After centrifugation, the supernatant was evaporated and the residue was reconstituted with 
acetonitrile-methanol solution. An aliquot was then injected into a LC-MS/MS system 
(Agilent 1290, C18 column) with APPI source (ABSciex 4000) and the detection of the 
specific fragment ions was performed using multiple reactions monitoring mode. To assess 
the daily and long-term laboratory performance of the method, dedicated standard and quality 
control samples were analyzed daily with the unknown samples to ensure the accuracy and 
precision of the method. Data acquisition of extracted ion chromatograms, integration and 
quantification were performed using Analyst® software from ABSciex. 
Serum total cholesterol, HDL-cholesterol, non-esterified fatty acids (NEFA), TAG, apoB 
and CRP were determined using the ILAB 600 autoanalyser with standard kits and 
appropriate quality controls (reagents and analyser: Werfen (UK) Ltd; NEFA reagent: Alpha 
 
 
221 
 
Laboratories; apoB reagent: Randox Laboratories). The fasting LDL-cholesterol concentration 
was calculated from total cholesterol, HDL-cholesterol and TAG by using the Friedewald 
formula (20). ELISA kits were used to detect TNF-α (R&D Systems Europe Ltd), IL-6 (R&D 
Systems Europe Ltd) and insulin (Dako Ltd). Insulin resistance markers: QUICKI, Revised 
QUICKI (rQUICKI) and HOMA IR were calculated by using standard equations (21). Plasma 
samples were analysed for nitrite and nitrate using Eicom NOx Analyzer (ENO-30) as 
described elsewhere (22). 
Blood was collected into K2EDTA tubes (Greiner BioOne Limited) at baseline, 8 and 24 h 
after the consumption of the test meal for whole blood culture and cytokine analysis as 
previously described (23). Cytokines of TNF-α and IL-6 were measured in whole blood 
culture supernatants using ELISA kits (R&D Systems Europe Ltd). The data were normalized 
for monocyte number and only samples stimulated for 24 h with lipopolysaccharide (0.5 
µg/ml) were used in the final analysis.    
 
Study power 
According to earlier research by Jetter et al. (24), the expected difference between the 
treatments (i.e. single dose of 20 µg vitamin D3 or 20 µg 25(OH) D3) for plasma 25(OH) D3 is 
3.7 ng/ml (peak concentration of the first day) with a standard deviation (SD) of 13.2 ng/ml. 
Thus, it was estimated that 15 subjects were required to detect a significant change in this 
primary outcome measurement with a power of 80% and 5% significance level. A total of 18 
subjects were recruited to allow for a drop-out rate of 15%. 
 
Statistical analysis 
All data analyses were conducted using STATA (version 13.0; STATA Corporation, 
2014). Results are expressed as means ± standard errors (SEMs). Data were checked for 
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normality and natural logarithm transformation was calculated if needed. The primary 
analysis of the time courses from baseline to 8 h for outcome variables were analysed by two-
factor repeated measures ANOVA to assess the effect of treatment, time, and treatment by 
time interactions with Bonferroni correction to control for multiple comparisons.  
For secondary data analysis, postprandial summary measures were calculated which 
included area under curve (AUC), incremental AUC (iAUC), maximum concentration 
(maxC), increment from baseline to maximal concentration imaxC (imaxC=maxC-fasting 
value) and time to reach maximum concentration (Tmax). These measures were analysed by 
one-way ANOVA and subsequently Bonferroni correction was applied if post-hoc multiple 
pairwise comparisons were performed. Kruskal-Wallis equality-of-populations rank test was 
applied to data which could not be normalised. 
For NEFAs, the postprandial summary measures AUC, iAUC, max C, imaxC, Tmax were 
calculated from the average minimum concentration (approximately 2 h) to 8 h (25). 
 
Results 
Of the 18 men who completed the study, the data for one subject whose baseline vitamin D 
status on the study visit was higher than 50 nmol/L was excluded from the statistical analysis. 
Therefore, 17 men were included in the current study dataset (Table 1) with mean ( SEM) 
sub-optimal vitamin D status of 31.7 ( 3.4) nmol/L and low dietary vitamin D intake of 4.4 
( 1.5) µg/d.  
There were no differences in fasting (0 min) vitamin D status, lipid, indices of insulin 
resistance and glycaemia, vascular biomarkers, SBP or vascular function measurements 
between study visits. However, the fasting DBP and pulse pressure (PP) were significantly 
different between study visits. Thus, only iAUC was calculated to determine the effects of the 
fortified and control dairy drinks on DBP and PP. 
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Postprandial response of plasma vitamin D3 and 25(OH) D3  
Following the test dairy drinks, there was a significant time by treatment interaction for the 
postprandial plasma 25(OH) vitamin D3 concentrations (P<0.0001) (Figure 1). After the 
25(OH) D3 fortified dairy drink consumption, imaxC (0-8h) (P=0.0001) was 1.2-fold higher 
than control and 1.7-fold higher than vitamin D3 fortified dairy drink (Table 2). Furthermore, 
the iAUC (0-8 h) for the 25(OH) D3 fortified dairy drink was 1.5-fold higher than vitamin D3 
fortified dairy drink and 1.8-fold higher than control (P=0.019), whereas the iAUC (0-8 h) for 
the vitamin D3 fortified dairy drink was not different from the control. The change in plasma 
25(OH) D3 concentration calculated from baseline to 24 h after the 25(OH) D3 fortified dairy 
drink was also significantly higher than following the vitamin D3 fortified and control dairy 
drinks (P<0.0001)(Table 2).  
Statistical analysis of the plasma vitamin D3 responses was not conducted as only 42/648 
plasma samples had vitamin D3 concentrations above the limit of detection of the LC-MS/MS 
technique (2.5 nmol/L).  
 
Vascular function and postprandial blood pressure 
Treatment effects on vascular function and postprandial BP are presented in Table 3. 
There was no difference in the change from baseline to 24 h for the vascular function 
measurements by EndoPAT and DVP devices. There were no significant effects of treatments 
on postprandial blood pressure (SBP and DBP) or PP. 
 
Blood lipid profile and indices of insulin resistance and glycaemia 
There were no treatment effects on postprandial blood lipids or indices of insulin resistance 
and glycaemia determined over the 8 h (Supplemental Table 1). In addition, there was no 
difference in the change from baseline to 24 h for any of these measures.  
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Postprandial responses of vascular and inflammatory biomarkers  
No significant effect of treatments on serum CRP, plasma NOx and IL-6 were observed 
(Supplemental Table 2). Statistical analysis of TNF-α was not conduced as 37% of the 
samples had concentrations below the lower level of detection of the ELISA kit (0.11 pg/ml). 
 
Ex vivo Cytokine production 
There was no effect of the fortified or control dairy drinks on ex vivo production of IL-6 or 
TNF-α after stimulation of whole blood cultures with LPS, measured using blood samples 
collected at baseline, 8 or 24 h, or calculated as change from baseline to 8 or 24 h 
(Supplemental Table 3). 
 
Discussion 
This study is the first to compare the postprandial responses to vitamin D3 and 25(OH) D3 
fortified dairy drinks on plasma 25(OH) D3 concentrations in addition to markers of 
cardiometabolic risk. It was observed that a 25(OH) D3 fortified dairy drink (20 µg ) resulted 
in higher and more sustained plasma 25(OH) D3 concentrations over 8 h and at the 24 h time 
point compared with the control and vitamin D3 fortified dairy drinks (20 µg). However, we 
did not detect changes in vascular function measurements or cardiometabolic risk markers 
after consumption of the test meals containing the dairy drinks. 
To date, no randomized controlled trials (RCTs) have evaluated the effects of fortified 
25(OH) D3 dairy products on vitamin D status. However, Jetter et al. (24) compared the effect 
of capsules containing 20 µg of 25(OH) D3 and vitamin D3 on plasma 25(OH) D3 in healthy 
postmenopausal women who had similar baseline plasma 25(OH) D3 concentrations (30.7 ± 
10.2 (SD) nmol/L) to the participants in the current study. A tendency for a 28% higher 
plasma 25(OH) D3 AUC (0 to 24 h) after the 25(OH) D3 supplementation compared with the 
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vitamin D3 supplement was reported, although this did not reach statistical significance. This 
direction of effect was in line with the current study where a 25(OH) D3 fortified dairy drink 
resulted in a 1.5-fold higher plasma 25(OH) D3 iAUC compared with the vitamin D3 fortified 
dairy drink which was evident within 8 h of ingestion, although in the current study the iAUC 
between treatments reached statistical significance. The differences between studies may be 
due in part to the characteristics of the study participants. The current study was conducted in 
men aged 30-54 y, while Jetter et al. (24) studied postmenopausal women aged 50-70 y, 
although there has been no evidence from any study reported of an age or sex effect on the 
absorption of vitamin D supplements. In addition, the form of the 25(OH) D3 may have 
influenced absorption, with a preferential absorption with a fat containing meal rather than 
from capsules taken with water. This speculative explanation would require further 
confirmation.  
We were unable to quantify plasma vitamin D3 concentrations since plasma levels were 
below the detection limit of the LC MS/MS assay. One explanation may relate to the findings 
of Barger et al. (9). Their study investigated the dose response to supplemental vitamin D3 
(25, 250, 1250 µg/d) and 25(OH) D3 (10, 20, 50 µg/d) for 8 and 4 weeks, respectively. It was 
observed that both serum vitamin D3 and 25(OH) D3 increased after vitamin D3 
supplementations, whereas only serum 25(OH) D3 increased after 25(OH) D3 
supplementations. The lack of detection of changes in plasma vitamin D3 after either fortified 
drink suggests that higher dose of vitamin D3 may be required over a longer period of time to 
change plasma vitamin D3 concentrations.  
A study by Stamp (26) investigated the acute effect of a single dose of supplemental 
25(OH) D3 at 10 µg per kg body weight in healthy subjects over 24 h. The peak concentration 
of circulating 25 (OH) D3 was reached between 4 and 8 h. In contrast, Jetter et al. (24) 
reported the time to reach peak plasma 25(OH) D3 concentrations for a supplemental dose of 
20 µg of 25(OH) D3 and vitamin D3 to be 10.8 and 22.2 h respectively. In the current study 
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the peak circulating concentration of 25(OH) D3 could not be identified precisely as blood 
samples were not collected between 8 and 24 h, although 24 h concentrations were still above 
baseline concentrations. Thus, it could be speculated that the peak concentration was reached 
earlier, after ingestion of 25(OH) D3 fortified dairy drink, compared with vitamin D3 fortified 
dairy drink, although this would need to be confirmed in a study with frequent blood sampling 
over 8-36 h.  
Effective dietary strategies to increase population vitamin D status are required to address 
the high incidence of sub-optimal vitamin D status within the population (5). The Scientific 
Advisory Committee for Nutrition published new dietary guidance in 2016 (1), 
recommending a daily vitamin D intake of 10 µg/day for adults, which is challenging to 
achieve through diet unless fortified foods are consumed. The average daily intake of vitamin 
D for adults is only 3.1 µg for men and 2.6 µg for women, respectively (5). Therefore, 
vitamin D fortified foods are one strategy that would increase vitamin D dietary intake. Milk 
and dairy are ideal foods for fortification as they are consumed by the majority of the 
population within Europe and USA (5, 27). The current study verified that dairy products 
were suitable vehicles for fortification with 25(OH) D3 resulting in a more rapid increase in 
markers of vitamin D status than using vitamin D3. The mechanism for the more rapid 
absorption of 25(OH) D3 is unclear, but it might be because hepatic metabolism of vitamin D3 
to 25(OH) D3 is circumvented (6), and so the bioactive form of vitamin D, 1,25(OH)2 D3, can 
be more rapidly synthesised by the kidney, whereas vitamin D3 needs to be transported in 
chylomicron particles from the gut to the liver for further metabolism (3).   
No treatment effects on postprandial arterial stiffness in men with sub-optimal vitamin D 
status were observed, which is in line with a previously study (28) which also reported no 
changes in arterial stiffness after consumption of a single dose of 7500 µg or 1875 µg vitamin 
D3. In addition, a recent systematic review and meta-analysis (29) has summarised 28 RCTs 
on vitamin D3 supplementation and concluded there was no effect of vitamin D 
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supplementation (doses ranged from 25 µg/day to 3000 µg/month) on arterial stiffness after 
administration periods ranging from 2 to 12 months.  
In contrast with our study of no effect on BP, Bischoff-Ferrari et al. (10) reported a 5.7-
mmHg decrease (P=0.0002) in SBP after daily 20 µg 25(OH) D3 supplementation compared 
with 20 µg vitamin D3 consumption over 4 months in subjects who had normal BP. Note that, 
in our study, the effect of the test meal containing the dairy drink was followed up for 24 h 
only as opposed to the study of Bischoff-Ferrari et al. (10) which was a 4 months intervention, 
which suggests that a chronic intervention period may have been required for significant 
changes in BP. 
Our findings for a lack of effect of the fortified dairy drinks on the postprandial lipid 
profiles (TAG and NEFA) are in line with a previously study (28), which also reported there 
were no effects of a single higher dose of vitamin D3 of 7500 µg or 1875 µg on postprandial 
lipid profiles (TAG, total-/HDL-/LDL-cholesterol) up to 8 h in overweight vitamin D 
deficient women (vitamin D level of 27.1 (SD=13.8) nmol/L). Furthermore, the current study 
is the first to investigate the effects of vitamin D fortified dairy drinks on the production of 
the inflammatory cytokines, IL-6 and TNF-α, in whole blood culture following stimulation 
with lipopolysaccharide. No differences between the dairy drinks were observed, suggesting 
that longer supplementation periods or higher doses may be required to determine the chronic 
effect on inflammation.  
This study has some potential limitations. It was powered to detect a significant difference 
in the primary outcome of postprandial plasma 25(OH) D3, however it may not have been 
suitably powered to detect changes in the secondary outcomes. In addition, blood samples 
were not collected between 8 and 24 h, which restricted estimation of the peak 25(OH) D3 
concentration. Furthermore, the participants were men with sub-optimal vitamin D levels and 
the results may not be representative of responses in women or those individuals with 
adequate vitamin D levels.  
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In conclusion, the current study confirmed that a 25(OH) D3 fortified dairy drink was able 
to increase a marker of vitamin D status more efficiently postprandially than a vitamin D3 
fortified dairy drink. For future studies it is important to investigate the impact of daily 
25(OH) D3 fortified dairy drink consumption on vitamin D status and cardiometabolic risk 
markers over a longer period in both men and women. 
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Table 1. Baseline characteristics of participants1. 
  All (n=17) 
Age, y 49 ± 3 
BMI,  kg/m2 26.4 ± 0.61  
Blood pressure (mmHg) 
   Systolic  122 ± 2  
   Diastolic  64 ± 2 
Total-cholesterol, mmol/L  5.04 ± 0.21  
LDL-cholesterol, mmol/L 3.61 ± 0.09  
HDL-cholesterol, mmol/L 1.21 ± 0.03  
Triacylglycerol, mmol/L 1.48 ± 0.21  
Glucose, mmol/L 5.42 ± 0.14  
Insulin, pmol/L 47.7 ± 3.2  
Vitamin D dietary intake2, µg/d  4.40 ± 1.51  
Vitamin D status, nmol/L 31.7 ± 3.4  
1Values are means ± SEM of three visits. BMI: body mass index; 
2Derived from 4-day diet diary. 
 
 
 
 
 
 
 
 
234 
 
 
Table 2. Baseline and postprandial changes of plasma 25(OH) D3 concentrations from baseline after consumption of 25(OH) D3 fortified dairy drink (25(OH) 
D3), vitamin D3 fortified dairy drink (Vitamin D3) or unfortified dairy drink (Control)
1. 
Measures of 25(OH) D3  
Meal     
Control   Vitamin D3   25(OH) D3   P
2 
Baseline, nmol/L 28.5 ± 2.8 
 
31.0 ± 3.4 
 
30.4 ± 3.3 
 
0.847 
maxC (0-8h), nmol/L 32.9 ± 3.6 
 
34.6 ± 3.8 
 
40.2 ± 3.9 
 
0.368 
imaxC (0-8h), nmol/L 4.4 ± 1.1b 
 
3.6 ± 0.7b 
 
9.8 ± 1.2a 
 
0.0001 
AUC (0-8h), nmol/L×8h  238.2 ± 24.9 
 
259.6 ± 29.1 
 
272.3 ± 28.4  
 
0.677 
IAUC (0-8h), nmol/L×8h 10.3 ± 5.8b 
 
11.7 ± 4.2b 
 
29.2 ± 5.2a 
 
0.019 
Change from baseline to 24h 1.6 ± 1.1b  4.5 ± 0.8b  8.7 ± 0.9a  <0.0001 
Change from 8 h to 24h -0.2 ± 1.2  3.1 ± 0.9  1.6 ± 1.0  0.101 
1Values are means ± SEMs. Different superscript letters within a row identify intervention groups significantly different from one another (P≤0.05). 
2One-factor ANOVA was applied to the outcome variable, Bonferroni multiple pairwise comparison post hoc tests was used to identify the significant 
differences between the treatments. 
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Table 3. Baseline and change from baseline to 24 h for the vascular measurements and postprandial blood pressure after consumption of 25(OH) D3 fortified 
dairy drink (25(OH) D3), vitamin D3 fortified dairy drink (Vitamin D3) or unfortified dairy drink (Control)
1. 
               Meal    
Measures          Control            Vitamin D3           25(OH) D3                                       
     P3 
   
EndoPAT device2 
    
 
   RHI     
 
   Baseline 1.94 ± 0.18  2.04 ± 0.15  1.85 ± 0.12 0.683 
 
   Change from baseline to 24h 0.15 ± 0.18  0.05 ± 0.14  0.13 ± 0.12 0.895 
F-RHI       
 
   Baseline 0.29 ± 0.11  0.41 ± 0.09  0.31 ± 0.08 0.625 
 
   Change from baseline to 24h6 0.20 ± 0.11  0.04 ± 0.10  0.08 ± 0.08 0.599 
AI        
 
   Baseline 3.85 ± 3.24  6.33 ± 3.37  4.66 ± 3.74 0.872 
     Change from baseline to 24h -0.51 ± 1.66  -3.21 ± 1.74  -2.99 ± 1.56 0.447 
 AI@75       
 
   Baseline  3.85 ± 3.24  6.33 ± 3.37  4.66 ± 3.74 0.872 
 
    Change from baseline to 24h  -0.51 ± 1.66  -3.21 ± 1.74  -2.99 ± 1.56 0.447 
DVP device       
 Heart Rate (HR)       
    Interaction of treatment × time5      0.545 
 
   Baseline, (beats/min) 57.9 ± 1.8  58.1 ± 1.9  57.5 ± 1.7 0.967 
   AUC (0-8h), beats/min×8h 475.9  ± 13.8  465.9 ± 14.3  476.3 ± 13.8 0.838 
    iAUC (0-8h), beats/min×8h 12.3 ± 7.3  0.9 ± 7.8  16.3 ± 7.4 0.331 
    Change from baseline to 24h, (beats/min)6 3.0 ± 1.5   1.6 ± 1.3  3.2 ± 0.9 0.505 
 Stiffness index (SI)       
    Interaction of  treatment  × time      0.084 
 
   Baseline, m/s 8.6 ± 0.6  9.0 ± 0.6  8.4 ± 0.7 0.804 
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    AUC (0-8h), beats/min×8h 60.9 ± 3.8  59.6 ± 3.7  62.9 ± 4.4 0.845 
    iAUC (0-8h), beats/min×8h6 -7.9 ± 8.3  -12.3 ± 15.6  -4.4 ± 12.7 0.393 
    Change from baseline to 24h, m/s6 -0.04 ± 0.41  -0.73 ± 0.63  0.04 ± 0.33 0.631 
 Reflection index (RI)       
    Interaction of  treatment  × time      0.307 
 
   baseline,% 73.7 ± 2.7  75.2 ± 2.7  71.1 ± 3.3 0.615 
   AUC (0-8h), beats/min×8h 552.3 ± 19.8  554.1  ± 16.1  552.4 ± 22.6 0.997 
    iAUC (0-8h), beats/min×8h -37.0 ± 12.6  -47.2 ± 17.7  -16.7 ± 17.9 0.410 
    Change from baseline to 24h,% -3.49 ± 2.61  -5.73 ± 3.16  -2.24 ± 2.80 0.686 
 Peak-to-peak time       
    Interaction of  treatment  × time      0.172 
 
   Baseline, m/s 220.7  ± 14.9  212.5  ± 15.3  233.9 ± 18.2 0.643 
   AUC (0-8h), beats/min×8h 1999.0 ± 465.0  2014.4 ± 456.4  1967.2 ± 516.1 0.958 
    iAUC (0-8h), beats/min×8h 233.6 ± 228.5  314.1 ± 355.6  95.7 ± 324.6 0.123 
    Change from baseline to 24h, m/s6 5.91 ± 7.59  20.07 ± 13.80  0.55 ± 7.76 0.530 
 Systolic blood pressure (SBP)       
    Interaction of  treatment  × time5      0.574 
    Baseline, mm Hg 119 ± 2   123 ± 3  121 ± 3 0.672 
    AUC (0-8h), mm Hg×8h 953 ± 15  961 ± 14  968 ± 17  0.802 
    IAUC (0-8h), mm Hg×8h -2 ± 11        -19 ± 10      -1 ± 9             0.376 
         Change from baseline to 24h, mm Hg -1 ± 2  -2 ± 2  -4 ± 1        0.551 
 Diastolic blood pressure (DBP)       
    Interaction of  treatment  × time      0.924 
    Baseline, mm Hg 67 ± 2  64 ± 2  73 ± 2 0.0007 
    IAUC (0-8h), mm Hg×8h 11 ± 12  -3 ± 15  -17 ± 12 0.334 
    Change from baseline to 24h, mm Hg -1 ± 2  2 ± 2  2 ± 2 0.584 
 Pulse pressure (PP)4       
    Interaction of  treatment  × time      0.873 
    Baseline, mm Hg 53 ± 2ab  58 ± 3b  48 ± 3a 0.041 
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 1Values are means ± SEMs. Different superscript letters within a row identify intervention groups significantly different from one another.  
 2RHI: reactive hyperemia index; F-RHI: Framingham reactive hyperemia index; AI: augmentation index; AI@75: augmentation index adjusted      for a 
heart rate of 75 beats/min.  
3Two-factor repeated measure ANOVA was applied to assess the treatment by time interactions; One-factor ANOVA was applied to the outcome variable to 
compare overall between-group diet, Bonferroni multiple pairwise comparison post hoc tests was used to identify the significant differences between 
treatments. 
4Calculated by subtraction of DBP from SBP. 
5Original data were transformed to natural logarithms for the analysis. 
6Kruskal-Wallis equality-of-populations rank test for non-normally distributed data. 
    IAUC (0-8h), mm Hg×8h -13 ± 14  -17 ± 19  16 ± 15 0.317 
    Change from baseline to 24h, mm Hg -1 ± 2  -5 ± 3  -6 ± 3 0.366 
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Figure 1. Postprandial responses of mean plasma 25(OH) D3 concentrations after consumption of 25(OH) D3 fortified dairy drink, vitamin D3 dairy drink and 
unfortified dairy drink. Values are means ± SEM, n=17 for each treatment. Two-factor repeated measure ANOVA was applied to assess the effect of 
treatment, time, and treatment by time interactions.    
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A) Participant flowchart 
 
B) Study design  
 
Supplemental Figure 1. Participant flowchart and study design (BP: blood pressure measurement; vascular function measurements: DVP or Endo-PAT. 
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Supplemental Table 1. Postprandial responses of blood lipid profile, indexes of insulin resistance after consumption of 25(OH) D3 fortified dairy drink 
(25(OH) D3), vitamin D3 fortified dairy drink (Vitamin D3) or unfortified dairy drink (Control)
1. 
  Meal   
Measures Control Vitamin D3 25(OH) D3 P
2 
Glucose      
 
Interaction of meal × time for the postprandial timecourse 1.000 
 Baseline, mmol/L3 5.39 ± 0.17 5.50 ± 0.13 5.49 ± 0.15 0.788 
 
maxC (0-8h), mmol/L3 7.63 ± 0.49 7.93 ± 0.50 7.93 ± 0.51 0.872 
 
imaxC (0-8h), mmol/L3 2.24 ± 0.43 2.43 ± 0.45 2.44 ± 0.46 0.922 
 
Tmax (0-8h), min3 81 ± 13 67 ± 12 62 ± 15 0.259 
 
AUC (0-8h), mmol/L×8h3 44.6 ± 1.4 44.3 ± 1.4 43.7 ± 1.4 0.881 
 
IAUC (0-8h), mmol/L×8h 1.5 ± 1.2 0.3 ± 1.2 -0.2 ± 0.8 0.526 
 
Change from baseline to 24h, mmol/L 0.12 ± 0.06 0.08 ± 0.08 0.02 ± 0.06 0.583 
Insulin     
 
Interaction of meal × time for the postprandial timecourse3  0.875 
 Baseline, pmol/L 43.7 ± 5.4 49.3 ± 5.6 50.0 ± 5.7 0.685 
 
maxC (0-8h) pmol/L 411.10 ± 41.77 478.23 ± 46.99 459.57 ± 46.25 0.558 
 
imaxC (0-8h), pmol/L3 367.39 ± 38.96 428.94 ± 44.23 409.61 ± 42.73 0.575 
 
Tmax (0-8h), min 72 ± 9  56 ± 8 58 ± 7 0.320 
 
AUC (0-8h), nmol/L×8h 1.2 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 0.810 
 
IAUC (0-8h), nmol/L×8h 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.837 
 
Change from baseline to 24h, pmol/L 18.6 ± 3.7 5.4 ± 4.0 10.0 ± 3.8 0.055 
HOMA-IR     
 
Baseline 1.76 ± 0.23 2.03 ± 0.24 2.06 ± 0.26 0.634 
 
Change from baseline to 24h 0.80 ± 0.17 0.25 ± 0.18 0.40 ± 0.16 0.072 
QUICKI     
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Baseline3 0.16 ± 0.00 0.15 ± 0.00 0.15 ± 0.00 0.672 
 
Change from baseline to 24h4 -0.01 ± 0.00 -0.00 ± 0.00 -0.01 ± 0.00 0.150 
Revised QUICKI     
 
Baseline4 0.08 ± 0.00 0.08 ± 0.00 0.08 ± 0.00 0.825 
 
Change from baseline to 24h4 -0.00 ± 0.00 -0.00 ± 0.00 -0.00 ± 0.00 0.690 
Total cholesterol     
 
Baseline, mmol/L 5.11 ± 0.20 5.12 ± 0.22 5.14 ± 0.20 0.995 
 
Change from baseline to 24h, mmol/L 0.36 ± 0.08 0.40 ± 0.09 0.36 ± 0.07 0.900 
HDL-cholesterol     
 
Baseline, mmol/L 1.22 ± 0.06 1.19 ± 0.06 1.23 ± 0.06 0.881 
 
Change from baseline to 24h, mmol/L 0.06 ± 0.01 0.04 ± 0.02 0.05 ± 0.01 0.632 
LDL-cholesterol      
 
Baseline, mmol/L 3.58 ± 0.15 3.63 ± 0.17  3.61 ± 0.16 0.974 
 
Change from baseline to 24h, mmol/L 0.31 ± 0.07 0.34 ± 0.07 0.30 ± 0.06 0.914 
Triacylgycerol      
 
Interaction of meal × time for the postprandial timecourse3 0.977 
 Baseline, mmol/L3 1.54 ± 0.17  1.50 ± 0.20 1.49 ± 0.16 0.978 
 
maxC (0-8h), mmol/L 2.88 ± 0.27 3.01 ± 0.33 2.96 ± 0.29 0.953 
 
imaxC (0-8h), mmol/L  1.34 ± 0.14 1.50 ± 0.20 1.47 ± 0.18 0.793 
 
Tmax (0-8h), min 275 ± 19 221 ± 17 277 ± 21 0.073 
 
AUC (0-8h), mmol/L×480min 1033 ± 104 1042 ± 121 1041 ± 102 0.998 
 
IAUC (0-8h), mmol/L×480min 296 ± 37 319 ± 49 325 ± 44 0.879 
 
Change from baseline to 24h, mmol/L -0.04 ± 0.07 0.16 ± 0.06 0.05 ± 0.04 0.079 
Non-esterified fatty acids (NEFA)     
 
Interaction of meal × time for the postprandial timecourse3 0.999 
 Baseline, µmol/L3 475.0 ± 38.6 484.0 ± 51.4 489.0 ± 30.0 0.824 
 
minC (0-8h), µmol/L3 146.5 ± 11.3 138.6 ± 12.7 143.3 ± 11.9 0.827 
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Suppression (0-2h) %4 -62.0 ± 4.5 -61.3 ± 5.3 -67.8 ± 3.0 0.749 
 
maxC (2-8h), µmol/L3 654.8 ± 54.0 651.0 ± 56.6 720.7 ± 61.7 0.702 
 
imaxC (2-8h), µmol/L3 492.6 ± 55.1 489.4 ± 59.8 569.3 ± 59.4 0.569 
 
Tmax (2-8h), min 431 ± 14 441 ± 13 441 ± 11 0.792 
 
AUC (2-8h), mmol/L×6h 2.8 ± 0.2 2.8 ± 0.2 2.9 ± 0.2 0.909 
 
IAUC (2-8h), mmol/L×6h -0.1 ± 0.2 -0.1 ± 0.3 -0.1 ± 0.2 0.983 
  Change from baseline to 24h, µmol/L -12.7 ± 51.6 -12.7 ± 51.0 -24.4 ± 27.3 0.977 
Apolipoprotein B     
 
Interaction of meal × time for the postprandial timecourse  
 
0.570 
 Baseline, µg/mL 1039± 48 1043 ± 49.0 1043 ± 49.0 1.000 
 
maxC (0-8h), µg/mL 1089 ± 48 1099 ± 13 1091 ± 53 0.989 
 
imaxC (0-8h), µg/mL 49.6± 9.2 55.8 ± 8.0 52.0 ± 8.3 0.875 
 
Tmax (0-8h), min4 247 ± 50 251 ± 48 173 ± 47 0.607 
 
AUC (0-8h), µg/mL×8h 8293 ± 352 8302 ± 351 8272 ± 401 0.998 
 
IAUC (0-8h), µg/mL×8h -22.9 ± 71.4 -42.5 ± 73.3 -37.7 ± 44.0 0.975 
 
Change from baseline to 24h, µg/mL 89.8 ± 10.5 78.3 ± 15.8 87.2 ± 12.7 0.811 
1Values are means ± SEMs. Different superscript letters within a row identify different from one another 
2Two-factor repeated measure ANOVA was applied to assess the treatment by time interactions; One-factor ANOVA was applied to the outcome variable to 
compare overall between-group diet, Bonferroni multiple pairwise comparison post hoc tests was used to identify the significant differences between the 
treatments. 
3Original data were transformed to natural logarithms for the analysis. 
4Kruskal-Wallis equality-of-populations rank test for non-normally distributed data. 
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Supplemental Table 2. Postprandial responses of the inflammatory and vascular biomarkers after consumption of 25(OH) D3 fortified dairy drink (HyD3), 
vitamin D3 fortified dairy drink (25(OH) D3) or unfortified dairy drink (Control)
1. 
    Meal   
Measures Control Vitamin D3 25(OH) D3 P
2 
C-reactive protein  
    
 
Interaction of meal × time for the postprandial timecourse3 
 
0.669 
Baseline, µg/ mL3 1.37 ± 0.43 1.14 ± 0.49 0.71 ± 0.17 0.690 
 
maxC (0-8h), µg/ mL3 1.50 ± 0.43 1.23 ± 0.48 0.83 ± 0.18 0.553 
 
imaxC (0-8h), µg/ mL3 0.13  ± 0.03 0.10  ± 0.01 0.12  ± 0.01 0.578 
 
Tmax (0-8h), min4 124 ± 25 106 ± 12  111 ± 16    0.945 
 
AUC (0-8h),  µg/ml×8h3 11.0 ± 3.3 8.8 ± 3.3 6.1 ± 1.4   0.623 
 
IAUC (0-8h),  µg/ml×8h4 0.0 ± 0.3 -0.3 ± 0.6 0.4 ± 0.1 0.342 
 
Change from baseline to 24h, mg/mL4 -0.15 ± 0.17 -0.21 ± 0.25 0.06 ± 0.04 0.579 
Nitric oxide 
    
 
Interaction of meal × time for the postprandial timecourse 0.755 
Baseline, µmol/L 13.0 ± 1.3 11.6 ± 1.3 11.6 ± 1.5 0.730 
 
maxC (0-8h), µmol/L3 14.4 ± 0.9 13.8 ± 0.7 13.4 ± 0.7 0.635 
 
imaxC (0-8h), µmol/L3 1.5 ± 1.3 2.2 ± 1.0 1.7 ± 0.8 0.634 
 
Tmax (0-8h), min 81 ± 36 141 ± 46 184 ± 44 0.238 
 
AUC (0-8h), µmol/L×8h3 86.6 ± 11.1 77.2 ± 8.9 76.1 ± 8.3 0.808 
 
IAUC (0-8h), µmol/L×8h -17.1 ± 6.3 -15.9 ± 4.5 -10.5 ± 4.3 0.630 
 
Change from baseline to 24h, µmol/L -3.3 ± 1.0 -0.2 ± 2.0 -2.3 ± 1.3 0.318 
Interleukin 6 
    
 
Interaction of meal × time for the postprandial timecourse3 
 
   0.667 
Baseline, pg/mL 1.16 ± 0.14 1.00 ± 0.12 1.03 ± 0.11 0.624 
 
maxC (0-8h), pg/mL3 2.28 ± 0.11 2.36 ± 0.13 2.25 ± 1.12  0.995 
 
imaxC (0-8h), pg/mL3 1.12 ± 0.23 1.36 ± 0.32 1.22 ± 0.28 0.933 
 
Tmax (0-8h), min 388 ± 28 388 ± 38 356 ± 43 0.781 
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AUC (0-8h), pg/mL×8h3 12.0 ± 1.3 11.1 ± 1.2 11.6 ± 1.3 0.858 
 
IAUC (0-8h), pg/mL×8h 2.8 ± 0.9 3.1 ± 1.3 3.4 ± 1.2 0.926 
 
Change of 24 h from baseline, pg/mL 0.09 ± 0.17 -0.04 ± 0.11 -0.06 ± 0.09 0.664 
1Values are means ± SEMs. Different superscript letters within a row identify intervention groups significantly different from one another 
2Two-factor repeated measure ANOVA was applied to assess the treatment by time interactions; One-factor ANOVA was applied to the outcome variable to 
compare overall between-group diet, Bonferroni multiple pairwise comparison post hoc tests was used to identify the significant differences between 
treatments. 
3Original data were transformed to natural logarithms for the analysis. 
4Kruskal-Wallis equality-of-populations rank test for non-normally distributed data. 
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Supplemental Table 3.Ex vivo lipopolysaccharide - stimulated interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) production in whole blood 
cultures after consumption of 25(OH) D3 fortified dairy drink (25(OH) D3), vitamin D3 fortified dairy drink (Vitamin D3) or unfortified dairy drink 
(Control)1. 
    Meal   
Measures Control Vitamin D3 25(OH) D3 P
2 
IL-6 
    
 
Interaction of meal × time for the postprandial time course 3 0.872 
 
Baseline, pg/mL3 3693 ± 629 3827 ± 498 4689 ± 690 0.496 
 
Change from baseline to 8h, pg/mL3 -420 ± 327 -145 ± 323 -611 ± 450 0.528 
 
Change from baseline to 24h, pg/mL4 741 ± 437 594 ± 502 460 ± 423 0.910 
TNF-α      
 
Interaction of meal × time for the postprandial time course 3 0.255 
 
Baseline, pg/mL 465 ± 99 421 ± 58 400 ± 41 0.996 
                    Change from baseline to 8h, pg/mL4 -101 ± 89 -12.1 ± 54.7 -15.1 ± 29.6 0.281 
                     Change from baseline to 24h, pg/mL4 -34 ± 88 52 ± 52 110 ± 52 0.257 
1Values are means ± SEMs, data were corrected for the number of monocytes. 
2Two-factor repeated measures ANOVA was applied to the outcome variable 
3Original data were transformed to natural logarithms for the analysis. 
4Kruskal-Wallis equality-of-populations rank test for non-normally distributed data. 
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  Chapter 9 – General discussions and conclusions. 
General discussion 
Hypovitaminosis D is prevalent through EU, due to diet and lifestyle changes (1, 2). In the 
UK, 40% and 8% adults (19-64y) whose plasma 25(OH) D concentration < 25 nmol/L in the 
winter and summer, respectively (3). To date, there is growing evidence for the association 
between low vitamin D status and increased risk of non-skeletal health outcomes, such as 
cardiovascular disease (CVD), diabetes and certain cancers (4). The fact that CVD and 
diabetes are responsible for over 18 million mortalities globally (5). Estimates from study of 
Grant et al. (2009) suggest a reduction of economic burden of disease is €187,000 
million/year if serum 25(OH) D level to 100 nmol/L(6).  
Evidence from Caerphilly Prospective Study (CAPS) in Chapter 3 is the first to show 
higher vitamin D dietary intake was associated with a lower plasma triacylglycerol level 
cross-sectionally and also at the 5-years examination, an independent risk factor for CVD and 
a characteristic of type 2 diabetes (T2D) (7). The findings agrees with the results of a 
randomized controlled trial (RCT) which showed a daily 100 µg vitamin D3 for 6 months 
resulted in a decreased triacylglycerol level, however, the study was conducted in the post-
menopausal women with T2D. Furthermore, evidence in Chapter 3 also suggest higher 
vitamin D intake was modest positive associated with diastolic blood pressure, but there were 
no associations between vitamin D intake and CVD after over 20 years follow-up (Chapter 3). 
This is consistent with a recent report and meta-analysis (8) that reports the direct associations 
between vitamin D and CVD are not certain. The impact of vitamin D intake on CVD events 
and risk markers is a complex tropical area of research, which need further large cohort 
studies or RCT to verify.  
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Due to diet and lifestyle changes and the frequent use of sunscreen, many individuals do 
not endogenously synthesise sufficient vitamin D from sunlight exposure (9), thus, awareness 
of tackling inadequate vitamin D intake has been increased (10). Egg yolk, oily fish and wild 
mushrooms have been regarded as foods naturally enriched with vitamin D (11). Previous 
studies indicated vitamin D content of salmon and some mushrooms significantly varied 
between different production systems (12, 13). Our research in Chapter 5 is the first UK study 
to show that the vitamin D content of the eggs from indoor was significantly less than free 
range and organic. However, study of Matt et al. (2009) (14) demonstrated eggs from organic 
have lower vitamin D content than indoor eggs. The inconsistencies in the findings probably 
be explained by the variation of system management, such as the difference in the diet or 
pasture usage for the birds. With the limitation of the current study, the original diet of the 
poultry and daily activity of the birds are unknown, but current results represent what the 
consumer purchases and consumes. Furthermore, the current study confirmed that one egg per 
day contributed about 2 µg/day vitamin D, which equivalent to 20% of RNI (10 µg/day) 
vitamin D.  
Eggs are a nutrient-dense food with high quality protein and minerals, but also enriched 
with cholesterol, which could increase the risk of CVD and this has become a controversial 
issue (15). National Diet and Nutrition Survey (NDNS) of the UK (16) reported the average 
daily intake of vitamin D for adults is 3.1 µg for men and 2.6 µg for women, respectively. The 
percentage contribution of egg is 13%, which is much less that one egg. Therefore, it is 
speculate the conception of ‘egg limitation’ is still continues to influence the public diet. If 
eggs are recommended as a source of vitamin D to the general population, it is important to 
determine whether there are any potential detrimental effects of the consumption. Some meta-
analyses have reported that higher egg consumption was associated with increasing risk of 
coronary heart disease in diabetic patients, but the evidence are inconsistencies (17, 18). 
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Therefore we investigated the association between eggs and CVD events (Chapter 4) in two 
UK cohort studies, the CAPS and NDNS. Our findings in agreement with previous studies, 
there were no association between egg consumption and CVD events in the general health 
population over 20 years follow-up. However, our analysis is the first study to show higher 
egg consumption to be associated with increasing stroke and elevated fasting glucose in the 
sub-group of subjects with T2D and/or impaired glucose tolerance (IGT). In addition, cross-
sectional analyses of CAPS and NDNS showed egg consumption was associated with higher 
blood glucose and HbA1c concentrations in a T2D and/or IGT sub-group. However, the 
potential mechanism by eggs could increase fasting plasma glucose and stroke in T2D and/or 
IGT subjects is unknown. With the limitation of epidemiology studies cannot prove causality 
and simply represent an association, it is therefore recommended that this should be explored 
further by performing RCTs to verify the relationship between egg consumption and CVD 
risk in T2D and/or IGT subjects. Nonetheless, results of current study recommend daily 
consumption of one egg in general population to increase vitamin D intake.  
Vitamin D naturally enriched foods are few in number and in many cases not widely 
consumed (19), thus, vitamin D enriched foods or vitamin D fortified foods are important 
strategies which will help to facilitate sufficient vitamin D intake within the general 
population. As highlighted in the literature review in Chapter 2, there are several studies 
which have enriched foods with vitamin D through a food chain approach by feeding vitamin 
D3 or 25(OH) D3 supplements to poultry, which resulted in increasing vitamin D content in 
the eggs. However, feeding 25(OH) D3 supplements to poultry only resulted in elevation of 
25(OH) D3 content of the egg yolk but not significant increase in the vitamin D3 content (20), 
whilst feeding vitamin D3 supplements to poultry would increase vitamin D3 content in egg 
yolk much more than 25(OH) D3 (21). Comparison of beneficial effect of vitamin D3 and 
25(OH) D3 enriched eggs on human’s serum 25(OH) D concentrations and health need further 
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RCT to verify. To my knowledge, only one RCT (22) has investigated the effect of vitamin 
D3 and 25(OH) D3 enriched eggs on serum 25(OH) D concentrations and showed both types 
of enriched eggs sustained serum 25(OH) D through the winter period compared with 
consumption of normal commercial eggs. However, studies on the chronic effect of vitamin D 
enriched eggs on vitamin D status or health outcome are lacking. 
Milk and dairy products are consumed widely all around the world (23, 24) and which 
contributing a substantial amount and variety of nutrients (25).Thus, milk and dairy products 
are ideal foods for fortification, such as USA and Canada, as a strategy to address lower 
vitamin D status within the general population (26). However they are not available in all 
countries, including the UK, due to different food policies. As mentioned previously in 
relation to eggs, it is important to determine any potential detrimental effects of milk and 
dairy products on public health if they are to be used as a vehicle for vitamin D fortification. 
There is relatively consistent evidence that shows that dairy, particularly milk, consumption is 
associated with a no long-term effect on risk of CVD or mortality (27) with some studies 
reporting an inverse association with CVD risk (28, 29). However, a recent study (30), which 
included two large Swedish cohorts (61,433 women and 45,339 men) reported higher milk 
consumption to be associated with a doubling of all-cause mortality risk in the women and 
received considerable media attention. Therefore, an updated dose-response meta-analysis of 
all available published perspective cohort studies up to Sep 2016, including Michaelson et al. 
(30) was conducted (Chapter 6). No association between milk consumption and CVD was 
observed from the pooled data of 29 prospective cohort studies. Our results were in agreement 
with recent meta-analysis study of Larsson et al. (2015) (31) who also reported the neutral 
associations between milk and dairy intake with mortality or CVD mortality. Although the 
comprehensive meta-analysis, our results are limited by the observed heterogeneity of the 
pooled results. Therefore, RCT of investigating the effect of milk and dairy production 
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consumption on CVD event should be considered in the future to provide robust evidence. 
Nevertheless, our research results provide the evidence that milk and dairy products have 
neutral effect on CVD event, and which can be considered as suitable food for vitamin D 
fortification.   
Vitamin D3 has become the preferred form of vitamin D for fortification (32). A few 
previous studies (33-37), highlighted in the literature review in Chapter 2, reported that the 
vitamin D metabolite 25(OH) D3, was more effective in raising vitamin D status, and was 
absorbed more rapidly than vitamin D3. To address this issue further, we performed the study 
to investigate the effect of feeding dairy cows with 25(OH) D3 compared with vitamin D3 on 
vitamin D content of their milk (Chapter 7). The results showed bovine plasma increased 
significantly after feeding 25(OH) D3 (not vitamin D3), but vitamin D concentration in the 
milk is relatively low (mean 25(OH) D3 concentration in milk was 0.88 µg/L). Consistent 
with the studies of Hollis et al. 1981 (38); Reeve et al. 1982 (39); McDermott et al. 1985 (40) 
and Weiss et al., 2015; (41) (as highlighted in Chapter 2, Table 3): vitamin D concentrations 
of the milk were not significantly increased by feeding cows with vitamin D supplements. 
Our results from this enrichment study illustrated that although it was possible to produce 
vitamin D enriched milk by a food chain approach, the absolute concentrations of vitamin D 
were insufficient to have any impact on the vitamin D status of the general population. 
Therefore, vitamin D fortification would seem a logical and more practical strategy to 
increase vitamin D content of milk or dairy products. 
USA has fortified fluid 100 g milk with 42 IU vitamin D3 and which has been become one 
of predominant food vehicles for vitamin D intake in USA and Canada, but Calvo et al. (26) 
indicated the amount of vitamin D added to milk may not be adequate to produce the 
sufficient 25(OH) D concentrations (26). As highlighted in Chapter 2, previous studies 
showed 25(OH) D3 is highly effective in raising serum 25(OH) D level (42). Therefore, may 
25(OH) D3 fortified milk or dairy product is needed to increase vitamin D status. With 
 251 
 
 
novelty as the first study to investigate the potential differential effects of 25(OH) D3 and 
vitamin D3 fortified dairy drink on vitamin D status and CVD risk markers, a double-blind, 
randomised, controlled acute human study (Chapter 8) was performed in 17 men with sub-
optimal vitamin D status (mean ( SEM) plasma 25(OH) D3: 32.8  2.4 nmol/L). As 
expected, the 25(OH) D3 fortified dairy drink was found to be more effective and faster at 
raising vitamin D status postprandially within 24 hours than the vitamin D3 fortified dairy 
drink. Although novel, may the neutral results of the vitamin D fortified dairy drinks and 
cardiometabolic markers may due to the study is limited by the number of subjects which 
resulted in a lack of power to detect the significant difference of the secondary outcomes of 
cardiometabolic markers. In addition, the longer term effects of consuming a 25(OH) D3 
fortified dairy drink is unknown, which should be explored further. 
In the UK, estimation from NDNS data suggesting 64-75% of adults consume semi-
skimmed milk (16). However, due to lactose intolerance or low dairy product consumption in 
some individuals (e.g. vegetarian), other foods (such as bread or flour) should be considered 
as possible vehicles for vitamin D fortification to accommodate the food diversity. However, 
few studies have investigated if vitamin D is stable and bioavailable by adding into those 
foods.  
Regarding the cost of the vitamin D supplementation, a study of Holick et al. (43) 
identified which strategy would be a cost-effective, however, there were no studies comparing 
the cost-effectiveness of vitamin D3 fortification compared with 25(OH)D3 fortified foods. 
More evidence on this is needed. Furthermore, apart from the general population, the effect of 
food fortification strategies for people who are at greatest risk of sub-optimal vitamin D status 
(e.g. dark-skinned and elderly subjects) should be explored.  
 
Conclusions 
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This thesis has presented new and valuable epidemiological, animal and human studies on the 
role of eggs and dairy products in relation to vitamin D status and cardiovascular health. 
Novel findings that the vitamin D content of eggs is significantly affected by production 
system; association of higher egg consumption and increasing risk of stroke in subjects with 
T2D and/or IGT; an inverse association between vitamin D intake and plasma triacylglycerol 
level was demonstrated, as well as an updated dose-response meta-analysis of dairy 
consumption and CVD or mortality. Furthermore, the efficiency and faster effect of the 
vitamin D metabolic form 25(OH) D3 in raising plasma 25(OH) D3 in both dairy cows and 
humans were confirmed. Therefore to increase vitamin D dietary intake, one egg per day is 
recommended to a generally healthy population but not to subjects who have T2D and/or 
IGT. Additionally, the strategy of daily consumption of vitamin D fortified foods should be 
recommended to the general population, especially in winter and spring, to guarantee 
adequate vitamin D dietary intake.  
 
Future research 
The present studies have addressed a number of important research questions, while also 
highlighting some key opportunities for future research. In Chapter 3, whether vitamin D is 
associated with CVD events is a contentious topic with conflicting findings from the 
literature. In Chapter 4: with no prior longitudinal prospective evidence for higher egg 
consumption in increasing risk of stroke in T2D and/or IGT subjects. Both Chapter 3 and 
Chapter 4 are mainly based in same cohort of CAPS. As there are some limitations of the 
CAPS (highlighted in Chapter 3 and 4), further cohort studies with large subject numbers and 
both genders are needed to verify the findings in Chapters 3 and 4. In addition, updated meta-
analysis of prospective studies on the association between egg consumption and CVD risk in 
T2D and/or IGT is needed in the future; also large RCTs are needed to verify the findings in 
relation to T2D and/or IGT.  
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A further area of research address in Chapter 6 was the meta-analysis of milk and dairy 
consumption and risk of cardiovascular disease and all-cause mortality. There is distinct lack 
of RCTs research into the impact of milk and dairy consumption on CVD events, thus, 
generating a considerable opportunity for future research. Intervention-based evidence has 
focused mainly on milk component (e.g. why protein), rather than milk as whole. 
Furthermore, milk and dairy products should be studies for particular effect of different dairy 
foods (e.g. high-/low-fat milk, yogurt, cheese) on CVD events.  
The study presented in Chapter 5 was the effect of production system, supermarket and 
purchase date on the vitamin D content of the eggs at UK retail. Such kind of study is not 
possible to investigate the reasons behind the vitamin D variation of the eggs from different 
production system. Therefore, future research of collected eggs from different farm through 
the whole UK, even EU to investigate the effect of the production system on vitamin D 
content of the eggs, additional investigation of the effect of the hens feeding on vitamin D 
content of the eggs should be explored as well.  
The study presented in Chapter 7 demonstrated supplemental 25(OH) D3 is an effective 
means of enhancing 25(OH) D3 concentration than vitamin D3 supplementation to cows. 
However, vitamin D content of the milk was not significantly increased by either 25(OH) D3 
or vitamin D3 supplementation, may future studies could explore the physiology reason 
behind this. 
The beneficial effects of consuming dairy drinks with added 25(OH) D3 or vitamin D3 on 
vitamin D status is presented in Chapter 8.  Further research including undertaking chronic 
RCT in a large, health subjects or subjects who have liver disease to compare the effect of 
consuming dairy drinks fortified 25(OH) D3 with vitamin D3 on raising vitamin D 
concentrations.  
Furthermore, the amount of vitamin D added to milk and dairy products in the UK for 
public population to reach desired circulating 25(OH) D concentrations should be studied. For 
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people who are not milk or dairy consumers, the possible 25(OH) D3 fortification of other 
staple foods (e.g. bread) could be explored with the aim of ensuring that a high proportion of 
the population achieved a satisfactory vitamin D status throughout the year. Finally, the 
stability of the vitamin D fortified foods in terms of processing and storage conditions should 
be explored to guarantee the vitamin D content of the fortification foods are in compliance.  
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